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DECIPHERING THE ROLE OF HUMAN ARYLAMINE N-ACETYLTRANSFERASE 1 (NAT1) IN 
BREAST CANCER CELL METABOLISM USING A SYSTEMS BIOLOGY APPROACH  
 
Samantha Marie Carlisle 
 
July 20, 2018 
 
Background: Human arylamine N-acetyltransferase 1 (NAT1) is a phase II xenobiotic 
metabolizing enzyme found in almost all tissues. NAT1 can additionally hydrolyze acetyl-
coenzyme A (acetyl-CoA) in the absence of an arylamine substrate. NAT1 expression varies 
inter-individually and is elevated in several cancers including estrogen receptor positive (ER+) 
breast cancers. Additionally, multiple studies have shown the knockdown of NAT1, by both small 
molecule inhibition and siRNA methods, in breast cancer cells leads to decreased invasive ability 
and proliferation and decreased anchorage-independent colony formation. However, the exact 
mechanism by which NAT1 expression affects cancer risk and progression remains unclear. 
Additionally, consequences of the hydrolysis of acetyl-CoA by NAT1 on cellular metabolism 
remains uninvestigated. 
 
Hypothesis and Rationale: Samples with decreased levels or knockout of NAT1 will have 
increased free acetyl-CoA since those cell lines have less NAT1 to hydrolyze acetyl-CoA. 
Conversely, samples with increased NAT1 will have decreased free acetyl-CoA since those cell 
lines have more NAT1 to hydrolyze acetyl-CoA. These differences in free acetyl-CoA are 
hypothesized to lead to alterations in cellular pathways/metabolism when compared to cells with 
basal NAT1 that can be measured by global bioenergetics, metabolomics, and transcriptomics 
experiments. 
 
Methods: This dissertation utilized a systems biology approach with four layers. The first layer 
consists of six constructed MDA-MB-231 cell lines whose only genetic difference (theoretically) is 
 vi 
in NAT1. The second, third, and fourth layers are bioenergetics (Chapter 3), metabolomics 
(Chapter 4), and transcriptomics (Chapter 5) measurements of the constructed cell lines. 
Resulting data were analyzed individually and also integrated and analyzed (Chapter 6). 
 
Results: The manipulation of NAT1 in MDA-MB-231 breast cancer cells severely altered cellular 
metabolism as measured by mitochondrial bioenergetics, metabolomics, and transcriptomics. 
More differences were observed in the cell lines with decreased levels and knockout NAT1 than 
the cell line with increased NAT1. 
 
Conclusions: This dissertation has generated novel hypotheses about the role of NAT1 in breast 
cancer, and more generally cellular metabolism. Furthermore, biochemicals that are likely 
products of NAT1 N-acetylation, N-acetylasparagine and N-acetylputrescine, have been 
identified. This dissertation presents strong evidence that NAT1, whether directly or through an 
effect of NAT1 on acetyl-CoA levels, has an effect on acyl-CoA carnitine conjugates, lysine 
degradation, and mitochondrial function. While the exact mechanism by which NAT1 affects 
cellular metabolism or breast cancer progression has not been identified, the data presented in 
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BACKGROUND AND SIGNIFICANCE 
 
Breast Cancer 
According to the American Cancer Society (ACS), breast cancer will account for 
approximately 30% of new cancer cases and 14% of cancer related deaths in American women 
in 20181. Additionally, 1 in 8 women will develop breast cancer in their lifetime1. Breast cancer is 
a heterogeneous disease with many underlying genetic transformations that lead to a diseased 
state. This heterogeneity makes predicting breast cancer risk and developing one-size-fits-all 
treatment strategies difficult. As the cost of genomic profiling has decreased dramatically, the 
feasibility of developing personalized treatment strategies based on the genomic profile of an 
individual’s tumor has become attainable. For example, the National Cancer Institute (NCI) 
presently has a clinical trials program called Molecular Analysis for Therapy Choice (MATCH) in 
which DNA of tumors from patients for whom standard treatment has not been successful are 
sequenced and the results are utilized to provide personalized treatment2; the program currently 
has 14 treatment arms to which patients are assigned based on mutations, including 
amplifications, translocations, and fusions, in 14 different genes: EGFR, MET, ALK, ROS1, 
HER2, mTOR, TSC1, TSC2, GNAQ/GNA11, SMO/PTCH1, cKIT, NTRK, BRCA1, and BRCA22. 
These advances in precision medicine have led to an urgent need to understand and catalogue 
gene targets involved in breast cancer initiation, transformation, and metastasis so that 




Arylamine N-acetyltransferase 1 and arylamine N-acetyltransferase 2 (NAT1 and NAT2; 
collectively NATs) are polymorphic phase II xenobiotic metabolizing isozymes that catalyze the 
acetylation of a wide range of arylamine and hydrazine substrates using acetyl coenzyme A 
(acetyl-CoA) as the acetyl group donor via a ping-pong bi-bi reaction mechanism3,4. The human 
NAT1 and NAT2 genes are located in close proximity on chromosome 8p225 and share 
approximately 87% protein coding sequence and 81% deduced amino acid sequence homology6. 
The open reading frame (ORF) regions of NAT1 and NAT2 are both 870 base pairs and 
intronless6,7. NAT1 and NAT2 have distinct but overlapping substrate specificities with NAT1 
selectively acetylating p-aminobenzoic acid (PABA) and p-aminosalicylate (PAS) while NAT2 
selectively acetylates isoniazid, sulfamethazine (SMZ), procainamide, and hydralazine8. Both 
isozymes can acetylate a plethora of arylamines including 4-aminobiphenyl (4-ABP) and 2-
aminoflourene (2-AF)8. Many NAT substrates are known carcinogens found in well-done red 
meats, cigarette smoke, and commercial dyes9,10. Additionally, NAT1 and NAT2 have differing 
tissue distributions (reviewed in 11); NAT1 is expressed in nearly every tissue12-22 while NAT2 
tissue distribution is thought to be much more limited with the highest expression found in the 
liver12 and gastrointestinal (GI) tract19. 
Regulation of NATs 
NAT1 and NAT2 expression also vary inter-individually, but independent of one 
another12,23, based on single nucleotide polymorphisms (SNPs)4,23-29. As of the most recent 
update (April 2016), 28 different NAT1 alleles30 and 64 (108 including those predicted) different 
NAT2 alleles31 have been identified and named in human populations, conferring either rapid, 
intermediate, slow, or unknown acetylator phenotypes. NAT1 and NAT2 allelic frequencies vary 
by ethnic population32. The effect of SNPs in NAT2 on N-acetylation activity have been well 
described and characterized (reviewed in 27) however the effect of SNPs (located both in and 
outside the ORF) in NAT1 on N-acetylation activity are not understood as well with conflicting 
reports (reviewed in 33). Large inter-individual variation exists in NAT1 activities within single 
genotypes suggesting additional regulation mechanisms are present34-36. Additionally, there is 
considerable evidence that NAT1 activity is highly regulated by post-transcriptional and post-
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translational mechanisms, and substrate concentrations (reviewed in 37). Although the ORF of 
NAT1 is contained in a single exon (exon 9), there are 8 upstream non-coding exons38 that are 
included, in varying patterns, in alternatively spliced transcripts21. NAT1 is also known to have two 
alternative promoters, NATa and NATb, that differ in promotor strength and tissue specificity39-41 
producing mRNAs with distinct 5’-UTRs. Notably, there are 9 variant NAT1 transcripts known, 
each with identical protein coding sequences38,39,41.  
Through chemical modifications of the NAT1 active site as well as changes in the 
turnover of NAT1 protein, NAT1 activity can be modulated post-translationally. NAT1 substrates, 
including PABA, p-aminosalicylic acid, ethyl-p-aminobenzoate, and p-aminophenol, are capable 
of down-regulating NAT1 activity and protein expression in cultured human peripheral blood 
mononuclear cells42; this phenomenon was also observed in confluent human cell lines incubated 
with PABA42. It is hypothesized this occurs because substrate binding causes the cysteine in the 
NAT1 active site to become de-acetylated leading to polyubiquitination and degradation of the 
protein37. N-hydroxyl metabolites of NAT1 substrates, including PABA and sulfomethoxazole, 
have also been shown to irreversibly inhibit NAT143; however, the molecular mechanism remains 
unknown. NAT1 gene expression can also be regulated indirectly by androgens44,45. Additionally, 
NAT1 is known to be inhibited by many chemically diverse non-substrate compounds including 
tamoxifen46, cisplatin47, thiram (a dithiocarbamate pesticide)48, isothiocyanates49, hydrogen 
peroxide and peroxynitrite50,51, acrolein52, carbon black nanoparticles53, cadmium54, and 
disulfiram55. Additionally, hsa-miRNA-1290, implicated in lung adenocarcinoma56, ovarian 
cancer57, non-small cell lung cancer58,59, glioma60, and colorectal cancer61, has been shown to 
directly target the 3’UTR region of human NAT1 mRNA leading to dose-dependent down-
regulation of NAT1 expression62,63. 
Brief History of NATs 
Arylamine N-acetyltransferase activity was first described in the late 1930’s when 
acetylated para-aminobenezenesulfonamide was detected in the urine of humans and rabbits, but 
not dogs, after administration of para-aminobenezenesulfonamide64, although it would be nearly 
40 years before the specific enzyme(s) responsible for the transformation was/were isolated and 
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identified. NAT activity was described for a second time in the mid 1940’s when it was observed 
that liver homogenates and extracts could acetylate sulfanilamides65 and again in the mid 1950’s 
when it was shown that the enzyme responsible for the acetylation of sulfanilamides was also 
responsible for the acetylation of isoniazid66. NATs were first isolated and described kinetically in 
1967 by Weber and Cohen in partially purified preparations from rabbit liver67. NAT was shown to 
catalyze the acetylation of isoniazid and several sulfonamides via a ping-pong bi-bi reaction 
mechanism using acetyl-CoA as the acetyl donor67. It is also important to note that at the times of 
those early studies, NAT1 and NAT2 were thought to be a single enzyme that could be 
monomorphic or polymorphic depending on the substrate acetylated. It was not realized until 
1990 that there were actually two individual N-acetylating isozymes6,12 with distinct but 
overlapping substrate specificities.  
NATs & Breast Cancer 
While NAT1 has been implicated in many cancers, NAT1’s role in breast cancer has 
been investigated more frequently than any other cancer. The earliest studies on N-
acetyltransferases and breast cancer were epidemiological studies that investigated associations 
between acetylator phenotype and breast cancer risk68-72. Since those initial studies there have 
been many more looking at the association in various ethnic and regional populations and in 
combination with several possible modifying factors with conflicting results leading to multiple 
meta-analyses of these data.  
Briefly, of the 5 meta-analyses published on NAT2 and breast cancer risk, 4 investigated 
the independent effect of NAT2 phenotype (determined by genotype) on breast cancer risk with 
none observing a significant association73-77. However, one of the meta-analyses found evidence 
of decreased breast cancer risk for women with a slow phenotype when separately analyzing 
studies in which NAT2 phenotype was determined by acetylation rate of xenobiotics metabolized 
by NAT2 rather than genotype76. Three of the 5 meta-analyses further analyzed data by including 
cumulative smoking exposure into the risk calculation as a modifying variable with all 3 studies 
observing a significant association between high pack years and increased breast cancer risk in 
the slow acetylator group compared to the rapid acetylator group74,75,77. A single meta-analysis 
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considered menopausal status as a modifying factor of NAT2 genotype in breast cancer risk and 
observed no significant difference in risk74. None of the meta-analyses included intake of well-
done meat as a possible modifying factor of NAT2 genotype in breast cancer risk. There has 
been one meta-analysis of NAT1 genotype and breast cancer risk which found no significant 
association78, however possible modifying factors such as smoking exposure and well-done meat 
intake were not considered in the study.  
Although NAT1 and NAT2 both catalyze N-acetylation and have been associated with 
breast cancer, their roles in etiology may differ. Numerous studies have investigated possible 
roles for NAT1 in breast cancer etiology and progression79-84, given the association between 
increased expression of NAT1 and estrogen receptor (ER)-positive breast cancers85-91. Notably, 
NAT1 expression is not directly regulated by estrogens or dihydrotestosterone92, thus suggesting 
that there may be a common regulatory element between NAT1 and ESR1. Furthermore, 
congenic rats expressing higher NAT2 activity (orthologous to human NAT1) have been reported 
to exhibit greater carcinogen-induced mammary tumor susceptibility independent of carcinogen 
metabolism83. Notably, NAT1 is one of fifty genes whose expression is utilized in the PAM50-
based Prosigna breast cancer gene signature array to determine the intrinsic subtype of breast 
cancer tumors93,94. Conversely, SNPs in NAT2 have been well described and revealed to 
influence acetylation rates of many known carcinogens; an association between NAT2 genotype 
with breast cancer risk among smokers has been reported (reviewed in 95).  
The mRNA expression levels of NAT1 and NAT2 have been detected by reverse 
transcription-polymerase chain reaction (RT-PCR) in human mammary tissue13,96. NAT1 N-
acetylation activity has been widely reported in normal breast tissue and breast tumor 
tissue13,14,38,97-99 whereas NAT2 N-acetylation activity has not been observed as consistently; 
when NAT2 activity is observed the activity is much lower than NAT1 activity13,97,98. In addition, 
since NAT1 and NAT2 have overlapping substrate specificities, activity studies of the two 
isozymes can be complex. For example, Deitz probed human mammary tissue samples for NAT1 
and NAT2 activities with p-aminobenzoic acid (PABA; selective for NAT1) and sulfamethazine 
(SMZ; selective for NAT2), and reported that SMZ was acetylated by NAT1 at very low levels99. 
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By normalizing the SMZ N-acetylation activity to NAT1 activity, Deitz demonstrated that the SMZ 
N-acetylation activity was most likely catalyzed by NAT1 rather than NAT2. NAT1 and NAT2 
activities have also been reported in rat mammary tissues100. 
Wakefield et al profiled NAT1 expression and activity in seven breast cancer cell lines 
(MCF-7, T47D, ZR-75-1, Cal51, MDA-MB-231, MDA-MB-437 and MDA-MB-453) and detected 
NAT1 mRNA expression and activity in all seven cell lines88; however, NAT2 expression and 
activity were not co-investigated. In addition, NAT2 mRNA has been detected in MCF-7 breast 
cancer cells at very low levels96; however, NAT1 was not measured at the same time preventing 
a direct comparison of expression between the two isozymes. Bradshaw et al detected NAT1 and 
NAT2 by western blotting in the ER-positive breast cancer cell line MCF-7; however, the 
expression levels were not compared between the two proteins101. Based on limited data, it has 
been hypothesized that NAT2 expression is very low in breast tissue and negligible in comparison 
to NAT1 expression. However, a more comprehensive evaluation of NAT1 and NAT2 co-
expression in breast tissues and established breast cancer cell lines is needed. 
Minchin and Butcher have recently shown, utilizing the publicly available data repositories 
Molecular Taxonomy of Breast Cancer International Consortium (METABRIC) and The Cancer 
Genome Atlas (TCGA), that NAT1 mRNA expression in primary breast tumors, but not prostate, 
cervical, or colorectal tumors, can be segregated into three distinct patient subpopulations, 
expressing low, intermediate and high levels of NAT1 mRNA102. Gene correlation analysis with 
NAT1 in each subset suggested different regulation mechanisms are in place, given the small 
overlap in genes correlated with NAT1 mRNA expression in each subpopulation102. Additionally, a 
better 10-year survival rate in patients with high NAT1 was observed compared to patients with 
low NAT1102. Notably, patients whose tumors had low NAT1 expression exhibited a distinct poor 
response to chemotherapy102. It will be important for future studies on NAT1 to investigate how 
NAT1 expression in breast tumors influences chemo-sensitivity. 
Possible Endogenous Role of NAT1 
Although NAT1 has traditionally been described as a xenobiotic metabolizing enzyme, 
there is a wealth of evidence suggesting NAT1 may also have unknown endogenous role(s). 
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Phylogenetic analysis of the NATs suggested evolutionarily NAT1 did not tolerate mutations while 
NAT2 was predicted to have mostly evolved under positive selection103. NATs are found in all 
kingdoms of life, excluding plants104. Additionally, NAT1 activity and mRNA have been detected in 
mid-gestational fetal tissues15, placenta105,106, and nearly every adult tissue. NAT1 has been 
shown to have redundancy with methylthioribose-1-phosphate isomerase (MRI1) in the 
methionine salvage pathway, but this role was not observed in MDA-MB-231 cells since they do 
not have a functional methionine salvage pathway due to a lack of methylthioadenosine 
phosphorylase (MTAP) activity107. To date, NAT1 is known to acetylate only one endogenous 
compound, p-aminobenzoylglutamate (pABG)-- a folate catabolite108,109, with unknown 
consequence. However, NAT1 has been linked to folate metabolism110,111. Additionally, it has also 
been shown that in the absence of an arylamine substrate NAT1 can catalyze the hydrolysis of 
acetyl-CoA using folate as a co-factor112,113. Furthermore, NAT1 expression and activity are highly 
regulated by many diverse mechanisms whereas NAT2 expression and activity appear to be less 
regulated. Taken together, these facts lead to the hypothesis that NAT1 is not just a xenobiotic 
metabolizing enzyme. It remains to be determined whether that role is through a NAT1 catalyzed 
reaction or a result of NAT1’s ability to catalyze the hydrolysis of acetyl-CoA, a central molecule 
in metabolism and cellular energetics. 
Construction of MDA-MB-231 Breast Cancer Cell Lines Expressing Varying NAT1  
To better investigate NAT1’s role in breast cancer a single established breast cancer cell 
line was genetically modified to vary only in NAT1. The MDA-MB-231 triple negative breast 
cancer cell line was selected for modification because it expresses an approximate mid-level of 
NAT1 RNA compared to other breast cancer cell lines; NAT1 RNA expression has been shown to 
be a suitable predictor of NAT1 activity114. Additionally, two different construction methods were 
utilized, siRNA and CRISPR/Cas9, to ensure observed results were due to manipulation of NAT1 
rather than the specific construction method utilized. 
Construction of siRNA Generated Cell Lines 
The construction and characterization of the siRNA generated cell lines has been 
described extensively elsewhere82,84,115,116. Briefly, three cell lines were constructed, Scrambled, 
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Up, and Down, expressing parental, increased, and decreased NAT1 N-acetylation activity, 
respectively (Figure 1.1). Each cell line was constructed from the parent MDA-MB-231 cell line, 
purchased from American Type Culture Collection (ATCC), that had a flippase recognition target 
(FRT) site inserted, thus ensuring all plasmids were transfected into the same genomic location. 
Genetically modified cell lines were characterized for NAT1 PABA N-acetylation, NAT1 mRNA 
expression, endogenous acetyl-CoA levels, cell doubling rates, anchorage-independent growth, 
anchorage-dependent growth, and relative invasive ability. The Scrambled cell line was included 
as a transfection control and expressed approximately the same NAT1 N-acetylation activity and 
NAT1 mRNA as the parent MDA-MB-231 cell line. NAT1 PABA N-acetylation activity and NAT1 
mRNA in the Up cell line were increased 7-fold and 4-fold, respectively, compared to the 
Scrambled cell line. Conversely, NAT1 PABA N-acetylation activity and NAT1 mRNA in the Down 
cell line were decreased approximately 35% and 53%, respectively, compared to the Scrambled 
cell line. Doubling times, relative invasive ability, and anchorage-dependent growth of the three 
constructed cell lines did not significantly vary while anchorage-independent growth was 
decreased 7-fold in the Down cell line compared to the Scrambled cell line82. 
Construction of CRISPR/Cas9 Generated Cell Lines 
 The CRISPR/Cas9 constructed cell lines were constructed from the MDA-MB-231 cell 
line that had an FRT site inserted to allow direct comparison to a single cell line regardless of the 
method used to construct the cell line (Figure 1.2). All cell lines were cultured in high-glucose 
Dulbecco's Modified Eagle Medium (DMEM), with 10% fetal bovine serum, 5% glutamine, and 
5% penicillin/streptomycin added and grown in a humidified incubator set at 37 °C with 5% CO2. 
Horizon Discovery Group (Waterbeach, United Kingdom) designed 5 different guide RNAs 
(gRNAs) specific for NAT1 and DNA2.0 Inc. (Newark, CA) cloned the gRNAs into a Cas9 
expressing vector that also expressed a dasher-green fluorescent probe (GFP) tag. Separately, 
each of the 5 gRNA/Cas9 vectors (gRNA sequences listed in Table 1.1) were transiently 
transfected in the Scrambled MDA-MB-231 cell line using the Amaxa Nucleofector II (Lonza, 






Figure 1.1: Construction of MDA-MB-231 Cell Lines via siRNA. 
The Flp-In™ System (Life Technologies, Grand Island, NY) was used to insert a single flippase 
recognition site (FRT) site into the parent MDA-MB-231 cell line. The MDA-MB-231 cell line 
containing the FRT site was then stably transfected with either a plasmid containing a nonspecific 
shRNA plasmid into the FRT site (Scrambled), a plasmid containing NAT1 specific shRNA into 
the FRT site (Down), or a plasmid containing the NATb/NAT1*4 vector into the FRT site (Up). 
Each plasmid contained a hygromycin resistant cassette. Therefore stably transfected cells were 
selected for using hygromycin. The resulting MDA-MB-231 cell lines, Scrambled, Down, and Up, 
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Figure 1.2: Construction of MDA-MB-231 NAT1 Knockout Cell Lines via CRISPR/Cas9. 
The CRISPR/Cas9 system was used to decrease and knockout NAT1 in the parent MDA-MB-231 
cell line with a previously inserted flippase recognition target (FRT) site utilizing two different 
guide RNAs, 2 and 5. The resulting MDA-MB-231 cell lines, CRISPR 2-12, CRISPR 2-19, and 
CRISPR 5-50, express decreased, knockout, and knockout levels of PABA NAT1 N-acetylation 
activity, respectively. The CRISPR 2-12 and CRISPR 2-19 cell lines were constructed with guide 
RNA 2 while the CRISPR 5-50 cell line was constructed using guide RNA 5. 
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Guide RNAs 2 and 5 were utilized to construct two homozygous NAT1 knockout MDA-MB-231 
cell lines and a heterozygous NAT1 knockout MDA-MB-231 cell line. 
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The Transgenomic Inc. (Omaha, NE) SURVEYOR Mutation Detection Kit was used to determine 
the effectiveness of each gRNA’s ability to cut the genomic DNA and induce DNA strand breaks 
effectively. gRNAs #2 and #5 were the most effective at inducing DNA strand breaks, and were 
chosen to separately knockout the function of NAT1 in the following studies.  
The Scrambled MDA-MB-231 cell line was transfected with either #2 or #5 gRNA/Cas9 
vectors as described above. Forty-eight hours after transfection cells were sorted for GFP 
fluorescence. The fluorescent positive cells were collected and plated at very dilute cell 
concentrations so that individual clones could be isolated. Once individual cells had grown into 
large enough colonies (several weeks), cloning cylinders were utilized to isolate those colonies 
using trypsin to release them from the plate and transferred to a 96-well culture plate. Clones 
were passaged until there were enough cells to plate in a 10 cm dish. Cells were then tested for 
NAT1 activity as previously described117. Activity assays showed NAT1 activity was not 
detectable (knocked out) in a low number of clones and these clones were selected for further 
characterization. Clones with no detectable NAT1 activity were further screened by sequencing 
the NAT1 open reading frame (ORF). We were specifically interested in clones that had 
deleted/inserted nucleotides in the NAT1 ORF that resulted in frame-shift mutations and thus 
premature protein termination signals resulting in predicted nonfunctional NAT1. Individual 
knockout cell lines representing the knockout of NAT1 activity for gRNA #2 or #5 were chosen 
based on NAT1 enzymatic activity and genomic sequence.  
Sequencing of the NAT1 Gene in the CRISPR/Cas9 Constructed Cell Lines 
Genomic DNA was isolated from the MDA-MB-231 CRISPR/Cas9 constructed cell lines. 
The NAT1 open reading frame was TOPO cloned using pcDNA™ 3.1/V5-His TOPO® TA 
Expression Kit (Invitrogen, California, USA) following manufacturer's recommendations. The 
TOPO Cloning reaction for each cell line was transformed into One Shot TOP10 Chemically 
Competent E. coli. Five transformed E. coli colonies for each cell line were selected and grown 
overnight. Cultures of bacteria were then harvested for plasmid purification. Purified plasmids and 
primers were sent for DNA sequencing (Eurofins, Louisville, KY, USA). Sequence data was 
analyzed and aligned with SeqMan Pro™ (Version 12.0, DNASTAR, Madison, WI.) 
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Characterization of CRISPR/Cas9 constructed cell lines are described in detail 
elsewhere115. Briefly, the CRISPR 2-19 and CRISPR 5-50 cell lines had no detectable NAT1 
activity while NAT1 N-acetylation activity in the CRISPR 2-12 cell line was decreased 
approximately 50% compared to the parent MDA-MB-231 and Scrambled cell lines. Endogenous 
acetyl-CoA was increased approximately 2-fold in both NAT1 knockout cell lines compared to the 
parent MDA-MB-231 cell line. Doubling times, relative invasive ability, and anchorage-dependent 
colony formation did not significantly vary between two NAT1 knockout cell lines and the parent 
MDA-MB-231 cell line. Notably, NAT1 knockout cell lines formed less anchorage-independent 
colonies compared to the parent MDA-MB-231 cell line115. 
Summary and Importance 
Colleagues, Mark Doll and Dr. Marcus Stepp, have constructed six MDA-MB-231 cell 
lines via two different methodologies that express parental, increased, decreased, and no 
detectable (limit of detection = 0.05 nmoles acetylated PABA/min/mg) NAT1 N-acetylation activity 
(Figure 1.3). All cell lines have been confirmed by STR-profiling to be MDA-MB-231 breast cancer 
cells. NAT1 mRNA has also been quantitated in each cell line (Figure 1.4). The genetic 
modification of a single established breast cancer cell line that varies only NAT1 provides an 
excellent model for studying the possible role of NAT1 in breast cancer metabolism. While breast 
cancer cell lines that endogenously express varying levels of NAT1 could have been selected, 
that would also complicate the analysis of results due to the multiple unique mutations each cell 
line would have. The approach utilized in this dissertation ensures each cell line has the same 
genetic background and only varies in NAT1 allowing a more straightforward comparison 
between cell lines. 
Cancer Metabolism 
Cancer as a disease can be concisely described as a dysregulation of normal cellular 
functions leading to increased and uncontrolled growth. Hanahan and Weinberg suggested in 
2000 that cancer could be summarized by six basic acquired capabilities or hallmarks: 1. evading 





Figure 1.3: NAT1 N-Acetylation Activity of the Parent and Genetically Modified MDA-MB-
231 Cell Lines. 
NAT1 N-acetylation activity was measured in the 6 cell lines included in this study. The Parent 
and Scrambled cell lines express approximately the same level of NAT1 N-acetylation activity 
while NAT1 N-acetylation activity in the Down and CRISPR 2-12 cell lines is decreased by 
approximately 50%. NAT1 N-acetylation activity in the Up cell line is increased by approximately 




































































Figure 1.4: NAT1 mRNA of the Parent and Genetically Modified MDA-MB-231 Cell Lines 
Relative to Parent. 
NAT1 mRNA was quantitated in the 6 cell lines included in this study. The Parent and Scrambled 
cell lines express approximately the same level of NAT1 mRNA while NAT1 mRNA in the Down 
CRISPR 2-12, and CRISPR 2-19 cell lines is decreased by approximately 50%. NAT1 mRNA in 
the Up cell line is increased by approximately 400%. The CRISPR 5-50 cell line had very low 








































invasion and metastasis, 5. limitless replicative potential, and 6. sustained angiogenesis118. A 
decade later Hanahan and Weinberg updated the hallmarks of cancer to add two new emerging 
hallmarks: 1. deregulating cellular energetics and 2. avoiding immune destruction119. Based on 
these hallmarks of cancer, the dysregulation of metabolism and energetics plays a crucial role in 
cancer risk and progression by enabling uncontrolled cell growth. A better understanding of the 
role NAT1 has in metabolism and cellular energetics could help lead to a better understanding of 
the connection between NAT1 and breast cancer. Given that NAT1 can catalyze the hydrolysis of 
acetyl-CoA, a central biochemical in metabolism and cellular energetics120-122, different levels of 
NAT1 are hypothesized to lead to observable differences in mitochondrial function, metabolites, 
and transcripts. Acetyl-CoA has a central role in fatty acid synthesis and degradation, ketone 
body and isoprenoid synthesis, and feeds into the citric acid cycle. 
Systems Biology Approach 
There are three concepts, 1. emergence, 2. robustness, and 3. modularity, that are 
necessary for understanding complex biological systems123. The first concept, emergence, states 
that complex systems display properties as a whole that cannot otherwise be predicted by 
studying individual parts. The second concept, robustness, states there are many diverse 
mechanisms in place for biological systems to maintain phenotypic stability when presented with 
perturbations whether through the environment, stochastic events or genetic variation. The final 
concept, modularity, states complex systems are divided into specialized modules allowing 
damage to be confined as well as robustness. In many studies of cancer and/or metabolism a 
reductionist approach, rather than a systems biology approach, is taken because studies of 
cancer biology and cellular metabolism are complex and can be difficult to interpret especially in 
multidimensional biological systems; however, a systems biology approach provides many 
advantages. Publications of systems biology studies has grown exponentially over the last 15 
years (by count of PubMed keyword “systems biology” search by year) as technologies and 
methods have developed and grown to allow complex global measurements (Figure 1.5). The 
first advantage of a systems biology approach is that there is less of a reliance on what is 





Figure 1.5: Systems Biology Publications by Year.  
Systems biology publications have grown exponentially over the last 15 years. The first 
publication on “systems biology” was in 1988. Publication count by year with keyword “systems 
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unknown cellular reactions or metabolic functions. A second advantage of a systems biology 
approach is that when combined with omics technologies, valuable data on the flow of information 
in biological systems can be discerned by studying the interactions between different components 
of the system124. A systems biology approach was therefore utilized in an attempt to decipher the 
role of NAT1 in breast cancer cell metabolism. The systems biology approach utilized in this 
dissertation was three pronged, integrating bioenergetics, metabolomics, and transcriptomics with 
an added genomics dimension (by using the newly constructed MDA-MB-231 cell lines that vary 
only in NAT1) to gain a global view of the role of NAT1 in metabolism and cellular energetics 
(Figure 1.6).  
Combining Datasets 
A comprehensive understanding of a specific biological system cannot be accurately 
predicted by that system’s individual parts, even with full understanding of the parts alone124. 
Combining information from bioenergetics, metabolomics, and transcriptomics experiments 
allows a holistic systems biology view of metabolism in samples that vary only in NAT1. 
Integrating all three datasets allows maximization of observations of the system at different points 
of regulation and varying complexities. Utilizing a systems biology approach has many 
advantages: 1. confidence in conclusions in increased because of the overlap in data at multiple 
levels of regulation and 2. combining multiple omics techniques can help overcome the limitations 
of a specific omics technique. One potential limitation of these studies is the complexity of 
metabolism; metabolism is very highly regulated but many of the regulation mechanisms are 
either poorly understood or undefined.  
Dissertation Aims 
 Given human NAT1 both hydrolyzes acetyl-CoA and utilizes acetyl-CoA as a cofactor in 
metabolic reactions, increased and decreased levels of NAT1 are hypothesized to contribute to 
reprogramming of cellular metabolism by altering the levels of free acetyl-CoA. Increased NAT1 
activity would lead to increased hydrolysis of acetyl-CoA and/or increased use of acetyl-CoA for 
acetylation, therefore less free acetyl-CoA would be available. Conversely, decreased NAT1 





Figure 1.6: Systems Biology Approach. 
The work presented in this dissertation utilizes a systems biology approach with four layers. The 
first layer consists of the six genetically modified MDA-MB-231 cell lines whose only genetic 
difference (theoretically) is in NAT1. The second, third, and fourth layers are bioenergetics, 
metabolomics, and transcriptomics measurements of the constructed cell lines and represent 
Specific Aim 1, Specific Aim 2. and Specific Aim 3, respectively. Progressing from the genome to 
the transcriptome to the proteome to the metabolome, regulatory mechanisms as well as 
complexity increase.
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acetylation, therefore more free acetyl-CoA would be available (Figure 1.7). As discussed above, 
acetyl-CoA is involved in many cellular pathways, such as fatty acid synthesis and the citric acid 
cycle (TCA), which produce important membrane lipids and substrates for cellular energy 
metabolism125. Cancer cells characteristically exhibit rapid, uncontrolled growth therefore 
requiring increased levels of energy and cellular components when compared to normal cells. 
Although, the exact mechanism by which cellular metabolism is reprogrammed remains unclear, 
it is likely specific to each cancer and is also influenced by a combination of factors. Varying 
levels of NAT1 N-acetylation activity in the MDA-MB-231 breast cancer cell line are predicted to 
lead to measurable changes in bioenergetics, metabolite abundances, and transcripts. The 
overall goal of this dissertation is to evaluate the effect of varying levels of NAT1 on breast cancer 
cell metabolism via a systems biology approach. The Specific Aims of this project are: 
Aim 1: To identify bioenergetic changes induced by altering the levels of human NAT1 
through mitochondrial stress test profiling using the Seahorse XF24 Bioanalyzer. 
Varying levels of NAT1 are expected to lead to differences in mitochondrial energetics 
since acetyl-CoA is central to energy metabolism.  
Aim 2: To identify metabolic changes induced by altering the levels of human NAT1 
through a comprehensive untargeted metabolomics approach. 
Differing levels of acetyl-CoA are predicted to lead to differences in the abundances of 
metabolites found in the fatty acid synthesis and amino acid degradation pathways. We 
additionally predict the abundance of total fatty acids and energy metabolism intermediate 
subclasses of metabolites will be altered when compared to samples of cells with ‘parental’ levels 
of NAT1 activity. 
Aim 3: To identify differential changes in gene expression induced by altering the levels 
of human NAT1 through a RNA-seq analysis of the transcriptome. 
The expression profile of genes involved in acetyl-CoA containing pathways are expected 
to be differentially expressed. Given metabolism is highly regulated we expect altered acetyl-CoA 





Figure 1.7: Dissertation Hypothesis. 
The overall hypothesis and rationale for this dissertation is that cell lines with decreased levels or 
knockout NAT1 will have increased free acetyl-CoA since those cell lines have less NAT1 to 
hydrolyze acetyl-CoA; Conversely, the cell line with increased NAT1 will have decreased free 
acetyl-CoA since that cell line has more NAT1 to hydrolyze acetyl-CoA. These differences in free 
acetyl-CoA are hypothesized to lead to alterations in cellular pathways/metabolism when 
compared to the cell line with basal NAT1 that can be measured by global bioenergetics, 
metabolomics, and transcriptomics experiments.
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data collected in this aim will build upon the data generated in Specific Aim 2 by collecting 
complementary transcriptomics data from the same biological samples. Differences in the 
expression of genes involved in fatty acid and membrane lipid synthesis are expected because 
cancer cells have an increased demand for these cellular building blocks.  
Significance 
This study is the first to investigate the effect of varying human NAT1 activity on the 
bioenergetics profile, metabolome, and transcriptome of a breast cancer cell line. Methods for the 
evaluation of the bioenergetic profile of living cells in real-time have recently been developed to 
identify fluxes in energy pathways and have yet to be utilized when studying the effect varying 
levels of NAT1 have on breast cancer cells. The omics disciplines have developed into an 
extremely beneficial and information-rich area of research but have been under-utilized in 
research on human NAT1. Analysis of metabolomics and transcriptomics data can help reveal 
what pathways are altered as a result of varying levels of NAT1 activity thus providing insights 
about NAT1’s effect on cellular metabolism and into the role of NAT1 in breast cancer disease 
and progression. A greater understanding of the role of NAT1 in breast cancer could lead to 




NAT EXPRESSION IN ESTABLISHED BREAST CANCER CELL LINES & BREAST TISSUES 
 
Background 
Based on limited data, it has been hypothesized that NAT2 expression is very low in 
breast tissue and negligible in comparison to NAT1 expression. However, a more comprehensive 
evaluation of NAT1 and NAT2 co-expression in breast tissues and established breast cancer cell 
lines is needed. Additionally, while many studies have reported an association between NAT1 
and ESR1 expression85-91, NAT2 and ESR1 association has not been evaluated even though 
NAT1 and NAT2 are isozymes that have overlapping substrate specificities and very similar 
protein structure. There are many publicly available data repositories of cancer samples that offer 
a wealth of gene expression data. These data repositories have been under-utilized in NAT 
research.  
Materials and Methods 
Acquisition of publicly available data from the Cancer Cell Line Encyclopedia (CCLE) and 
TCGA data repositories 
RNA expression (RNA-Seq) data for ESR1, NAT1 and NAT2 in established breast cancer 
cell lines were accessed on 8/11/17 (n=57) from the CCLE126; RNA expression values were 
reported in Reads Per Kilobase of transcript per Million mapped reads (RPKM). A total of 15 
breast cancer cell lines had no detectable NAT2 gene expression. Data from TCGA127 for the 
breast invasive carcinoma (BRCA) cohort were accessed on 2/4/18 (primary breast tumor tissue, 
n=1,043; normal breast tissue, n=99) via FirebrowseR128, an R client to the Broad Institute’s 
RESTful Firehose Pipeline; RNA expression values were reported in RNA-Seq by Expectation-
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Maximization (RSEM). A total of 59 of the breast tumor samples and seven of the normal tissue 
samples did not have gene expression data for NAT2. 
Established breast cancer cell lines analyzed 
The following breast cancer cell lines were analyzed in this study: AU565, BT-20, BT-
474, BT-483, BT-549, CAL-120, CAL-148, CAL-51, CAL-85-1, CAMA-1, DU4475, EFM-19, EFM-
192A, HCC1143, HCC1187, HCC1395, HCC1419, HCC1428, HCC1500, HCC1569, HCC1599, 
HCC1806, HCC1937, HCC1954, HCC202, HCC2157, HCC2218, HCC38, HCC70, HDQ-P1, 
HMC-1-8, HMEL, Hs 274.T, Hs 281.T, Hs 343.T, Hs 578.T, Hs 606.T, Hs 739.T, Hs 742.T, JIMT-
1, KPL-1, MCF-7, MDA-MB-134-VI, MDA-MB-157, MDA-MB-175-VII, MDA-MB-231, MDA-MB-
361, MDA-MB-415, MDA-MB-436, MDA-MB-453, MDA-MB-468, SK-BR-3, T-47D, UACC-812, 
UACC-893, ZR-75-1 and ZR-75-30. 
Statistical analyses 
Shapiro-Wilk tests were conducted to determine if the expression of the genes under 
study were approximately normally distributed. Significant evidence of departures from 
approximate normality was observed; therefore, non-parametric statistical techniques were 
employed for subsequent analyses. Spearman’s correlation was used to evaluate the RNA 
expression levels between gene pairs (i.e. ESR1 and NAT1, ESR1 and NAT2, NAT1 and NAT2). 
Differences in the mRNA expression levels of NAT1 and NAT2 in each dataset, and differences in 
RNA expression between primary breast tumor samples and normal breast tissue samples, were 
evaluated using the Wilcoxon Rank-Sum test; median values were compared to determine fold-
differences.  
RNA expression data for each gene were stratified by ER status (+ or -) as defined in the 
literature129-131 for the CCLE data, or as determined by immunohistochemistry during sample 
collection and cataloging for TCGA data. Differences in gene expression following stratification 
were evaluated using Wilcoxon Rank-Sum tests for each gene; median values were compared to 
determine fold-differences. A total of 10 of the breast cancer cell lines had either conflicting or 
unknown ER status in the literature.  
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Wakefield et al published the NAT1 PABA N-acetylation activities of seven (ZR-75-1, 
T47D, MCF-7, MDA-MB-453, MDA-MB-436, MDA-MB-231 and CAL-51) of the 57 breast cancer 
cell lines included in the present study88. The association between previously reported NAT1 
activity and NAT1 RNA expression data for the same cell lines in the CCLE repository was 
evaluated. All statistical analyses were performed in R: A Language and Environment for 
Statistical Computing, version 3.4.2132. 
Results 
Association between NAT1 & ESR1, NAT2 & ESR1, and NAT1 & NAT2 
NAT1 RNA and ESR1 RNA were significantly correlated (P<0.0001 for all) at moderately 
high magnitudes in breast cancer cell lines (Spearman rho r=0.59; Figure 2.1A and B), human 
primary breast tumors (r=0.59; Figure 2.1C and D) and normal breast tissue (r=0.57; Figure 2.1E 
and F). A significant (p<0.005 for all) association between ESR1 and NAT2 expression was 
observed, although the magnitude of the association was low and varied across datasets. The 
primary breast tumor dataset exhibited the weakest association (r=0.16; Figure 2.1C and D), 
whereas the normal breast tissue (r=0.38; Figure 2.1E and F) and breast cancer cell line (r=0.39; 
Figure 2.1A and B) datasets exhibited similar, albeit low, association. Strong evidence of an 
association (p<0.0001 for all) between NAT1 RNA and NAT2 RNA levels was observed in all 
three datasets, with moderately high magnitude in the breast cancer cell lines (r=0.64; Figure 
2.1A and B). The primary breast tumor and normal breast tissue datasets exhibited 
interdependence similar to each other (r=0.43 and 0.46, respectively; Figures 2.1C-F); however, 
the association was lower than that observed in the breast cancer cell lines.  
Comparison of NAT1 & NAT2 expression 
NAT1 RNA expression in breast cancer cell lines, primary breast tumors, and normal 
breast tissue was significantly higher compared with NAT2 expression by 33-, 222- and 52-fold, 
respectively (p<0.0001 for all; Figure 2.2A-C). NAT1 expression was higher than NAT2 
expression in all 57 breast cancer cell lines tested, with the exception of the UACC-893 cell line, 
which expressed the highest NAT2 RNA of any of the breast cancer cell lines analyzed. A total of 












Figure 2.1: Scatterplot and correlation matrices for NAT1, NAT2, and ESR1.  
Associations between NAT1, NAT2, and ESR1 RNA expression were analyzed in breast cancer cell lines, primary breast tumor tissue, and normal 
breast tissue using the Spearman method. In the scatterplot matrices, each open circle represents a single sample and is color-coded according to 
ER status; pink circles, ER− samples; blue circles, ER+ samples; black circles, samples with unknown ER status. In the association matrices, 
boxes are labeled with the Spearman correlation coefficient (ρ) for each comparison and color reflects strength of association; dark blue 
represents high association, light blue represents low association, and white represents no association. (A) Scatterplot matrix of the association 
between NAT1, NAT2 and ESR1 RNA expression in breast cancer cell lines (n=57). (B) Correlation matrix between NAT1, NAT2 and ESR1 RNA 
expression in breast cancer cell lines (n=57). (C) Scatterplot matrix of the association between NAT1, NAT2 and ESR1 RNA expression in primary 
breast tumor samples (n=1,043 for NAT1 vs. ESR1, n=984 for NAT1 vs. NAT2 and NAT2 vs. ESR1). (D) Correlation matrix between NAT1, NAT2, 
and ESR1 RNA expression in primary breast tumor samples (n=1,043 for NAT1 vs. ESR1, n=984 for NAT1 vs. NAT2 and NAT2 vs. ESR1). (E) 
Scatterplot matrix of the association between NAT1, NAT2 and ESR1 RNA expression in normal breast tissue samples (n=99 for NAT1 vs. ESR1, 
n=92 for NAT1 vs. NAT2 and NAT2 vs. ESR1). (F) Correlation matrix between NAT1, NAT2 and ESR1 RNA expression in normal breast tissue 
samples (n=99 for NAT1 vs. ESR1, n=92 for NAT1 vs. NAT2 and NAT2 vs. ESR1). ER, estrogen receptor; ESR1, estrogen receptor 1; NAT1, 

















Figure 2.2: NAT1 and NAT2 RNA expression in breast cancer cell lines, primary breast tumor samples, and normal breast tissue 
samples.  
Differences in gene expression between NAT1 and NAT2 in breast cancer cell lines, primary breast tumor tissue and normal breast tissue were 
statistically evaluated by Wilcoxon rank-sum test; ***p<0.001. Each dot represents a single sample and is color-coded according to ER status; pink 
dots, ER− samples; blue dots, ER+ samples; black dots, samples with unknown ER status. In the boxplots, the solid black line represents the 
median, the upper hinge represents the 75th quartile and the lower hinge represents the 25th quartile. The upper whisker represents the largest 
observation less than or equal to the upper hinge + 1.5 x IQR, the lower whisker represents the smallest observation greater than or equal to the 
lower hinge - 1.5 x IQR. (A) NAT1 RNA expression was significantly higher than NAT2 RNA expression in the breast cancer cell lines. (B) NAT1 
RNA expression was significantly higher than NAT2 RNA expression in the primary breast tumor samples. (C) NAT1 RNA expression was 
significantly higher than NAT2 RNA expression in the normal breast tissue samples. ER, estrogen receptor; IQR, interquartile range; NAT1, 
arylamine N-acetyltransferase 1; NAT2, arylamine N-acetyltransferase 2; RPKM, reads per kilobase of transcript per million mapped reads; 
RSEM, RNA-Seq by Expectation-Maximization. 
 
  30 
281.T, KPL-1, Hs 606.T, HCC70, EFM-19, CAL-148, HCC1569, HMC-1-8, HCC1599 and 
HCC1395) had no reported NAT2 RNA expression, whereas all 57 reported NAT1 RNA 
expression. The KPL-1 breast cancer cell line has been reported to be contaminated/misidentified 
and to be an MCF-7 derivative133. 
In TCGA dataset, normal breast tissue samples were collected from patients in which 
primary breast tumor samples were also collected (but only for 99 individuals), allowing 
comparison of gene expression between normal breast tissue and primary tumor breast tissue 
within single individuals. In the primary breast tumor samples, only nine of the 984 samples had 
higher NAT2 RNA expression than NAT1; of those nine samples, two were ER+ and seven were 
ER–, and only one sample had a corresponding normal breast tissue sample. Notably, in that 
individual’s normal breast tissue sample, NAT2 RNA expression was not higher than NAT1 RNA 
expression. In the normal breast tissue samples, only one of the 92 samples had higher NAT2 
RNA expression than NAT1; the corresponding primary breast tumor sample from the same 
patient had lower NAT2 than NAT1.  
Comparison of gene expression between ER+ and ER- samples 
ESR1 and NAT1 gene expression were significantly increased, 86- and 2.6-fold, 
respectively, in ER+ breast cancer cell lines (p<0.0001 for both; Figure 2.3A), whereas NAT2 
gene expression did not significantly vary between ER+ and ER- breast cancer cell lines (p>0.05; 
Figure 2.3A). Of the breast cancer cell lines with ER status defined in the literature129-131, a 
connection between ESR1 RNA expression and the reported ER status was observed. In the 
dataset, it was observed that samples with ESR1 RNA expression <1.7 RPKM were defined as 
ER- in the literature, whereas samples with ESR1 expression >2.3 RPKM were defined as ER+ in 
the literature. The expression levels of all three genes were significantly higher in ER+ primary 
breast tumor samples (p<0.0001 for all; Figure 2.3B); however. the fold-change between NAT2 
expression in ER+ and ER- samples was smaller (1.8-fold difference) than for NAT1 and ESR1. 
In comparison, ESR1 and NAT1 were ~108- and 27-fold higher, respectively. The expression 
levels of genes were not significantly different between ER+ and ER- normal breast tissue  
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Figure 2.3: ESR1, NAT1 and NAT2 RNA expression in breast cancer cell lines, primary 
breast tumor samples, and normal breast tissue stratified by ER status.  
Differences in the expression levels of ESR1, NAT1 and NAT2 genes in breast cancer cell lines, 
primary breast tumor tissue, and normal breast tissue stratified by ER status were evaluated by 
Wilcoxon rank-sum test; ***p<0.001; NS, not significant. Boxplots are color-coded according to ER 
status; pink boxplots, ER− samples; blue boxplots, ER+ samples. In the boxplots, the solid black 
line represents the median, the upper hinge represents the 75th quartile and the lower hinge 
represents the 25th quartile. The upper whisker represents the largest observation less than or 
equal to the upper hinge + 1.5 x IQR, the lower whisker represents the smallest observation 
greater than or equal to the lower hinge - 1.5 x IQR. (A) ESR1 and NAT1 RNA expression were 
significantly higher in ER+ breast cancer cell lines compared with ER− breast cancer cell lines. 
NAT2 RNA expression was not significantly different in ER+ breast cancer cell lines compared 
with ER− breast cancer cell lines. A total of 10 cell lines had either conflicting reports or no 
available data for ER status in the literature and were excluded from the analysis. (B) ESR1, 
NAT1 and NAT2 RNA expression were significantly higher in ER+ samples compared with ER− 
samples in the primary breast tumor dataset. (C) ESR1, NAT1 and NAT2 RNA expression levels 
were not significantly different in ER+ samples compared with ER− samples in the normal breast 
tissue dataset. ER, estrogen receptor; IQR, interquartile range; ESR1, estrogen receptor 1; 
NAT1, arylamine N-acetyltransferase 1; NAT2, arylamine N-acetyltransferase 2; RPKM, reads 
per kilobase of transcript per million mapped reads; RSEM, RNA-Seq by Expectation-
Maximization. 
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samples (p>0.05 for all; Figure 2.3C). Most of the breast cancer cell lines were ER-, whereas 
most of the primary breast tumor and normal breast tissue samples were ER+.  
Comparison of NAT1, NAT2, and ESR1 gene expression between normal breast tissue 
and primary breast tumors 
Differences in gene expression between normal breast tissue and primary breast tumor tissue 
were evaluated for each gene, ESR1, NAT1, and NAT2. More spread was observed in the 
primary breast tumor samples compared with the normal breast tissue samples for each gene. 
ESR1 and NAT1 gene expression were significantly elevated 2.5- and 5.9-fold, respectively, in 
primary breast tumor samples compared with normal breast tissue samples (p<0.0001 for both; 
Figure 2.4). NAT2 expression was also significantly higher in primary breast tumor samples 
compared with normal breast tissue samples, but at a lower significance and fold-change (1.4-
fold) than ESR1 and NAT1 (p<0.05; Figure 2.4) 
Relationship between previously reported NAT1 N-acetylation activity and NAT1 RNA expression.  
NAT1 N-acetylation activity previously reported in the literature and NAT1 RNA 
expression in seven of the 57 breast cancer cell lines were significantly associated (p<0.05) with 
a high magnitude (r=0.89; Figure 2.5).  
Co-expression of NAT1 and NAT2 RNA expression in established breast cancer cell lines 
Co-expression profiles of NAT1 and NAT2 RNA for each established breast cancer cell 
line included in this study are presented in Figure 2.6. Of all the cell lines included in the present 
study, the UACC-893 cell line expressed the highest level of NAT2 RNA, whereas the HCC1500 
cell line expressed the highest level of NAT1 RNA. The ZR-75-1 cell line expressed high levels of 
both NAT1 and NAT2 RNA, whereas the HCC1395 cell line expressed low levels of both. 
Discussion 
The present study analyzed established breast cancer cell lines and samples from 
patients with breast cancer to evaluate the extent to which breast cancer cell lines serve as 
appropriate models for NAT1, NAT2 and ESR1 expression in breast tumors. Overall, the present 
findings demonstrated a strong association between NAT1 and ESR1 expression, which is in 
agreement with previous reports that NAT1 and ESR1 are positively associated85-91, and this 
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Figure 2.4 
 
Figure 2.4: Comparison of ESR1, NAT1 and NAT2 RNA expression in normal breast tissue 
and primary breast tumor samples.  
Differences in gene expression of ESR1, NAT1 and NAT2 in normal breast tissue and primary 
breast tumor tissue were evaluated by Wilcoxon rank-sum test; ***p<0.001; *p<0.05. Boxplots are 
color-coded according to tissue type; green boxplots, normal breast tissue samples; blue 
boxplots, primary breast tumor samples. In the boxplots, the solid black line represents the 
median, the upper hinge represents the 75th quartile and the lower hinge represents the 25th 
quartile. The upper whisker represents the largest observation less than or equal to the upper 
hinge + 1.5 x IQR, the lower whisker represents the smallest observation greater than or equal to 
the lower hinge - 1.5 * IQR. For all genes, more spread was observed in data from the primary 
breast tumor samples compared with the normal breast tissue samples. ESR1 and NAT1 gene 
expression were significantly elevated in primary tumor tissue compared with normal breast 
tissue. NAT2 expression was also significantly higher in primary tumor tissue compared with 
normal breast tissue, but at a lower significance than ESR1 and NAT1. IQR, interquartile range; 
ESR1, estrogen receptor 1; NAT1, arylamine N-acetyltransferase 1; NAT2, arylamine N-
acetyltransferase 2; RSEM, RNA-Seq by Expectation-Maximization.
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Figure 2.5 
 
Figure 2.5 Association between NAT1 RNA expression and previously reported NAT1 N-
acetylation activity in seven established breast cancer cell lines.  
NAT1 RNA expression from Cancer Cell Line Encyclopedia and previously reported NAT1 N-
acetylation activity88 in seven breast cancer cell lines were significantly associated (p<0.05; 
ρ=0.89). Dots represent a single cell line and are color-coded according to ER status: Pink dots, 
ER− samples; blue dots, ER+ samples. ER, estrogen receptor; NAT1, arylamine N-
acetyltransferase 1; NAT2, arylamine N-acetyltransferase 2; PABA, p-aminobenzoic acid; RPKM, 











Figure 2.6: NAT1 and NAT2 association in breast cancer cell lines.  
Association between NAT1 and NAT2 RNA expression was analyzed in breast cancer cell lines (each labeled in this figure). Each dot represents a 
single breast cancer cell line and is color-coded according to ER status; pink dots, ER− samples; blue dots, ER+ samples; black dots, samples 
with unknown or conflicting ER status in the literature. NAT1 and NAT2 RNA expression was significantly associated in breast cancer cell lines 
(p<0.0001, ρ= 0.64).
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association was observed in all three sample types at approximately the same magnitude. These 
findings suggested that breast cancer cell lines may accurately reflect this relationship and 
provide a useful model for further research into the relationship. It is well known that ESR1 
expression is frequently altered in breast cancer; therefore, the decrease in association between 
NAT2 and ESR1 in primary breast tumors compared with in normal breast tissue samples and 
established breast cancer cell lines may be due to more dysregulation of ESR1 than NAT2 in 
primary breast tumors. The results of an analysis between NAT2 and ESR1 expression 
suggested that, while NAT2 and ESR1 are associated, the magnitude is low.  
Interdependence between NAT1 and NAT2 expression was moderately high in the breast 
cancer cell line dataset, but substantially lower in the primary breast tumor and normal breast 
tissue datasets. Additionally, the strength of the association between NAT1 and NAT2 in the 
breast cancer cell line dataset was similar to the strength of the association observed between 
NAT1 and ESR1 in that dataset; however, in the primary breast tumor and normal breast tissue 
datasets, the association between NAT1 and NAT2 was lower. These findings suggested that 
breast cancer cell lines may over-represent the interdependence between NAT1 and NAT2, and 
not fully replicate the relationship observed in primary breast tumors or normal breast tissue.  
In the breast cancer cell line data there appears to be a cut-off (between 1.7 and 2.3 RPKM) 
linking ESR1 RNA expression and the reported ER status of the breast cancer cell lines. This 
may provide a method to predict the ER status of breast cancer cell lines that currently have 
conflicting or unknown ER status in the literature. Using that method, it may be predicted that the 
HCC1500 and HCC1419 cell lines are ER+, whereas the HMC-1-8, Hs 742.T, Hs 343.T, Hs 
739.T, HMEL, Hs 274.T, Hs 281.T and Hs 606.T cell lines are ER-. Notably, although 67-82% of 
breast cancers are ER+134 and most of the primary breast tumor samples were ER+, the majority 
of established breast cancer cell lines are ER-.  
NAT1 and NAT2 RNA expression were reported in almost all samples included in the 
present study, which concurs with published results that have detected NAT1 and NAT2 mRNA 
by RT-PCR in human mammary tissue in smaller cohorts13,14,96. NAT1 RNA expression was 
significantly higher than NAT2 RNA expression in the breast cancer cell lines, primary breast 
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tumor samples and normal breast tissue. In addition, with only a few exceptions, NAT1 RNA 
expression was always higher than NAT2 RNA expression in matched samples from the breast 
cancer cell line, primary breast tumor sample and normal breast tissue sample datasets, thus 
supporting previous findings that indicated NAT1 transcripts were 2- to 3-fold higher than NAT2 
transcripts in human mammary tissues135. The UACC-893 cell line, the only breast cancer cell 
line observed in this study to express higher NAT2 RNA than NAT1 RNA, is an ER- and 
progesterone receptor-negative cell line that has a ~20-fold amplification of the human epidermal 
growth factor receptor 2/neu oncogene sequence. Further study of this cell line may aid in the 
identification of additional regulatory mechanisms of NAT1 and/or NAT2, since it expresses a 
unique profile of NAT1 and NAT2 compared with the other breast cancer cell lines. 
While NAT1 expression was reported in all 57 breast cancer cell lines in the present 
study, 15 of those breast cancer cell lines had no reported NAT2 RNA expression (Figure 2.6). 
The cell lines with no detected NAT2 RNA are plotted at ~-6.6 log2 RPKM NAT2. One of those 15 
cell lines, MCF-7, has been reported to express NAT2 RNA96,136 albeit at very low levels. One 
reason for the difference in observation between this study and the previous studies may be that 
the detection threshold for NAT2 was higher when measured by RNA-Seq for the CCLE dataset 
than in the previous studies. Additionally, in the previous studies that detected NAT2 RNA in the 
MCF-7 breast cancer cell line, NAT1 RNA was not measured at the same time; therefore, direct 
comparisons of the NAT isozymes was not possible. To the best of our knowledge, NAT2 RNA 
expression has not been investigated in any of the other 56 breast cancer cell lines until this 
study. The results of this study indicated that NAT2 may be expressed in breast tissues and 
expression should be considered when studying NAT1, due to their overlapping substrate 
specificities and the high degree of structural similarity. 
In normal breast tissue samples no significant difference in gene expression for ESR1, 
NAT1 and NAT2 was observed when data were stratified by ER status. However, in the primary 
breast tumor samples and in the breast cancer cell lines, ESR1 and NAT1 exhibited increased 
expression in the ER+ samples compared with in the ER- samples. NAT2 RNA expression did 
not significantly vary in breast cancer cell lines when comparing ER+ and ER- samples, but was 
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significantly increased in ER+ primary breast tumor samples compared with ER- primary breast 
tumor samples, although the difference was small. This finding suggested that the dysregulation 
of NAT1 and ESR1 during tumorigenesis may share similar mechanisms; however, NAT2 does 
not. 
 ESR1, NAT1 and NAT2 RNA expression were each increased in primary breast tumor 
samples compared with normal breast tissue samples although the significance and fold-change 
of NAT2 were smaller than that of ESR1 and NAT1. Additionally, for all genes, more widely 
spread expression was observed in the primary breast tumor samples compared with normal 
breast tissue. These data suggested that expression of all three genes may become modified 
during breast cancer tumorigenesis; however, the expression of NAT1 and ESR1 appear to be 
dysregulated to a greater extent. As recently reviewed95, the role of NAT2 in breast cancer 
etiology is considered to be due to its effects on carcinogen metabolism. The present study 
suggested that the role of NAT2 in breast cancer is less likely a product of cell transformation, as 
the expression levels of NAT2 between normal and tumor tissues exhibited smaller variance than 
the expression levels of NAT1 and ESR1.  
NAT1 N-acetylation activity has been reported in normal breast tissue and breast tumor 
tissue13,14,96-99, whereas NAT2 N-acetylation activity has not been observed as consistently; when 
NAT2 activity is observed, the activity is much lower than that of NAT1 activity13,97,98. Wakefield et 
al profiled NAT1 expression and activity in seven breast cancer cell lines (MCF-7, T47D, ZR-75-1, 
Cal51, MDA-MB-231, MDA-MB-437 and MDA-MB-453); NAT1 mRNA and activity was observed 
in all seven cell lines88; however, NAT2 mRNA and activity were not co-investigated. The high 
degree of association between the previously reported NAT1 N-acetylation activity and the NAT1 
RNA expression of the same seven breast cancer cell lines suggested that NAT1 RNA 
expression is highly reflective of NAT1 N-acetylation activity. mRNA expression is not always 
predictive of enzyme activity, due to the numerous regulatory mechanisms that can occur 
between RNA expression and protein function; however, these results suggested that RNA 
expression of NAT1 may serve as an appropriate predictor of NAT1 N-acetylation activity. Further 
studies with an increased number of breast cancer cell lines in which NAT1 N-acetylation activity 
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has been measured are required to confirm this hypothesis. Additionally, further studies are 
required to determine the association between NAT2 RNA expression and NAT2 N-acetylation 
activity. 
Summary and Conclusions 
 The CCLE and TCGA repositories offer a wealth of publicly available data. The present 
study utilized this data to analyze and annotate the previously undefined relationships between 
NAT1, NAT2 and ESR1 in breast cancer cell lines, primary breast tumors and normal breast 
tissue. The results demonstrated that NAT1 and NAT2 RNA were expressed in normal breast 
tissue and primary breast tumor tissue; however, NAT1 RNA expression was much higher than 
NAT2. The expression of NAT1 and NAT2 were found to be associated; however, the magnitude 
was lower than that observed between NAT1 and ESR1 in the primary breast tumors and normal 
breast tissue. Additionally, although the association between NAT1 and NAT2 was slightly 
exaggerated in the breast cancer cell line dataset, the cell lines generally reflected the NAT1 and 
NAT2 expression profiles of the primary breast tumors investigated. The present study 
demonstrated that while NAT1 and ESR1 expression were moderately associated in all datasets 
included in this study, NAT2 and ESR1 expression were associated at a lower magnitude, 
particularly in the primary breast tumor samples. 
 NAT1 and ESR1 expression were increased in primary breast tumor samples compared 
with normal breast tissue samples and were increased in ER+ primary breast tumors compared 
with ER- primary breast tumors. NAT2 expression was slightly increased in primary breast tumor 
samples compared with normal breast tissue samples and in ER+ primary breast tumors 
compared with ER- primary breast tumors. Although NAT1 and NAT2 are both implicated in 
breast cancer, the majority of previous breast cancer studies have investigated each isozyme 
individually. The present study suggested that both isozymes should be considered in each study, 
since both are expressed in breast tissues. Defining the association between NAT1, NAT2 and 
ESR1 is of great importance, as modification of NAT1 is currently being studied for breast cancer 
prevention81,82,137,138.  






Defects in mitochondrial metabolism have been linked to cancer (reviewed in 139) and are 
increasingly recognized as contributors, not only to the deregulation of cellular energetics, but 
also as contributors to tumorigenesis. Bioenergetics evaluation provides a method to investigate 
mitochondrial function in living cells140. By utilizing real-time profiling of the oxygen consumption 
rate (OCR) and extracellular acidification rate (ECAR) as well as sequential injection of 
compounds that inhibit specific portions of the electron transport chain, mitochondrial evaluation 
can be conducted141. Oxygen consumption rate is a proxy measurement for cellular respiration 
while extracellular acidification rate is a proxy measurement for glycolysis allowing us to probe 
mitochondrial energetics. One can measure and quantify multiple mitochondrial parameters such 
as basal OCR, ATP-linked OCR, proton leak, maximum mitochondrial capacity, and reserve 
capacity142. Although it is known that NAT1 can catalyze the hydrolysis of acetyl-CoA using folate 
as a cofactor, the implications of this NAT1-catalyzed reaction in cellular energetics remains to be 
investigated. Measuring bioenergetics in the MDA-MB-231 cell lines we have constructed to vary 
only in NAT1 activity allows evaluation of how varying levels of NAT1 impact mitochondrial 
function.  
Materials and methods 
The Seahorse XF24 Analyzer (Agilent Technologies, Santa Clara, CA) was utilized to 
interrogate differences in mitochondrial cellular metabolism via oxygen consumption rate (OCR) 
and extracellular acidification rate (ECAR) measurements of live cells. All cell lines were cultured 
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in high-glucose Dulbecco's Modified Eagle Medium (DMEM), with 10% fetal bovine serum, 5% 
glutamine, and 5% penicillin/streptomycin added.  
 Twenty-four hours prior to each bioenergetics experiment, 100 μL of cell suspension from 
each cell line was plated in quadruplicate in a 24-well Seahorse XF24 cell culture microplate at a 
density of 40,000 cells per well, thus giving four biological replicates for each cell line. 
Additionally, four wells contained medium only for background correction purposes. To minimize 
the edge effects of plating and to ensure a monolayer of cells was formed on the bottom of the 
well, microplates were left in the cell culture hood at room temperature for one hour before being 
placed in a 37°C, 5% CO2 incubator. After cells had adhered to the plate (three hours after 
placing in the incubator), 150 μL of medium was added to each well and cells were allowed to 
grow overnight. One hour prior to the experiment, medium was aspirated from each well and 
replaced with 675 μL Seahorse running medium. Seahorse running medium consisted of 8.3 
grams/liter of Dulbecco’s Modified Eagle’s Medium (DMEM) base without glucose, L-glutamine, 
phenol red, sodium pyruvate and sodium bicarbonate (Sigma, St. Louis, MO), and 1.85 g NaCl 
per liter, glucose added to a final concentration of 25 mM, sodium pyruvate added to a final 
concentration of 1 mM, and 10 mL/liter of 100 x Glutamax-1 added, all at pH 7.4. Microplates 
were then incubated for one hour in a non-CO2 37 °C incubator. The XF24 sensor cartridge was 
hydrated overnight in XF calibrant solution in a non- CO2 37 °C incubator.  
 Before each experiment, solutions of compounds to be loaded in the ports of the sensor 
cartridge were freshly made from stock solutions. Selected compounds inhibit specific portions of 
the mitochondrial electron transport chain to allow the elucidation of several different 
measurements of mitochondrial function141. Seventy-five microliters of 15 μM Oligomycin (ATP 
synthase inhibitor) was loaded into port A of the sensor cartridge, eighty-three microliters of 5 μM 
carbonyl cyanide-p-trifluoromethoxyphenylhydrazone (FCCP; mitochondrial inner membrane 
uncoupler) was loaded into port B of the sensor cartridge, and ninety-two microliters of 10 μM 
Antimycin A (complex III inhibitor) and 2 μM Rotenone (complex I inhibitor) was loaded into port C 
of the sensor cartridge. For background correction wells seahorse running media was loaded into 
each port in place of the compound solutions. The sensor cartridge was then loaded into the 
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Seahorse XF24 analyzer and calibrated. Once calibration of the sensor cartridge was complete, 
the microplate was loaded into the machine and the experiment was started. Timed sequential 
injections of Oligomycin, FCCP, and Antimycin A/Rotenone occurred at 35, 50, and 64 minutes, 
respectively. 
 Six independent experiments were conducted (Figure 3.1). Each experiment consisted of 
four biological replicates for each of the cell lines. Baseline OCR, Baseline ECAR, Baseline 
OCR/ECAR, ATP-Linked OCR, Reserve Capacity, Coupling Efficiency, Proton Leak, Glycolytic 
Reserve, Maximum Mitochondrial Capacity, and Non-Mitochondrial Respiration were calculated 
as described in Table 3.1 following each experiment141,143. Results from each independent 
experiment were summarized as mean ± SEM from four biological replicates on the microplate. 
Results from all six independent experiments were then compiled with final results represented as 
mean ± SEM. One-way ANOVA was conducted for each measurement to test for overall 
differences, followed by multiplicity adjusted post hoc tests on only those measurements that 
were found to be significant.  
MTT Cell Growth Assays 
MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide) assays were 
conducted in triplicate to determine if there were differences in cell viability between the cell lines 
given that the cells were allowed to grow in the plate for 24 hours prior to bioenergetics 
measurements. Cells were plated in the Seahorse XF24 plates following the same procedure that 
was used when plating cells for bioenergetics experiments. Instead of measuring the 
bioenergetics of the cells 24 hours after plating, media was removed from each well and cells 
were incubated with 250 μL of 5 mg/mL MTT dissolved in growth medium in a 37°C, 5% CO2 
incubator. After one hour, the media was aspirated and 250 μL of dimethyl sulfoxide (DMSO) was 
added to each well to solubilize the MTT. The microplate was gently rocked for 10 minutes and 
then the resulting solution in each well was transferred to a 96-well plate. Absorbance was 
measured at 570 nm using the Gen5 microplate reader (BioTek Instruments Inc., Winooski, VT). 
All absorbance values were within the linear range of MTT. Absorbance measurements were 
median-scaled by plate to minimize between-day variance. Scaled absorbance values were  





Figure 3.1: Bioenergetics Experimental Approach. 
Mitochondrial bioenergetics of five genetically modified MDA-MB-231 cell lines stably transformed 
to differ only in human arylamine N-acetyltransferase 1 (NAT1) were measured. The Parent and 
Scrambled cell lines express parental NAT1 activity, the Up cell line expresses increased NAT1 
activity, and the CRISPR 2-19 and CRISPR 5-50 cell lines express no detectable NAT1 activity 
(knockout). Bioenergetics were measured in six independent experiments with four biological 
replicates of each cell line in each experiment. 












Plate Cells 40,000 Cells/Well in 
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Table 3.1 
 
Definition of Measurement Calculations and ANOVA p-value Summary Statistics 
Measurement Calculation ANOVA p-value 
Baseline OCR* 
OCR after equilibration but before 
the injection of any compounds 
(mean of two measurements) 
0.055 
ATP-Linked OCR (Minimum OCR after Oligomycin injection) – (Baseline OCR) 0.052 
Reserve Capacity (Maximum Mitochondria Capacity) – (Baseline OCR). <0.0001 
Proton Leak 
(Minimum OCR after Oligomycin 
injection) – (Non-Mitochondrial 
Respiration) 
0.021 
Non-Mitochondrial Respiration Minimum OCR after Rotenone/Antimycin A injection 0.229 
Maximum Mitochondrial Capacity 
(Maximum OCR measurement 
after FCCP† injection) – (Non-
Mitochondrial Respiration) 
<0.0001 
Coupling Efficiency ATP-linked OCR/baseline OCR 0.368 
Baseline ECAR‡ 
ECAR after equilibration but 
before the injection of any 
compounds (mean of two 
measurements) 
<0.0001 
Glycolytic Reserve Capacity (Minimum ECAR after Oligomycin injection) – (Baseline ECAR) <0.0001 
Baseline OCR/ECAR (Baseline OCR)/(Baseline ECAR) 0.011 
*OCR = oxygen consumption rate 
†FCCP = carbonyl cyanide-p-trifluoromethoxyphenylhydrazone 
‡ECAR= extracellular acidification rate 
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tested for equivalence between cell lines. Equivalence was assessed using a two-one sided t-test 
(TOST) procedure that evaluated equivalence given a 20% margin.  
Results 
Although NAT1 is overexpressed in breast tumors91,144-147 and catalyzes the hydrolysis of 
acetyl-CoA, the impact of NAT1 inactivation or overexpression on cellular  bioenergetics has yet 
to be reported. We examined glucose oxidation and mitochondrial bioenergetics in MDA-MB-231 
triple negative breast cancer (TNBC) cells constructed to knockout or overexpress NAT1 and 
compared OCR and ECAR in these cells to the parental MDA-MB-231 cells by extracellular flux 
analysis. A summary of ANOVA p-values for each measurement are presented in Table 3.1. We 
did not observe an effect of modulation of NAT1 activity in MDA-MB-231 cells on basal OCR, 
ATP-linked OCR, or non-mitochondrial respiration (p>0.05 for all; Table 3.1).  
Knockout of NAT1 activity increased reserve capacity and maximum mitochondrial 
capacity when compared to the cell lines with parental (Parent, Scrambled) and increased (Up) 
NAT1 activity (p<0.05 for all; Figure 3.2). In the Parent, Scrambled, and Up cell lines the maximal 
respiration was lower than the basal OCR measurements resulting in a negative value for the 
reserve capacity calculation; since reserve capacity cannot be negative biologically, we termed 
the reserve capacity measurements in these groups as 0. Reserve capacity was increased 91- 
and 50-fold in the CRISPR 2-19 and CRISPR 5-50 cell lines, respectively. The 1.8-fold increase 
in reserve capacity of the CRISPR 2-19 cell line compared to the CRISPR 5-50 cell line was also 
statistically significant. Maximum mitochondrial capacity of the CRISPR 2-19 cell line was 
significantly increased 3.2-fold, 6.0-fold, and 5.4-fold, with respect to the Parent, Scrambled and 
Up cell lines. Maximum mitochondrial capacity of the CRISPR 5-50 cell line was also significantly 
increased 2.5-fold, 4.7-fold, and 4.2-fold, with respect to the Parent, Scrambled and Up cell lines. 
Proton leak was increased 1.8-fold in one of the NAT1 knockout (CRISPR 2-19) cell lines 
but only when compared to the cell line with increased (Up) NAT1 activity (Figure 3.2). We cannot 
conclude that this effect is due to NAT1 knockout since we did not observe the same result in the 




























































Figure 3.2: OCR measurements in each cell line. 
Evidence of a difference in baseline oxygen consumption rate (OCR), ATP-linked OCR, and non-mitochondrial respiration across cell lines was 
not observed. Reserve capacity was significantly increased in the CRISPR 2-19 and CRISPR 5-50 cell lines when compared to the Parent, 
Scrambled, and Up cell lines. Reported reserve capacity measurements for Parent, Scrambled, and Up cell lines were truncated at 0 since reserve 
capacity cannot be negative. Proton leak was significantly increased in the CRISPR 2-19 cell line but not the CRISPR 5-50 cell line when 
compared to the Up cell line. Maximum mitochondrial capacity was significantly increased in the CRISPR 2-19 and CRISPR 5-50 cell lines when 
compared to the Parent, Scrambled, and Up cell lines. Order of bars are preserved throughout figure (Parent, Scrambled, Up, CRISPR 2-19, 
CRISPR 5-50) and represent mean ± SEM. N=6. *=p<0.05, **=p<0.01, ***=p<0.001, ****=p<0.0001. The Parent and Scrambled cell lines express 
parental NAT1 activity, the Up cell line expresses increased NAT1 activity, and the CRISPR 2-19 and CRISPR 5-50 cell lines express no NAT1 
activity (knockout).  
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Baseline ECAR was increased in the two NAT1 knockout cell lines compared to the cell 
line with parental (Parent) NAT1 activity (Figure 3.3). Baseline ECAR in the CRISPR 2-19 cell line 
was increased 2.1-fold, 1.8-fold, 1.6-fold, and 1.4-fold with respect to the Parent, Scrambled, Up, 
and CRISPR 5-50 cell lines. Baseline ECAR in the CRISPR 5-50 cell line was also increased 1.5-
fold compared to the Parent cell line (p<0.05 for all).  
In the NAT1 knockout cell lines glycolytic reserve was increased compared to the cell 
lines with parental (Parent, Scrambled) and increased (Up) NAT1 activity (Figure 3.3). Glycolytic 
reserve of the CRISPR 2-19 cell line was increased 3.8-fold, 9.0-fold, and 45-fold with respect to 
the Parent, Scrambled and Up cell lines. Similarly, glycolytic reserve of the CRISPR 5-50 cell line 
was increased 3.8-fold, 9.2-fold, and 46-fold with respect to the Parent, Scrambled and Up cell 
lines (p<0.05 for all). 
 Transfection of the Parent cell line with the scrambled control showed no effect on 
baseline OCR/ECAR results. However, the cell line with increased NAT1 activity as well as one of 
the NAT1 knockout cell lines had decreased baseline OCR/ECAR relative to the Parent cell line 
(Figure 3.3). Both the Up and CRISPR 2-19 cell lines were decreased 1.7-fold with respect to the 
Parent cell line (p<0.05). We did not observe an effect of modulation of NAT1 activity on coupling 
efficiency, also called coupling ratio, which is defined as (oligomycin-sensitive OCR)/(basal OCR) 
(Figure 3.4). This result agrees with the data in Figure 3.3 showing that altering NAT1 activity had 
no effect on basal OCR or ATP-linked OCR in these cell lines.  
 Overall, it is important to note that the two cell lines with parental NAT1 activity (Parent, 
Scrambled) showed comparable results. The knockout of NAT1 in MDA-MB-231 cells led to 
differences in multiple bioenergetics measurements while the overexpression of NAT1 led to no 
significant (p>0.05) differences when compared to the cell lines expressing parental (Parent, 
Scrambled) NAT1 activity. 
To rule out differences in cell growth rate between cell lines over the course of our 
experiments, an MTT assay was conducted and the equivalence of MTT absorbance values were 
evaluated. With the exception of the Parent to Scrambled comparison, there was sufficient 
evidence to assert equivalence (p<0.05) in each of the pairwise equivalence tests. The Parent to 
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Figure 3.3 
 
Figure 3.3: ECAR measurements in each cell line. 
Baseline extracellular acidification rate (ECAR) was significantly increased in the CRISPR 2-19 
cell line when compared to the Parent, Scrambled, Up, and CRISPR 5-50 cell lines. The CRISPR 
5-50 cell line was also significantly increased compared to the Parent cell line. Glycolytic reserve 
capacity was significantly increased in the CRISPR 2-19 and CRISPR 5-50 cell lines compared to 
the Parent, Scrambled, and Up cell lines. Baseline OCR/ECAR was significantly decreased in the 
Up and CRISPR 2-19 cell lines when compared to the Scrambled cell line. Order of bars are 
preserved throughout figure (Parent, Scrambled, Up, CRISPR 2-19, CRISPR 5-50) and represent 
mean ± SEM. N=6. *=p<0.05, **=p<0.01, ***=p<0.001, ****=p<0.0001. The Parent and Scrambled 
cell lines express parental NAT1 activity, the Up cell line expresses increased NAT1 activity, and 
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Figure 3.4 
 
Figure 3.4: Coupling Efficiency measurements in each cell line. 
Coupling efficiency did not significantly differ between cell lines. Bars represent mean ± SEM. 
N=6. The Parent and Scrambled cell lines express parental NAT1 activity, the Up cell line 
expresses increased NAT1 activity, and the CRISPR 2-19 and CRISPR 5-50 cell lines express no 
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Scrambled equivalence test was marginally significant (p = 0.065; Figure 3.5). This data suggests 
that modulation of NAT1 activity does not affect MDA-MB-231 cell viability over the course of 
these experiments.  
Discussion  
It has been previously reported that TNBC cell lines, including MDA-MB-231 cells, have 
profound metabolic changes characterized by decreased mitochondrial respiration and increased 
glycolysis when compared to breast cancer cell lines that are ER positive, PR positive, and/or 
HER2 positive148. Since the purpose of this study was to evaluate how increased and knockout 
levels of human NAT1 affected the cellular bioenergetics of MDA-MB-231 breast cancer cells, the 
Parent MDA-MB-231 (no genetic alterations or transfections) was used as a baseline 
comparison. The Scrambled cell line (the Parent MDA-MB-231 cell line with a FRT site added into 
the genome and a scrambled shRNA transfected into that FRT site) was included as a 
transfection control84. We did not observe a significant effect of the scrambled shRNA on cellular 
bioenergetics in MDA-MB-231 cells. The Up cell line (the Parent MDA-MB-231 cell line with a 
FRT site added into the genome and a plasmid overexpressing human NAT1 stably transfected 
into that FRT site) yields overexpression of NAT184. Finally, two complete NAT1 knockout cell 
lines (CRISPR 2-19 and CRISPR 5-50) constructed using CRISPR/Cas9 technology (as 
described in the Methods section), were evaluated to verify that observed effects were due to 
differences in NAT1 as opposed to off-target effects caused by a specific guide-RNA. Therefore, 
we have concluded a result was due to the knockout of NAT1 only when the same trend was 
observed in both CRISPR/Cas9 constructed cell lines.  
 Knockout of NAT1 in MDA-MB-231 cells significantly altered the bioenergetics profile of 
the cells while increased NAT1 expression did not significantly alter the bioenergetics profile 
when compared to the Parent MDA-MB-231 cell line. Significant increases in reserve capacity, 
maximum mitochondrial capacity, and glycolytic reserve were observed in both NAT1 knockout 
cell lines compared to cell lines expressing parental and increased NAT1 activity. While basal 
OCR was unaffected by altered NAT1 activity, baseline ECAR was significantly increased in 
NAT1 knockout cells, suggesting an increase in glycolysis.  




Figure 3.5: MTT Equivalence Test Results. 
Equivalence between MTT absorbance values in each cell line was tested to access if there were 
differences in growth of the cell lines during bioenergetics experiments. There was sufficient 
evidence to assert equivalence in each of the pairwise equivalent tests. 
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 Baseline OCR is an indicator of baseline mitochondrial respiration. ATP-linked OCR is 
the difference between OCR before and after ATP synthase is inhibited with oligomycin. This 
allows estimation of the OCR that is used to drive mitochondrial ATP synthesis and is largely set 
by the ATP demand of the cells149. Modulation of NAT1 expression did not alter baseline or ATP-
linked OCR in MDA-MB-231 cells. This result suggests NAT1 does not play a role in the ATP 
demand responses in the cells. Coupling efficiency is calculated as the fraction of baseline OCR 
used for ATP synthesis (ATP-linked OCR/baseline OCR)140. Coupling efficiency was also 
unaffected by modulation of NAT1 in MDA-MB-231 cells providing further evidence to support the 
conclusion that that NAT1 does not play a role in ATP demand responses in these cells. 
Reserve capacity is the difference between the basal and maximal respiration of the 
mitochondria and is broadly an evaluation of a cell’s ability to respond to increased energy 
demands such as those found in rapidly dividing cancer cells149. Increases in reserve capacity, as 
observed in the NAT1 knockout cell lines, could reflect enhanced oxidative capacity, 
mitochondrial biogenesis, or increased substrate provision149. Reserve capacity does not 
explicitly implicate or identify molecular mechanisms of action since it is dependent upon multiple 
parameters. The significant increase in reserve capacity measured in the two NAT1 knockout cell 
lines appears to be driven by the increase in maximal respiration in those cell lines. Maximal 
respiration rate is primarily determined by substrate supply and oxidation149. This includes 
substrate transport across the mitochondrial membrane as well as rate controlling metabolic 
enzymes. Taken together, these results indicate NAT1 may have a role, either directly or through 
its influence on acetyl-CoA levels, in regulation of mitochondrial substrate transport or 
metabolism. One could speculate that knockdown of NAT1 increases acetyl-CoA thereby 
increasing substrate(s) for the TCA cycle which could increase mitochondrial reserve capacity. 
This hypothesis should be investigated in future studies.  
 Glycolytic reserve is the difference between oligomycin-induced ECAR and baseline 
ECAR and is a measure of the maximum rate of conversion of glucose to pyruvate or lactate that 
can be achieved acutely by a cell150. This measurement is an important parameter to evaluate in 
cancer cells because there is such an increased demand for energy precursors. Increases in 
  56 
glycolytic reserve, as we observed in the two NAT1 knockout cell lines, also indicate that these 
cells can respond better to these increased energy demands. Here we report that NAT1 
knockout, using two guide RNAs, increased the glycolytic reserve in MDA-MB-231 cells. There 
have been many studies49,81,137,151 investigating the inhibition of NAT1 with small molecule 
inhibitors as a possible way to decrease the cancerous and metastatic properties of malignant 
cells; however, this data suggest knockout of NAT1 may allow cells to increase glycolysis and 
use mitochondrial reserve.  
 Mitochondria facilitate cellular stress responses, including the response to hypoxia and 
the activation of programmed cell death via the release of pro-apoptotic molecules152. Differences 
in mitochondrial function between cells that express varying levels of NAT1 may play a role in 
cancer initiation or tumorigenesis by modulating these responses. It appears knockout of NAT1 
allows cells to express more plasticity in terms of response to energy demand. Our data suggest 
that NAT1 may play a role in an unknown response mechanism that keeps cancer cells from 
hijacking the mitochondrial machinery to produce increased amounts of ATP that would be 
needed by cancer cells.  
Summary and conclusions 
In conclusion, differences in NAT1 activity, particularly the knockout of NAT1, significantly 
altered the bioenergetics profile of MDA-MB-231 triple negative breast cancer cells. Reserve 
capacity, maximal respiration, and glycolytic reserve capacity were increased in the NAT1 
knockout cell lines. Increases in these measurements suggest that NAT1 knockout cells may be 
better able to respond to stress. These findings provide evidence that NAT1 modifies cellular 
acetyl-CoA levels and mitochondrial bioenergetics. Further investigation into the specific role 
NAT1 is playing in regulating cellular metabolism and bioenergetics is needed, ongoing, and will 
best be investigated via a multidisciplinary approach.  
 






Metabolomics is particularly well-suited for studying global metabolism as metabolites are 
the end-products of metabolism. In addition, performing an untargeted metabolomics study allows 
the collection of abundance data on many metabolites at once, from a single sample, giving a 
global snapshot of metabolism. While we acknowledge that untargeted metabolomics is still 
unable to detect and/or quantify ALL metabolites found in humans, it is the best way to get a 
global view of metabolism. The Human Metabolome Database (HMDB) approximates there are 
22,000 endogenous metabolites that have been detected153 however less than a thousand can be 
reliably measured. Many metabolomics studies have been conducted to better understand breast 
cancer and resulting alterations in metabolism154-164 and the use of metabolomics for systems 
biology approaches has recently been reviewed165. Additionally, there has been increased 
interest recently in “oncometabolites”—metabolites that when dysregulated can contribute to the 
progression of cancer166-170. Notably, it has been suggested that oncometabolites can affect 
mitochondrial dynamics166. 
Materials and Methods 
 A global, untargeted metabolomics approach was utilized to interrogate differences in 
metabolic profile across six biological replicates of previously constructed and characterized 
MDA-MB-231 breast cancer cell lines expressing parental (Scrambled), increased (Up), 
decreased (Down, CRISPR 2-12), or knockout (CRISPR 2-19, CRISPR 5-50) levels of human 
arylamine N-acetyltransferase 1 (NAT1). All cell lines were cultured in high-glucose Dulbecco's 
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Modified Eagle Medium (DMEM), with 10% fetal bovine serum, 5% glutamine, and 5% 
penicillin/streptomycin.  
 Cells were plated in triplicate per biological replicate at a density of 500,000 cells per 150 
x 25 mm cell plate, resulting in 18 plates total. Three plates were combined to form a single 
biological sample so that enough biological mass would be collected for future analysis. Cells 
were allowed to grow for three days in an incubator at 37 °C containing 5% CO2. Prior to 
collecting the cells, 200 μL of media from each plate was reserved. Media from the 3 plates that 
were combined as a single biological replicate were collected in the same vial. Vials containing 
media were centrifuged to pellet out any cells that may have been present and the resulting 
supernatants were placed into separate cryovials. Cryovials containing media samples were then 
flash frozen in liquid nitrogen for 1 minute and then stored in -80 °C freezer for possible future 
metabolomic analysis. 
 Cells were then harvested on ice by adding 5 mL 0.25% trypsin and scraping the cells 
from the plate. Three plates of cells were combined to form one sample (biological replicate) to 
ensure there was enough cells for analysis. After harvesting the cells were washed 3 times with 
ice-cold 1 x PBS. Supernatant was removed and 100 μL of cell pellet from 3 samples of each cell 
line was reserved for transcriptomic analysis (presented in Chapter 5). The cryovials containing 
cell pellets were then flash frozen in liquid nitrogen for 1 minute followed by immediate storage at 
-80 °C. Samples were then shipped on dry ice to Metabolon Inc. (Durham, NC) for sample 
preparation and analysis, as described below. 
Sample Accessioning 
Following receipt, samples were inventoried and immediately stored at -80 oC by 
Metabolon. The Metabolon Laboratory Information Management System (LIMS) system was 
utilized for sample management. Samples were assigned a unique identifier by the LIMS that was 
associated with the original source identifier only. This identifier was used to track all sample 
handling, tasks, results, etc. The samples (and all derived aliquots) were tracked by the LIMS 
system. All portions of any sample were automatically assigned their own unique identifiers by the 
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LIMS when a new task was created; the relationship of these samples was also tracked. All 
samples were maintained at -80 oC until processed. 
Sample Preparation 
Metabolon sample preparation has been described in great detail elsewhere171 but is 
presented briefly here. Samples were prepared using the automated MicroLab STAR® system 
(Hamilton Company, Reno, NV). Several recovery standards (described in great detail 
elsewhere171) were added prior to the first step in the extraction process for quality control (QC) 
purposes. To remove protein, dissociate small molecules bound to protein or trapped in the 
precipitated protein matrix, and to recover chemically diverse metabolites, proteins were 
precipitated with methanol under vigorous shaking for 2 min (Glen Mills GenoGrinder 2000) 
followed by centrifugation. The resulting extract was divided into five fractions: two for analysis by 
two separate reverse phase ultrahigh performance tandem mass spectroscopy (RP/UPLC-
MS/MS) methods with positive ion mode electrospray ionization (ESI), one for analysis by 
RP/UPLC-MS/MS with negative ion mode ESI, one for analysis by hydrophilic interaction liquid 
chromatography (HILIC)/UPLC-MS/MS with negative ion mode ESI, and one sample was 
reserved for backup. Samples were placed briefly on a TurboVap® (Zymark) to remove the 
organic solvent. The sample extracts were stored overnight under nitrogen before preparation for 
analysis.  
Quality Assessment/Quality Control (QA/QC) 
Several types of controls were analyzed in concert with the experimental samples: a 
pooled matrix sample generated by taking a small volume of each experimental sample served as 
a technical replicate throughout the data set; extracted water samples served as blanks; and a 
cocktail of QC standards that were carefully chosen not to interfere with the measurement of 
endogenous compounds were spiked into every analyzed sample, allowed instrument 
performance monitoring and aided chromatographic alignment. Instrument variability was 
determined by calculating the median relative standard deviation (RSD) for the standards that 
were added to each sample prior to injection into the mass spectrometers. Overall process 
variability was determined by calculating the median RSD for all endogenous metabolites (i.e., 
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non-instrument standards) present in 100% of the pooled matrix samples. Experimental samples 
were randomized across the platform run with QC samples spaced evenly among the injections. 
Ultrahigh Performance Liquid Chromatography-Tandem Mass Spectrometry (UPLC-
MS/MS) 
All methods utilized a Waters ACQUITY ultra-performance liquid chromatography (UPLC) 
and a Thermo Scientific Q-Exactive high resolution/accurate mass spectrometer interfaced with a 
heated electrospray ionization (HESI-II) source and an Orbitrap mass analyzer operated at 
35,000 mass resolution. The sample extract was dried, then reconstituted in solvents compatible 
to each of the four methods. Each reconstitution solvent contained a series of standards at fixed 
concentrations to ensure injection and chromatographic consistency. One aliquot was analyzed 
using acidic positive ion conditions, chromatographically optimized for more hydrophilic 
compounds. In this method, the extract was gradient eluted from a C18 column (Waters UPLC 
ethylene bridged hybrid (BEH) C18-2.1x100 mm, 1.7 µm) using water and methanol, containing 
0.05% perfluoropentanoic acid (PFPA) and 0.1% formic acid (FA). Another aliquot was also 
analyzed using acidic positive ion conditions, however it was chromatographically optimized for 
more hydrophobic compounds. In this method, the extract was gradient eluted from the same 
aforementioned C18 column using methanol, acetonitrile, water, 0.05% PFPA and 0.01% FA and 
was operated at an overall higher organic content. Another aliquot was analyzed using basic 
negative ion optimized conditions using a separate dedicated C18 column. The basic extracts 
were gradient eluted from the column using methanol and water, however with 6.5 mM 
ammonium bicarbonate at pH 8.0. The fourth aliquot was analyzed via negative ionization 
following elution from a HILIC column (Waters UPLC BEH Amide 2.1x150 mm, 1.7 µm) using a 
gradient consisting of water and acetonitrile with 10 mM ammonium formate, pH 10.8. The MS 
analysis alternated between MS and data-dependent MSn scans using dynamic exclusion. The 
scan range varied slightly between methods but covered 70-1000 m/z. Raw data files were 
archived and extracted as described below. 
Data Extraction and Compound Identification 
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Raw data were extracted, peak-identified and QC processed by Metabolon utilizing 
proprietary methods. Compounds were identified by comparison to library entries of purified 
standards or recurrent unknown entities. Metabolon maintains a library based on authenticated 
standards that contains the retention time/index (RI), mass to charge ratio (m/z), and 
chromatographic data (including MS/MS spectral data) on all molecules present in the library. 
Furthermore, biochemical identifications are based on three criteria: retention index within a 
narrow RI window of the proposed identification, accurate mass match to the library +/- 10 ppm, 
and the MS/MS forward and reverse scores between the experimental data and authentic 
standards. The MS/MS scores are based on a comparison of the ions present in the experimental 
spectrum to the ions present in the library spectrum. While there may be similarities between 
these molecules based on one of these factors, the use of all three data points can be utilized to 
distinguish and differentiate biochemicals. More than 3300 commercially available purified 
standard compounds have been acquired and registered into LIMS for analysis on all platforms 
for determination of their analytical characteristics. Additional mass spectral entries have been 
created for structurally unnamed biochemicals, which have been identified by virtue of their 
recurrent nature (both chromatographic and mass spectral). These compounds have the potential 
to be identified by future acquisition of a matching purified standard or by classical structural 
analysis. 
Curation 
A variety of curation procedures were carried out by Metabolon to ensure that a high 
quality data set was made available for statistical analysis and data interpretation. The QC and 
curation processes were designed to ensure accurate and consistent identification of true 
chemical entities, and to remove those representing system artifacts, mis-assignments, and 
background noise. Metabolon data analysts use proprietary visualization and interpretation 
software to confirm the consistency of peak identification among the various samples. Library 
matches for each compound were checked for each sample and corrected if necessary. 
Metabolite Quantification and Data Normalization 
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Peaks were quantified using area-under-the-curve. For studies spanning multiple days, a 
data normalization step was performed to correct variation resulting from instrument inter-day 
tuning differences. Essentially, each compound was corrected by registering the medians equal 
to one (1.00) and normalizing each data point proportionately. For studies that did not require 
more than one day of analysis, no normalization is necessary, other than for purposes of data 
visualization. Biochemical data was also normalized to total protein as determined by Bradford 
assay to account for differences in metabolite levels due to differences in the amount of material 
present in each sample. 
Statistical Analyses 
 Figure 4.1 illustrates experimental approach and data analyses methods. Normality of 
data was accessed via the Shapiro–Wilk test; normality of non-log and log transformed data was 
visualized (Figure 4.2). All statistical analyses were performed on log transformed data using R: A 
Language and Environment for Statistical Computing version 3.3.1132. One-way ANOVA was 
performed to test for significant differences between groups for each metabolite at an alpha level 
of 0.05. Q-values were then calculated using the false discovery rate method to correct for 
multiple hypothesis testing172. Dunnett’s post-tests were utilized to compare all groups (Up, 
Down, CRISPR 2-12, CRISPR 2-19, CRISPR 5-50) to the Scrambled group for those metabolites 
with one-way ANOVA q£0.05. Q-values were then calculated using the false discovery rate (FDR) 
method for Dunnett’s post-test p-values. 
 Fold-change was calculated using equation 1 (shown below). Briefly, the mean 
abundance for each metabolite was calculated for each group. We then divided the mean of the 
comparison group (Up, Down, CRISPR 2-12, CRISPR 2-19, CRISPR 5-50) by the mean of the 
Scrambled group to give us fold-change relative to the Scrambled group. 
!" = 2%&'()*+,+% Equation 1 
In the equation, FC = fold-change, -̅ = average metabolite abundance in the reference group, /0= 
average metabolite abundance in the comparison group. A negative sign was added to 
the fold-change when metabolite abundance was lower in the comparison group compared to the 
reference group. 




Figure 4.1: Metabolomics Experimental Approach Diagram. 
Six biological replicates from each cell line were collected (3 plates of cells were pooled to form a 
single biological replicate to have enough sample for analysis). Samples were then analyzed by 
UPLC-MS/MS at Metabolon using 4 methods optimized for the greatest coverage across the 
metabolome. Following metabolite identification, abundance data was protein normalized, median 
scaled, minimum values imputed, and log-transformed. Metabolite abundances were then 
analyzed for differential abundance, correlation with NAT1 N-acetylation activity, unbiased 
multivariate analysis/clustering, and pathway enrichment. 
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Figure 4.2 
 
Figure 4.2: Accessing Normality of Metabolomics Data. 
Normality of raw metabolite intensities before (A) and after log transformation was assessed (B). 
Normality of non-protein normalized metabolite abundances before (C) and after log 
transformation was assessed (D). Normality of protein normalized metabolite abundances before 
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Data were plotted as volcano plots to simultaneously visualize the between group differences in 
abundance of all detected metabolites and significance. Additionally, data were plotted as box-
plots to better visualize the abundance distribution of each metabolite between all groups. 
Pearson correlation was calculated between NAT1 activity and relative metabolite abundance for 
all metabolites to generate hypotheses about novel NAT1 substrates or products. Additionally, 
Pearson correlation was calculated between carnosine and metabolites whose abundance was 
concordantly altered in the two NAT1 KO cell lines. Data were also plotted as a heatmap and 
hierarchal clustering was conducted using the Weighted Pair Group Method with Arithmetic Mean 
(WPGMA) method. Principal component analysis was conducted by singular value decomposition 
of the centered data matrix. The loadings of the first (x-axis) and second (y-axis) principal 
component were plotted. Weighted gene co-expression network analysis (WGCNA) was 
conducted on metabolite abundance data. Enrichment analysis was conducted for each group 
compared to Scrambled. The normalized enrichment score was utilized to determine the relative 
degree of enrichment. 
Results 
Univariate Analyses 
A large proportion (515/567; 90.8%) of the detected metabolites were found to 
significantly differ (q £ 0.05) between the six cell lines (Table 4.1). Following Dunnett’s post tests 
it was observed that more metabolites differed in the cell lines constructed via CRISPR/Cas9 than 
the cell lines constructed via siRNA when compared to the Scrambled cell line. Thirty-four point 
four percent, 28.4%, 61.7%, 64.4%, and 53.8% of total detected metabolites were differentially 
expressed in the Down, Up, CRISPR 2-12, CRISPR 2-19, and CRISPR 5-50 groups, 
respectively. Metabolites were further characterized by direction of fold-change compared to 
Scrambled (Table 4.1; Figures 4.3 – 4.7); more metabolites were decreased than increased in all 
group comparisons to Scrambled except the CRISPR 2-19 cell line. The CRISPR/Cas-9 
generated cell lines had not only more total metabolites differentially expressed compared to the 
siRNA generated cell lines, but also more metabolites whose fold-changes were greater than 4. 
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Table 4.1 
 





























p ≤ 0.05 
220 199 380 384 326 
Metabolites 
(↑↓) 68|152 155|44 190|190 179|205 173|153 
Total 
Metabolites 
q ≤ 0.05 
198 161 352 365 305 
Metabolites 
(↑↓) 60|138 30|131 175|177 173|192 163|142 
 
One-way ANOVA was conducted for each metabolite abundance between all groups. q-values 
were calculated from resulting one-way ANOVA p-values to account for the multiple hypothesis 
testing. Dunnett’s t-test post tests were conducted for each group compared to Scrambled on 
metabolites found to significantly vary between all groups. Significant metabolites were further 
characterized by direction of fold-change; metabolites with increased abundance are shown in 
green while metabolites with decreased abundances are shown in red. q-values were calculated 
from resulting Dunnett’s t-test p-values. 
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Figure 4.3 
 
Figure 4.3: Down vs Scrambled Volcano Plot.  
Each dot represents a single metabolite and is color coded according to q-value. The black dots 
represent metabolites that had a Dunnett’s post test q-value greater than 0.05, blue dots 
represent metabolites that had a q-value less than or equal to 0.05 but greater than 0.01, and red 
dots represent metabolites that had a q-value less than or equal to 0.01. Negative fold changes 
represent a decrease in that metabolite compared to the Scrambled group while positive fold 
changes represent an increase in that metabolite compared to the Scrambled group. 
 



















0.05 ≥ q > 0.01 
q ≤ 0.01
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Figure 4.4 
 
Figure 4.4: Up vs Scrambled Volcano Plot. 
Each dot represents a single metabolite and is color coded according to q-value. The black dots 
represent metabolites that had a Dunnett’s post test q-value greater than 0.05, blue dots 
represent metabolites that had a q-value less than or equal to 0.05 but greater than 0.01, and red 
dots represent metabolites that had a q-value less than or equal to 0.01. Negative fold changes 
represent a decrease in that metabolite compared to the Scrambled group while positive fold 
changes represent an increase in that metabolite compared to the Scrambled group. 


















0.05 ≥ q > 0.01 
q ≤ 0.01
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Figure 4.5 
 
Figure 4.5: CRISPR 2-12 vs Scrambled Volcano Plot. 
Each dot represents a single metabolite and is color coded according to q-value. The black dots 
represent metabolites that had a Dunnett’s post test q-value greater than 0.05, blue dots 
represent metabolites that had a q-value less than or equal to 0.05 but greater than 0.01, and red 
dots represent metabolites that had a q-value less than or equal to 0.01. Negative fold changes 
represent a decrease in that metabolite compared to the Scrambled group while positive fold 
changes represent an increase in that metabolite compared to the Scrambled group. 
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Figure 4.6 
 
Figure 4.6: CRISPR 2-19 vs Scrambled Volcano Plot. 
Each dot represents a single metabolite and is color coded according to q-value. The black dots 
represent metabolites that had a Dunnett’s post test q-value greater than 0.05, blue dots 
represent metabolites that had a q-value less than or equal to 0.05 but greater than 0.01, and red 
dots represent metabolites that had a q-value less than or equal to 0.01. Negative fold changes 
represent a decrease in that metabolite compared to the Scrambled group while positive fold 
changes represent an increase in that metabolite compared to the Scrambled group. 
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Figure 4.7: CRISPR 5-50 vs Scrambled Volcano Plot. 
Each dot represents a single metabolite and is color coded according to q-value. The black dots 
represent metabolites that had a Dunnett’s post test q-value greater than 0.05, blue dots 
represent metabolites that had a q-value less than or equal to 0.05 but greater than 0.01, and red 
dots represent metabolites that had a q-value less than or equal to 0.01. Negative fold changes 
represent a decrease in that metabolite compared to the Scrambled group while positive fold 
changes represent an increase in that metabolite compared to the Scrambled group. 
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The overlap in significant metabolites with a fold-change greater than or equal to 2 was 
compared between the two NAT1 KO cell lines and the Scrambled group (Figure 4.8). Eighteen 
metabolites were increased concordantly in the two NAT1 KO cell lines compared to Scrambled 
with 102 and 32 metabolites uniquely increased in the CRISPR 2-19 and CRISPR 5-50 cell lines, 
respectively. Twenty-five metabolites were decreased concordantly in the two NAT1 KO cell lines 
compared to Scrambled with 58 and 38 metabolites uniquely decreased in the CRISPR 2-19 and 
CRISPR 5-50 cell lines, respectively. Table 4.2 lists metabolites whose abundances were 
concordantly changed in the NAT1 KO cell lines. More metabolites had conflicting differential 
abundance between the two CRISPR NAT1 KO cell lines compared to Scrambled than those that 
agreed. Notably, many of the metabolites decreased concordantly in the CRISPR NAT1 KO cell 
lines were carnitine conjugates. Assessing correlation between carnitine and all metabolites 
concordantly changed in the CRISPR NAT1 KO cell lines revealed the abundance of most 
metabolites were associated with carnitine (Table 4.2). This suggests dysregulation of carnitine is 
driving the differential abundances observed in this subset of metabolites. 
Eight metabolites, N-acetylasparagine, N-acetylputrescine, saccharopine, cytidine, 1-
palmitoyl-2-alpha linolenoyl-GPC (16:0/18:3n3), isovalerylcarnitine (C5), cysteine sulfinic acid, 
and serotonin, were significantly associated with NAT1 PABA N-acetylation activity (Table 4.3). 
The last five of the eight metabolites listed had a high degree of variation in the within-group 
measurement of metabolite abundance therefore the association is not as well defined as the 
others. The top two metabolites correlated with PABA N-acetylation, N-acetylasparagine (Figure 
4.9; Table 4.4) and N-acetylputrescine (Figure 4.10; Table 4.5), had a correlation coefficient (r) 
value greater than 0.9 and are N-acetylated compounds, suggesting they may be products of N-
acetylation by NAT1. Two of the metabolites significantly correlated with PABA N-acetylation, 
saccharopine (Figure 4.11; Table 4.6) and isovalerylcarnitine (C5), had an inverse relationship 
suggesting a role in a NAT1 catalyzed reaction as the substrate or possibly down-stream of a 
NAT1 catalyzed reaction. Additionally, differential acetyl-CoA levels due to NAT1’s ability to 
hydrolyze acetyl-CoA could be driving these observations. 
Multivariate/Multivariable Analyses 





Figure 4.8: Concordance of Metabolite Abundance Differences in CRISPR NAT1 Knockout 
Cell Lines. 
Significant metabolites with a fold-change greater than or equal to 2 were compared between 
CRISPR/Cas9 generated NAT1 knockout cell lines. Eighteen metabolites were increased 
concordantly in the two NAT1 KO cell lines compared to Scrambled with 102 and 32 metabolites 
uniquely increased in the CRISPR 2-19 and CRISPR 5-50 cell lines, respectively. Twenty-five 
metabolites were decreased concordantly in the two NAT1 KO cell lines compared to Scrambled 
with 58 and 38 metabolites uniquely decreased in the CRISPR 2-19 and CRISPR 5-50 cell lines, 
respectively. Green: metabolites increased compared to Scrambled; red: metabolites decreased 
compared to Scrambled. 
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Table 4.2 
 
Metabolites Concordantly Differentially Abundant in CRISPR 2-19 and CRISPR 5-50 Cell Lines 










M6 1-(1-enyl-palmitoyl)-2-linoleoyl-GPE  (P-16:0/18:2)* <0.0001 4.1 2.2 -0.60 
M26 13-HODE + 9-HODE 0<0.002 2.5 2.0 -0.68 
M33 1-linoleoyl-GPE (18:2)* <0.0001 5.4 3.6 -0.68 
M116 3-hydroxydecanoate <0.0001 2.7 3.3 -0.91 
M119 3-hydroxylaurate <0.0001 2.2 2.3 -0.77 
M120 3-hydroxyoctanoate <0.0001 2.8 3.3 -0.62 
M233 dihydroxyacetone phosphate  (DHAP) <0.0001 5.5 4.5 -0.77 
M339 lactose <0.0001 26.4 19.1 -0.82 
M387 N-acetyl-beta-alanine <0.0001 13.3 4.1 -0.72 
M417 nicotinamide ribonucleotide (NMN) <0.0001 25.9 2.9 -0.41 
M437 oleoylcholine <0.0001 8.3 2.6 -0.66 
M445 palmitoleoyl ethanolamide* <0.0001 3.0 2.3 -0.70 
M447 palmitoloelycholine <0.0001 8.4 2.4 -0.57 
M452 palmitoylcholine <0.0001 9.7 2.1 -0.53 
M456 penicillin G <0.0001 18.2 5.7 -0.70 
M481 pyridoxine (Vitamin B6) <0.0001 4.5 3.8 -0.83 
M526 stearoyl ethanolamide <0.0001 2.6 2.2 -0.82 
M555 urate <0.0001 2.0 3.5 -0.87 
M102 2'-O-methylcytidine <0.002 0.4 0.4 0.88 
M110 3-aminoisobutyrate <0.0001 0.3 0.5 0.79 
M132 4-hydroxyglutamate <0.0001 0.2 0.2 0.93 
M161 adrenoylcarnitine (C22:4)* <0.0001 0.1 0.1 0.92 
M176 arachidonoylcarnitine (C20:4) <0.0001 0.2 0.2 0.91 
M190 beta-guanidinopropanoate <0.0001 0.3 0.4 0.84 
M210 cis-4-decenoylcarnitine (C10:1) <0.0001 0.2 0.4 0.69 
M218 cystathionine <0.0001 0.2 0.1 0.92 
M226 cytidine diphosphate <0.0001 0.3 0.4 0.85 
M231 dihomo-linolenoylcarnitine  (20:3n3 or 6)* <0.0001 0.1 0.2 0.86 
M232 dihomo-linoleoylcarnitine (C20:2)* <0.0001 0.1 0.4 0.88 
*Continued on Next Page 
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M242 docosatrienoylcarnitine (C22:3)* <0.0001 0.1 0.2 0.88 
M344 laurylcarnitine (C12) <0.0001 0.2 0.5 0.85 
M352 linolenoylcarnitine (C18:3)* <0.0001 0.1 0.2 0.83 
M353 linoleoylcarnitine (C18:2)* <0.0001 0.0 0.3 0.77 
M371 myristoleoylcarnitine (C14:1)* <0.0001 0.1 0.4 0.75 
M376 N2,N2-dimethylguanosine <0.006 0.5 0.4 0.70 
M384 N-acetylasparagine <0.0001 0.1 0.1 0.28 
M412 N-carbamoylaspartate <0.0001 0.1 0.1 0.89 
M441 orotate <0.0001 0.1 0.1 0.95 
M448 palmitoyl dihydrosphingomyelin  (d18:0/16:0)* <0.0001 0.4 0.4 0.95 
M453 pantetheine <0.0001 0.5 0.3 0.78 
M508 sphingomyelin  (d18:0/18:0, d19:0/17:0)* <0.0001 0.4 0.5 0.63 
M544 tryptamine <0.0001 0.5 0.5 0.93 
M559 uridine 5'-triphosphate (UTP) <0.0001 0.04 0.1 0.95 
 
Metabolites concordantly differentially abundant in CRISPR 2-19 and CRISPR 5-50 cell lines 
were identified. Eighteen metabolites were concordantly increased while 25 metabolites were 
concordantly decreased. Pearson correlation between identified concordant metabolites and 
carnitine was conducted. M# represents an arbitraily assigned identifier for analysis purposes, 
biochemical is the metabolite identity, ANOVA q-value is the one-way ANOVA q-value, and 
correlation is the Pearson correlation coefficient between that metabolite and carnitine. Fold-
changes were color coded according to direction of fold-change with green for metabolites 
increased compared to Scrambled and red for metabolites decreased compared to Scrambled. 
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Table 4.3 
 
Metabolites Significantly Correlated with NAT1 N-acetylation Activity 
M# BIOCHEMICAL p-value 
CORRELATION 
COEFFICIENT 
M384 N-acetylasparagine 0.00030 0.986 
M404 N-acetylputrescine 0.0046 0.944 
M491 saccharopine 0.022 -0.876 
M224 cytidine 0.029 0.856 
M49 1-palmitoyl-2-alpha-linolenoyl-GPC (16:0/18:3n3)* 0.043 0.825 
M336 isovalerylcarnitine (C5) 0.046 -0.820 
M220 cysteine sulfinic acid 0.047 0.816 
M498 serotonin 0.050 0.811 
 
Pearson correlation between NAT1 N-acetylation activity in constructed cell lines and all 567 
detected metabolites was conducted. Eight metabolites were significantly correlated with NAT1 
N-acetylation activity. M# represents an arbitrability assigned identifier for analysis purposes, 
biochemical is the metabolite identity, p-value is the Pearson correlation p-value, and correlation 
is the Pearson correlation coefficient. Correlation coefficients were color coded according to 
direction of correlation, with green for positive correlation and red for inverse (negative) 
correlation. 























q-value <0.001 <0.00001 <0.0001 <0.00001 <0.00001 
Fold-
Change -2.3 3.0 -2.5 -11.6 -17.9 
 
One-way ANOVA was conducted for N-acetylasparagine abundance between all groups. q-
values were calculated from resulting one-way ANOVA p-values to account for the multiple 
hypothesis testing. Dunnett’s t-test post tests were conducted for each group compared to 
Scrambled. N-acetylasparagine abundance was further characterized by direction of fold-change; 
metabolites with increased abundance are shown in green while metabolites with decreased 
abundances are shown in red. q-values were calculated from resulting Dunnett’s t-test p-values.























q-value 0.03 <0.00001 0.95 <0.00001 0.003 
Fold-
Change -1.2 1.7 1 -1.9 -1.3 
 
One-way ANOVA was conducted for N-acetylputrescine abundance between all groups. q-values 
were calculated from resulting one-way ANOVA p-values to account for the multiple hypothesis 
testing. Dunnett’s t-test post tests were conducted for each group compared to Scrambled. N-
acetylputrescine abundance was further characterized by direction of fold-change; metabolites 
with increased abundance are shown in green while metabolites with decreased abundances are 
shown in red. q-values were calculated from resulting Dunnett’s t-test p-values























q-value <0.001 <0.00001 0.57 <0.00001 <0.00001 
Fold-
Change -1.4 -2.9 1 1.8 1.7 
 
One-way ANOVA was conducted for saccharopine abundance between all groups. q-values were 
calculated from resulting one-way ANOVA p-values to account for the multiple hypothesis testing. 
Dunnett’s t-test post tests were conducted for each group compared to Scrambled. Saccharopine 
abundance was further characterized by direction of fold-change; metabolites with increased 
abundance are shown in green while metabolites with decreased abundances are shown in red. 
q-values were calculated from resulting Dunnett’s t-test p-values.
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Figure 4.9: N-acetylasparagine Abundance Distribution and Correlation with NAT1 N-
acetylation Activity. 
(A) Boxplots of abundance distribution of N-acetylasparagine in each cell line. In the boxplots, the 
solid black line represents the median, the upper hinge represents the 75th quartile and the lower 
hinge represents the 25th quartile. The upper whisker represents the largest observation less 
than or equal to the upper hinge + 1.5 x IQR, the lower whisker represents the smallest 
observation greater than or equal to the lower hinge - 1.5 * IQR. (B) Correlation plot between N-
acetylasparagine abundance and NAT1 N-acetylation activity in each cell line. Error bars 
represent standard deviation. Pearson correlation coefficient = 0.986, p-value < 0.001 
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Figure 4.10: N-acetylputrescine Abundance Distribution and Correlation with NAT1 N-
acetylation Activity. 
(A) Boxplots of abundance distribution of N-acetylputrescine in each cell line. In the boxplots, the 
solid black line represents the median, the upper hinge represents the 75th quartile and the lower 
hinge represents the 25th quartile. The upper whisker represents the largest observation less 
than or equal to the upper hinge + 1.5 x IQR, the lower whisker represents the smallest 
observation greater than or equal to the lower hinge - 1.5 * IQR. (B) Correlation plot between N-
acetylputrescine abundance and NAT1 N-acetylation activity in each cell line. Error bars 
represent standard deviation. Pearson correlation coefficient = 0.944, p-value < 0.01 
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Figure 4.11: Saccharopine Abundance Distribution and Correlation with NAT1 N-
acetylation Activity. 
(A) Boxplots of abundance distribution of Saccharopine in each cell line. In the boxplots, the solid 
black line represents the median, the upper hinge represents the 75th quartile and the lower 
hinge represents the 25th quartile. The upper whisker represents the largest observation less 
than or equal to the upper hinge + 1.5 x IQR, the lower whisker represents the smallest 
observation greater than or equal to the lower hinge - 1.5 * IQR. (B) Correlation plot between 
Saccharopine abundance and NAT1 N-acetylation activity in each cell line. Error bars represent 
standard deviation. Pearson correlation coefficient = -0.876, p-value <0.05 
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Unsupervised hierarchical clustering of each sample revealed the global metabolomic 
profile of each cell line is distinct (Figure 4.12). The individual sample replicates clustered 
accurately by group except for sample 10 of the Down group that clustered with the Scrambled 
group. The first split in the dendrogram of the hierarchical clustering is between the two 
CRISPR/Cas9 cell lines constructed using guide RNA 2 and the other four cell lines; this provides 
evidence that those two cell lines have global metabolic profiles that are more similar to each 
other than to the respective cell lines that express the same level of NAT1 N-acetylation activity. 
The heatmap visualization of the data shows distinct clusters of metabolites whose relative 
abundance is much more similar between the two cell lines constructed using CRISPR/Cas9 
guide RNA 2 but have different levels of NAT1 activity than the two CRISPR/Cas9 cell lines that 
were constructed using two different guide RNAs but both had no detectable NAT1 activity. 
Similarly, principal component analysis showed that the CRISPR/Cas9 generated cell 
lines had global metabolomic profiles that were distinct from the siRNA generated cell lines as 
well as each other. In our dataset, principal component 1 explains 53% of the variance in the data 
while principal component 2 explains 14% of the variance (Figure 4.13). There are two types of 
variance within the data set; within group and between group variance. For our experimental 
question, we are most interested in the between group variance. The CRISPR 2-12 and CRISPR 
2-19 groups are separated from the other four groups by principal component 1. This reveals that 
these two groups have global metabolomics profiles that are similar to each other but very 
different from the other four groups given that PC1 represents 53% of the variance in our dataset. 
The CRISPR 5-50 group is separated from the other five groups along principal component 2. 
From the loadings of each principal component we can infer which metabolites, together, 
contribute the most to the separation between the groups and thus the variance between the 
groups (Figure 4.14). Most metabolites in the dataset are not contributing to the variance 
observed. There are groups of approximately 5-15 metabolites that are contributing the greatest 
to each principle component (in each direction). Adenosine and carnosine related metabolites are 










Figure 4.12: Metabolomics Heatmap and Hierarchical Clustering. 
Metabolites colored red on the heatmap had a median scaled relative abundance less than 1, metabolites colored white had a median scaled 
relative abundance of 1, and metabolites colored blue had a median scaled relative abundance greater than 1. Each column represents a single 
metabolite and each row represents a single metabolomics sample. Samples are color coded according to cell line identity. Unbiased hierarchical 
clustering reveals the two CRISPR/Cas9 cell lines constructed using guide RNA 2 are more similar than the two NAT1 complete knockout cell 
lines, as would be expected.




Figure 4.13: Principal Component Analysis Scores Plot. 
Each symbol represents an individual metabolomics sample, is numbered by sample number, 
and color coded by cell line. Principal component one (PC1) represents 53% of the total variance 
in our dataset and separates the CRISPR 2-12 and CRISPR 2-19 cell lines from all other cell 
lines. Principal component 2 (PC2) represents 14% of the total variance in our dataset and 















































Figure 4.14: Principal Component Loadings Plot. 
Loadings from principal component 1 and principal component 2 are plotted showing which metabolites have the greatest contribution to each 
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positively correlated. Lactate related metabolites are negatively correlated with principal 
component 2 while phosphate and carnitine related metabolites are positively correlated. 
Pathway Analysis 
Pathway enrichment analysis was conducted on each on each group compared to the 
Scrambled group (Figure 4.15). A normalized enrichment score of 1.2 in at least one of the 
groups was selected as the cut-off value for significance. The Kyoto Encyclopedia of Genes and 
Genomes (KEGG) pathways were used173,174. Disease associated pathways were removed from 
the analysis results. Amino acid, lipid, and fatty acid metabolism pathways were found to be 
significantly enriched. Some enriched pathways did not include all group comparisons suggesting 
differential impacts on metabolism.  
Discussion 
Given that (theoretically) only a single gene, NAT1, was genetically altered in each cell 
line, we expected only a small proportion of metabolite abundances to be significantly different, 
given the vast homeostasis mechanisms present175-177. However, we observed a very large 
proportion (~90%) of all metabolites detected to be significantly altered. Additionally, very few, if 
any, differences in metabolite abundances were expected between the two NAT1 knockout cell 
lines since each cell line should have the exact same genome. Yet one of the most striking 
observations of this study is the differences in relative metabolite abundance between the two 
complete NAT1 knockout cell lines. The hierarchical clustering, principal components analysis, 
and pathway enrichment analysis show there were significant differences between the two cell 
lines constructed using CRISPR/Cas9 guide RNA 2 and the cell line constructed using 
CRISPR/Cas9 guide RNA 5. Even though, in terms of NAT1 activity, the CRISPR 2-19 and 
CRISPR 5-50 cell lines are identical, their metabolic profiles are extremely different. This result 
suggests there are additional genetic differences between the two cell lines (discussed in greater 
detail in Chapter 7). However, we have not identified what genes the additional differences are in 
as whole genome sequencing of the cell lines would be required. The large number of 
differentially abundant metabolites between each knockout cell line compared to the Scrambled 
cell line and compared to each other could be because the cell lines have undergone additional 
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unique mutations during passaging or because each CRISPR guide RNA used caused unique 
off-target effects in addition to targeting NAT1. To focus on metabolome differences associated 
with varying levels of NAT1 in breast cancer, we have focused our interpretation of this study to 
metabolites that agreed between the two CRISPR NAT1 knockout cell lines. 
Ten of 25 metabolites decreased concordantly between the two CRISPR NAT1 KO cell 
lines were metabolites containing carnitine, more specifically fatty acyl-coA carnitine conjugates 
(Table 4.2). To further clarify whether this observation was due to dysregulation of fatty acyl-coA’s 
or carnitine in NAT1 KO cell lines, association between carnitine and metabolites decreased and 
increased concordantly in both NAT1 KO cell lines was determined. Nearly every metabolite 
concordantly differentially abundant showed strong correlation with carnitine suggesting the 
observation is due to dysregulation of carnitine. Carnitine is biosynthesized from lysine and 
methionine178 with important biological roles in the transport of activated long-chain fatty acids 
from the cytosol to the mitochondrial matrix for beta-oxidation179,180, modulation of the acyl-
CoA/CoA ratio180,181, and storage of energy as acetylcarnitine181,182. Further studies are required 
to discern whether these observations are due to NAT1 directly or indirectly due to NAT1’s effect 
on acetyl-CoA levels or other possible indirect effects. 
Notably, NAT1 has been shown to have redundancy with methylthioribose-1-phosphate 
isomerase (MRI-1) in the methionine salvage pathway, but this role was not observed in MDA-
MB-231 cells since they do not have a functional methionine salvage pathway due to a lack of 
methylthioadenosine phosphorylase (MTAP) activity107. However, this observation by other NAT 
researchers adds interest to deciphering the relationship between NAT1 and carnitine since 
carnitine is closely connected biochemically to methionine. It will be important for future studies to 
focus on these relationships and pathways to gain a better understanding of the role of NAT1 in 
breast cancer cell metabolism. 
The strong positive association between the abundance of N-acetylasparagine and NAT1 
activity in the 6 MDA-MB-231 cell lines is consistent with N-acetylasparagine being a product of 
NAT1 N-acetylation (Figure 4.16). There is currently no known mechanism or enzyme 
responsible for the acetylation of free amino acids. It is hypothesized that acetylated free amino  
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Figure 4.15 
 
Figure 4.15: Metabolomics Pathway Enrichment Analysis. 
Pathway enrichment analysis was conducted for each group compared to Scrambled and is 
color-coded by comparison. We utilized the normalized enrichment score to determine the 
relative degree of enrichment. U vs S: Up vs Scrambled; D vs S: Down vs Scrambled; C212 vs S: 















































































































































































































































































































































Figure 4.16: Possible Association Between NAT1 and N-acetylasparagine. 
The positive relationship between NAT1 N-acetylation activity and the abundance of N-
acetylasparagine suggests either L-asparagine is a NAT1 substrate or acetyl-CoA levels affect 
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acids originate from the breakdown of N-terminal acetylated proteins however L-asparagine 
residues in proteins are not known to be acetylated by N-terminal acetyltransferases (different 
family of N-acetyltransferases from NAT1 and NAT2)183. Additionally, the biosynthesis of N-
acetylasparagine is not defined in the literature. Recombinant murine and human aminoacylase 2 
(ASPA) have been reported to catabolize N-acetylasparagine, albeit at a much lower level than 
the prototypic ASPA substrate N-acetylaspartate184. Additionally, aminoacylase 1 deficiency 
(ACY1), a rare inborn error of metabolism disease, is diagnosed by increased N-acetylated amino 
acids in the urine, including N-acetylasparagine185 suggesting ACY1 can also metabolize N-
acetylasparagine. Given the abundance distribution of N-acetylasparagine in our constructed cell 
lines, we hypothesize L-asparagine is the substrate being N-acetylated by NAT1 to form N-
acetylasparagine however the substrate could be a different biochemical. 
Similarly, the strong positive association between the abundance of N-acetylputrescine 
and NAT1 N-acetylation activity in the 6 MDA-MB-231 cell lines is consistent with N-
acetylputrescine being a product of NAT1 N-acetylation (Figure 4.17). Putrescine is known to be 
N-acetylated by Spermidine/Spermine N1-Acetyltransferase 1 (SAT1) and Spermidine/Spermine 
N1-Acetyltransferase 2 (SAT2) but with much lower affinity than for other SAT substrates such as 
spermidine186. Redundancy in non-homologous metabolic enzymes has been shown to 
occur187,188 and we postulate NAT1 and the SATs may both be able to N-acetylate putrescine.  
Both L-asparagine and putrescine have been implicated in the promotion of cell 
growth189-194. The data indicate cell lines with higher levels of NAT1 activity have increased 
amounts of N-acetylated asparagine and putrescine while cell lines with decreased and knocked-
out NAT1 activity have decreased amounts of N-acetylated asparagine and putrescine. It is 
predicted this leads to decreased asparagine and putrescine in cell lines with high NAT1 and 
increased asparagine and putrescine in cell lines with decreased and knocked-out levels of NAT1 
relative to cell lines with basal NAT1 activity. It has been shown that intracellular asparagine 
exchanges with extracellular amino acids to promote mTORC1 activation, protein and nucleotide 
synthesis and cell proliferation under normal growth (non-starvation) conditions190. Additionally, it  




Figure 4.17: Possible Association Between NAT1 and N-acetylputrescine. 
The positive relationship between NAT1 N-acetylation activity and the abundance of N-
acetylputrescine suggests either putrescine is a NAT1 substrate or acetyl-CoA levels affect the 
activity of an enzyme for which putrescine is a substrate.
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has been reported that the invasiveness of a mouse breast cancer model could be modulated 
either by altering asparagine biosynthetic capacity or by modifying extracellular asparagine pools 
with decreases in asparagine leading to decreased metastatic burden189. Polyamines, such as 
putrescine, are known to facilitate the interactions of transcription factors, such as estrogen 
receptors with their specific response element and are involved in the proliferation of ER negative 
breast cancer tumor cells (reviewed in 195). Additionally, rises in intracellular polyamine 
concentrations has been associated with increased cell proliferation and has been linked to 
tumorigenesis196-200. This data, interpreted through the finding of previous studies, suggests cell 
lines with knocked-out NAT1 may have increased cell growth capabilities due to higher levels of 
asparagine and putrescine. 
 The strong negative association between the abundance of saccharopine and NAT1 
activity in the 6 MDA-MB-231 cell lines suggests saccharopine is a NAT1 substrate or located 
upstream of a NAT1 catalyzed reaction (Figure 4.18). Saccharopine is an intermediate in the 
main pathway responsible for the catabolism of lysine201,202. This observation may be connected 
to lysine’s role in carnitine biosynthesis178.  
Pathway analysis indicated pathways that directly involve acetyl-coA such as the lysine 
degradation (Figure 4.19) and tryptophan metabolism pathways were enriched for differences. 
Additionally, pathways that feed into the TCA cycle were also significantly enriched suggesting 
varying levels of NAT1 impact energy metabolism. 
Summary and Conclusions 
These results support the hypothesis that NAT1 is not just a xenobiotic metabolizing 
enzyme and may have a role in endogenous cellular metabolism whether that is directly or 
indirectly through the ability of NAT1 to metabolize acetyl-CoA remains unclear. The 
metabolomics data have shown NAT1 expression differentially affects cellular metabolism 
dependent on the level of expression. Additionally, potential novel substrates and products of N-
acetylation by NAT1 have been identified but further validation is required. These metabolites 
have recently been implicated in enhanced cell growth and metastatic potential in breast cancer 




Figure 4.18: Possible Association Between NAT1 and Saccharopine. 
The inverse relationship between NAT1 N-acetylation activity and the abundance of saccharopine 
suggests either saccharopine is a NAT1 substrate, acetyl-CoA levels affect the activity of an 
enzyme for which saccharopine is a substrate, lysine, the substrate that is degraded to form 
saccharopine, is a NAT1 substrate or acetyl-CoA levels affect the activity of an enzyme for which 










Figure 4.19: Lysine Degradation Pathway. 
NAT1 knockout cell lines, CRISPR 2-19 and CRISPR 5-50, metabolite abundance data compared to Scrambled cell line projected onto the KEGG 
lysine degradation pathway. Metabolites abundances in yellow are decreased in the NAT1 knockout cell lines, metabolites in gray are unchanged, 
and metabolites in blue are increased in the NAT1 knockout cell lines. 
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models suggesting they may be the key to understanding how varying levels of NAT1 affect 
breast cancer risk and progression. Additionally, many of the pathways significantly enriched in 
pathway analysis are pathways where acetyl-CoA plays a role, adding further evidence for the 
connection between NAT1 and acetyl-CoA in metabolism.






Transcriptomics allows measurement of global changes in gene abundance between 
samples and gives a snapshot of mRNA expression. Resulting information can be utilized to 
determine genes that may be interacting. While not all mRNAs will be translated into proteins and 
there are additional regulatory mechanisms that occur prior to protein expression, mRNA 
abundances can still provide a lot of information about a system. Additionally, numerous studies 
have utilized transcriptomics to better understand breast cancer203-207.  
Materials and Methods 
Collection of Samples 
 Figure 5.1 illustrates the experimental approach and workflow of sample collection 
described below. Cells were plated in triplicate per biological replicate at a concentration of 
500,000 cells per 150 x 25 mm cell plate for both transcriptomics and metabolomics analysis. All 
cell lines were cultured in high-glucose Dulbecco's Modified Eagle Medium (DMEM), with 10% 
fetal bovine serum, 5% glutamine, and 5% penicillin/streptomycin added. Cells were allowed to 
grow for three days at 37°C and 5% CO2 in an incubator.  
 Cells were then harvested on ice by adding 5 mL 0.25% trypsin and scraping the cells 
from the plate. Three plates were combined to form one sample (biological replicate). Three 
biological replicates for each cell line were collected for transcriptomics analysis. After harvesting 
the cells, cells were washed 3 times with ice-cold 1 x PBS. All supernatant was removed and 100 
µL of cell pellet was reserved for transcriptomics analysis. The remaining cell pellet was reserved 




Figure 5.1: Transcriptomics Experimental and data analysis approach. 
Three biological replicates from each cell line were collected. RNA was extracted and RNA-seq 
libraries prepared. Samples were then sequenced on the Illumina NextSeq 500 instrument. 
Following preprocessing of resulting data by the TopHat pipeline, genes were analyzed for 
differential abundance, unbiased multivariate analysis/clustering, and pathway enrichment. 
Notably, transcriptomics samples were the same samples collected for metabolomics analysis 
(discussed in Chapter 4).
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for metabolomic analysis (presented in Chapter 4). Samples were then flash frozen by placing in 
a pool of liquid nitrogen for 1 minute and stored in an -80 °C freezer.  
Transcriptomics 
RNA Isolation 
Total RNA was isolated from MDA-MB-231 breast cancer cells expressing parental 
(Scrambled), increased (Up), decreased (Down, CRISPR 2-12), and knockout (CRISPR 2-19, 
CRISPR 5-50) levels of NAT1 using the RNeasy® Mini Kit (Qiagen Sciences, Germantown, 
Maryland) according to manufacturer’s instructions. RNA purity was evaluated, and 
concentrations were measured in each sample using a NanoDrop Bioanalyzer (Life Technologies 
Sciences).  
Library Preparation 
Libraries were prepared in collaboration with the University of Louisville Genomics Core 
(who kindly allowed me to be a part of the process) using the TruSeq Stranded mRNA LT Sample 
Prep Kit- Set A (Illumina, San Diego, California; Cat# RS-122-2101) with poly-A enrichment per 
manufacturer’s instructions. One µg of total RNA (in a volume of 50 µL) from each sample was 
used in library preparation. Briefly, the total RNA was fragmented to improve sequence coverage 
over the transcriptome. Next, the first strand of cDNA was synthesized from the cleaved RNA 
fragments that were primed with random hexamers using reverse transcriptase and random 
primers. Then the second strand of cDNA was synthesized, thus providing double stranded blunt 
end cDNA. Next, a single ‘A’ nucleotide was added to the 3’ ends of the blunt fragments to 
prevent them from ligating to one another during the adapter ligation reaction. A corresponding 
single ‘T’ nucleotide on the 3’ end of the adapter provides a complementary overhang for ligating 
the adapter to the fragment. Then, multiple indexing adapters were ligated to the ends of the 
double stranded cDNA, preparing them for hybridization onto a flow cell. Next the DNA fragments 
were enriched using polymerase chain reaction (PCR) to selectively enrich those DNA fragments 
that have adapter molecules on both ends and to amplify the amount of DNA in the library. The 
PCR was performed with a PCR Primer Cocktail (included in the TruSeq Stranded mRNA LT 
Sample Prep Kit- Set A) that anneals to the ends of the adapters. Finally, 30 µl of eluted library 
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was collected and stored at -20 oC. To avoid skewing the representation of the library, the 
number of PCR cycles were minimized. This kit includes steps to validate and normalize 
constructed libraries and methods to check quality control. 
Library Validation 
Quality: Size, purity and semi quantitation were performed on an Agilent Bioanalyzer 
using the Agilent DNA 1000 Kit (Santa Clara, CA). The final fragment size for all the samples was 
approximately 300 basepairs as expected according to the protocol. 
Quantity: Sequencing library quantitation was performed by quantitative polymerase 
chain reaction (qPCR) using the KAPA Library Quantitation Kit (Roche, Basel, Switzerland) for 
Illumina Platforms. A standard curve method was generated for quantitation using 1-5 DNA 
standards provided with the kit.  
Normalize and Pool Libraries  
Ten µl of sample was transferred from the wells to a new MIDI plate. The concentration of 
the libraries were then normalized to 10 nM using Tris-HCl 10 mM, pH 8.5 with 0.1% Tween 20. 
Five µl of each sample was then transferred to be pooled into a new LowBind 1.5 ml micro 
centrifuge tube for a total volume of 60 µl pooled 10 nM library. Then 4 nM dilution was made 
from the 10 nM pooled library by diluting with Tris-HCl 10 mM, pH 8.5 with 0.1% Tween 20. 
Denaturing and diluting Libraries for the Nextseq 500 
A total volume of 1.3 mL of 1.8 pM denatured library was needed for sequencing using 
the NextSeq 500/550 75 cycle High Output Kit v2 (FC-404-2005; Illumina, San Diego, CA) kit. 
Pooled 4 nM library was denatured by mixing with diluted NaOH and incubated at room 
temperature for 5 minutes. Tris HCl, 200 mM, pH 7.0 was then added. The reaction mixture was 
diluted to 20 pM using a pre-chilled Hybridization Buffer (included in the NextSeq 500/550 75 
cycle High Output Kit v2). The 20 pM denatured library was further diluted to 1.8 pM using the 
same Hybridization Buffer. Before loading onto the reagent cartridge, 1.3 µl of denatured 20 pM 
Phix control (Illumina, San Diego, CA; FC-110-3001) was added to the 1299 µl of denatured 1.8 
pM library to a total volume of 1.3 mL for the first sequencing run (for the 2nd sequencing run 1.9 
pM library was used).  
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Sequencing  
Sequencing was performed on the University of Louisville Center for Genetics and 
Molecular Medicine’s (CGeMM) Illumina NextSeq 500 using the NextSeq 500/550 75 cycle High 
Output Kit v2 (FC-404-2005). A second run was performed to increase the number of reads. For 
each run, 72 single-end raw sequencing files (.fastq)208 representing six conditions with three 
biological replicates and four lanes per replicate were downloaded from Illumina’s BaseSpace209 
(https://basespace.illumina.com/) onto the Kentucky Biomedical Research Infrastructure Network 
(KBRIN) server for analysis using pre-written scripts. 
RNA-Seq Analysis 
Resulting data were preprocessed and analyzed using the tuxedo suite210,211 pipeline 
which includes TopHat, Cufflinks, Cuffmerge, and Cuffdiff. Cuffdiff was utilized to calculate 
differential gene expression for all groups (Up, Down, CRISPR 2-12, CRISPR 2-19, CRISPR 5-
50) compared to the Scrambled group211. Quality control (QC) of the raw sequence data was 
performed using FastQC (version 0.10.1)212. Although the FastQC results indicate the last base of 
all samples has a lower quality value, we chose not to trim in this case. Concatenated sequences 
were directly aligned to the Homo sapiens hg38 reference genome assembly (hg38.fa) using 
TopHat2 (version 2.0.13)213, generating alignment files in bam format. Table 5.1 indicates the 
number of raw reads successfully aligned for each of the samples. 
 Further analysis and visualization of the resulting data were performed using R: A 
Language and Environment for Statistical Computing version 3.3.1132. Fold-change and 
significance of differential gene expression between groups was visualized using volcano plots. 
The Pearson correlation coefficient was calculated between NAT1 and NAT2 transcript 
abundance and transcript abundance of all other genes to generate hypotheses about genes that 
may be interacting with NAT1 and NAT2, respectively. Data also were plotted as a heatmap and 
hierarchal clustering was conducted using the WPGMA method. Principal component analysis 
was conducted by singular value decomposition of the centered data matrix. The loadings of the 
first (x-axis) and second (y-axis) principal components were plotted. Weighted gene co-
expression network analysis (WGCNA) was conducted on metabolite abundance data to identify 
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Table 5.1 
 































The number of raw reads successfully aligned to the homo sapiens reference genome assembly 
hg.38 for each sample using TopHat2. Percent aligned was calculated by dividing aligned reads 
by input reads for each sample. 





Scrambled 1 37,984,684 36,841,298 97.0% 
Scrambled 2 35,361,628 34,368,699 97.2% 
Scrambled 3 38,238,715 36,597,025 95.7% 
Down 1 41,290,001 40,114,301 97.2% 
Down 2 41,339,117 40,184,597 97.2% 
Down 3 44,859,187 43,503,707 97.0% 
Up 1 38,199,308 37,143,906 97.0% 
Up 2 37,337,039 36,125,963 96.8% 
Up 3 39,022,651 37,890,392 97.1% 
CRISPR 2-12 1 33,319,727 32,384,934 97.2% 
CRISPR 2-12 2 38,610,686 37,399,482 96.9% 
CRISPR 2-12 3 38,275,581 37,201,657 97.2% 
CRISPR 2-19 1 38,870,999 37,718,655 97.0% 
CRISPR 2-19 2 34,811,726 33,815,087 97.1% 
CRISPR 2-19 3 34,097,370 33,138,856 97.2% 
CRISPR 5-50 1 35,429,756 34,386,174 97.1% 
CRISPR 5-50 2 42,535,551 41,226,671 96.9% 
CRISPR 5-50 3 37,749,977 36,718,233 97.3% 
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modules of related metabolites given the topology of the weighted network. Pathway enrichment 
analysis was conducted for each group compared to Scrambled. The normalized enrichment 
score was utilized to determine the relative degree of enrichment. 
Quantitative Measurement of NAT1 and NAT2 mRNA 
Reverse transcription- quantitative polymerase chain reaction (RT-qPCR) was conducted 
for NAT1 and NAT2 mRNAs in all 6 constructed cell lines as previously described40,96,214. Briefly, 
total RNA was isolated from each cell line using the RNeasy Mini Kit (Qiagen, Germantown, MD). 
Isolated RNA was used to transcribe cDNA using the High Capacity Reverse Transcriptase kit 
(Life Technologies, Carlsbad, CA). Resulting cDNA was utilized for quantitative measurement of 
NAT1 and NAT2 mRNAs via RT-qPCR. TaqMan analysis was performed using the ABI 7700 
sequence detection system (Applied Biosystems, Foster City, CA). Utilized gene probes were 
designed previously to discriminate between NAT1 and NAT2. 
NAT2 N-Acetylation Activity Assays 
In vitro NAT2 N-acetylation activity was determined in each constructed cell line as 
previously described12,215. Briefly, cell lysate from each cell line was incubated with 1 mM acetyl-
coenzyme A and 300 µM sulfamethazine (SMZ) at 37°C for 10 minutes. Reactions were 
terminated with the addition of 1/10 reaction volume 1 M acetic acid. Reaction products were 
collected and analyzed using an Agilent Technologies 1260 Infinity high performance liquid 
chromatography (HPLC) using a LiChrospher ® 100 RP-18 (5 µm) column to determine the 
amount of acetylated product. 
Results 
Expression of many genes was found to significantly differ (q £ 0.05, |FC|>2) between the 
six cell lines (Table 5.2). More genes were differentially expressed in the cell lines with decreased 
or knockout NAT1 (Down, CRISPR 2-12, CRISPR 2-19, CRISPR 5-50) than the cell line with 
increased NAT1 activity (Up) when compared to the Scrambled cell line. Two thousand sixty-five, 
544, 1911, 2383, and 1937 genes were differentially expressed in the Down, Up, CRISPR 2-12, 
CRISPR 2-19, and CRISPR 5-50 groups, respectively (Table 5.2). Genes were further 
characterized by direction of fold-change compared to Scrambled (Figures 5.2 - 5.6). MSR1 gene 
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Table 5.2 
 

















q ≤ 0.05; 
FC ≥ 2 
2065 544 1911 2383 1937 
DEGs 
(↑↓) 680|1385 310|234 1169|742 1472|911 1112|825 
DEGs = differentially expressed genes 
Cuffdiff was utilized to calculate differential gene expression for all groups (Up, Down, CRISPR 2-
12, CRISPR 2-19, CRISPR 5-50) compared to the Scrambled group211. Significantly differentially 
expressed genes were further characterized by direction of fold-change; genes with increased 






Figure 5.2: Up vs Scrambled Volcano Plot. 
Each dot represents a single gene and is color coded according to q-value. The black dots represent genes that had a Dunnett’s post test q-value 
greater than 0.05, blue dots represent genes that had a q-value less than or equal to 0.05 but greater than 0.01, and red dots represent genes that 
had a q-value less than or equal to 0.01. Negative fold changes represent a decrease in that gene compared to the Scrambled group while 
positive fold changes represent an increase in that gene compared to the Scrambled group. NAT1 is shown by a purple dot while NAT2 is shown 






Figure 5.3: Down vs Scrambled Volcano Plot. 
Each dot represents a single gene and is color coded according to q-value. The black dots represent genes that had a Dunnett’s post test q-value 
greater than 0.05, blue dots represent genes that had a q-value less than or equal to 0.05 but greater than 0.01, and red dots represent genes that 
had a q-value less than or equal to 0.01. Negative fold changes represent a decrease in that gene compared to the Scrambled group while 
positive fold changes represent an increase in that gene compared to the Scrambled group. NAT1 is shown by a purple dot while NAT2 is shown 






Figure 5.4: CRISPR 2-12 vs Scrambled Volcano Plot. 
Each dot represents a single gene and is color coded according to q-value. The black dots represent genes that had a Dunnett’s post test q-value 
greater than 0.05, blue dots represent genes that had a q-value less than or equal to 0.05 but greater than 0.01, and red dots represent genes that 
had a q-value less than or equal to 0.01. Negative fold changes represent a decrease in that gene compared to the Scrambled group while 
positive fold changes represent an increase in that gene compared to the Scrambled group. NAT1 is shown by a purple dot while NAT2 is shown 






Figure 5.5: CRISPR 2-19 vs Scrambled Volcano Plot. 
Each dot represents a single gene and is color coded according to q-value. The black dots represent genes that had a Dunnett’s post test q-value 
greater than 0.05, blue dots represent genes that had a q-value less than or equal to 0.05 but greater than 0.01, and red dots represent genes that 
had a q-value less than or equal to 0.01. Negative fold changes represent a decrease in that gene compared to the Scrambled group while 
positive fold changes represent an increase in that gene compared to the Scrambled group. NAT1 is shown by a purple dot while NAT2 is shown 






Figure 5.6: CRISPR 5-50 vs Scrambled Volcano Plot. 
Each dot represents a single gene and is color coded according to q-value. The black dots represent genes that had a Dunnett’s post test q-value 
greater than 0.05, blue dots represent genes that had a q-value less than or equal to 0.05 but greater than 0.01, and red dots represent genes that 
had a q-value less than or equal to 0.01. Negative fold changes represent a decrease in that gene compared to the Scrambled group while 
positive fold changes represent an increase in that gene compared to the Scrambled group. NAT1 is shown by a purple dot while NAT2 is shown 
by a green dot. 
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expression was compared between the cell lines since it has previously been reported that NAT1 
has redundancy with the MSR1 enzyme (Table 5.3). However MSR1 was differentially expressed 
only between the CRISPR 2-12 cell line and the Scrambled cell line. 
The overlap in genes that were differentially expressed with a fold-change greater than or 
equal to 2 was compared between the two NAT1 KO cell lines and the Scrambled group (Figure 
5.7). Five hundred ninety-nine genes were increased concordantly in the two NAT1 KO cell lines 
compared to Scrambled with 873 and 512 genes uniquely increased in the CRISPR 2-19 and 
CRISPR 5-50 cell lines, respectively. Three hundred nineteen genes were decreased 
concordantly in the two NAT1 KO cell lines compared to Scrambled with 592 and 506 genes 
uniquely decreased in the CRISPR 2-19 and CRISPR 5-50 cell lines, respectively. More genes 
had conflicting differential expression between the two CRISPR NAT1 KO cell lines compared to 
Scrambled that those that agreed.  
 Transcript expression of NAT1 and its isozyme, NAT2, were compared in all cell lines. 
Notably, in the two complete NAT1 knockout cell lines (CRISPR 2-19 & CRISPR 5-50), NAT2 
transcripts were significantly increased 6.7- and 2.8-fold, respectively, compared to the 
Scrambled cell line (Figure 5.8; Table 5.4), however NAT2 transcript expression was not 
increased in any of the other cell lines (p>0.05; Up, Down, CRISPR 2-12). Individual NAT2 
transcript mapping in the RNA-seq data in the Scrambled and NAT1 knockout cell lines, CRISPR 
2-19 and CRISPR 5-50, was visualized using Integrated Genomics Viewer (IGV; Figure 5.9). This 
observation was verified with RT-qPCR analysis for NAT1 and NAT2 in all six cell lines (Figure 
5.10). Although, not significant for all cell lines, there was a trend of decreased NAT1 transcripts 
and increased NAT2 transcripts in the RT-qPCR data. NAT2 activity assays were conducted for 
all 6 constructed cell lines using the NAT2 specific substrate sulfamethazine (SMZ) however no 
NAT2 activity was detected in any cell line. Currently, the functionality of the NAT2 transcripts 
produced in the NAT1 knockout cell lines is unknown. 
Many more genes correlated with NAT2 transcript abundance than NAT1 transcript 
abundance (r|≥0.9|). Twenty-two genes correlated with NAT1 (Table 5.5) while 342 genes were 
correlated with NAT2 (Table 5.6--abbreviated to show top 50 positively correlated and all 
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Table 5.3 
 
Differential Expression of the Methylthioribose-1-Phosphate Isomerase (MRI1) Gene 
COMPARISON Log2 FC Comparison/Scrambled q-value 
Up vs Scrambled 0.39 0.93 
Down vs Scrambled -0.03 0.98 
CRISPR 2-12 vs Scrambled 1.52 0.01 
CRISPR 2-19 vs Scrambled 1 0.16 
CRISPR 5-50 vs Scrambled 0.86 0.17 
 
Methylthioribose-1-phosphate isomerase (MRI1) transcript fold-changes between each cell line 
compared to the Scrambled cell line. Fold-change and q-value were calculated using cuffdiff. 
Significant differential gene expression is color-coded by direction of fold-change with increases 







Figure 5.7: Gene Concordance Between CRISPR 2-19 and CRISPR 5-50 Cell Lines Compared to Scrambled. 
Genes significantly differentially expressed with a fold-change greater than or equal to 2 were compared between CRISPR/Cas9 generated NAT1 
knockout cell lines. Five hundred ninety-nine genes were increased concordantly in the two NAT1 KO cell lines compared to Scrambled with 873 
and 512 genes uniquely increased in the CRISPR 2-19 and CRISPR 5-50 cell lines, respectively. Three hundred nineteen genes were decreased 
concordantly in the two NAT1 KO cell lines compared to Scrambled with 592 and 506 genes uniquely decreased in the CRISPR 2-19 and CRISPR 
5-50 cell lines, respectively. Green: genes up-regulated compared to Scrambled; red: genes down-regulated compared to Scrambled. 
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Figure 5.8 
 
Figure 5.8: NAT1 and NAT2 Gene Expression in Each Cell Line Compared to Scrambled 
and Up. 
Fold change of NAT1 and NAT2 between each cell line (Down, Up, CRISPR 2-12, CRISPR 2-19, 
and CRISPR 5-50) compared to Scrambled was assessed. We additionally compared NAT1 and 
NAT2 gene expression in all cell lines to the Up cell line. In the heatmap, red represents a 







Differential Expression of the N-acetyltransferase (NAT) Genes 
COMPARISON GENE Log2 FC Comparison/Scrambled q-value 
Up vs Scrambled 
NAT1 3.3 0.003 
NAT2 0.1 1 
Down vs Scrambled 
NAT1 -0.7 0.08 
NAT2 -0.9 1 
CRISPR 2-12 vs Scrambled 
NAT1 -1.0 0.009 
NAT2 -1.6 1 
CRISPR 2-19 vs Scrambled 
NAT1 -1.1 0.02 
NAT2 6.7 0.0005 
CRISPR 5-50 vs Scrambled 
NAT1 -1.9 0.0005 
NAT2 2.8 0.006 
 
NAT transcript fold-changes between each cell line compared to the Scrambled cell line. Fold-change and q-value were calculated using cuffdiff. 
Genes with q≥0.05 were considered significantly differentially expressed. Significant differential gene expression is color-coded by direction of 
fold-change with increases shown in green while decreases are shown in red.  






Figure 5.9: Integrated Genomics Viewer (IGV) NAT2 Transcript Mapping 
Raw transcript reads mapping to NAT2 were visualized with IGV. Each gray bar represents a single transcript read. Colored lines in the transcripts 
represent the presence of a SNP in comparison to the homo sapiens hg.38 reference genome.





Figure 5.10: NAT1 and NAT2 mRNA Expression. 
NAT1 and NAT2 were quantitated via RT-qPCR in the six constructed cell lines as well as the parental MDA-MB-231 cell line. 
Results represent are from 3 independent experiments with 3 replicates in each experiment and are reported relative to the Parent cell line. Bars 
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Table 5.5 
 
Genes Correlated with NAT1 Transcript Abundance 
ENSEMBLE  
GENE ID  
GENE q-value CORRELATION 
 
ENSG00000171428 NAT1 N/A 1.00 
ENSG00000202310 Y_RNA <0.00001 0.98 
ENSG00000253377 AC068672.2 <0.00001 0.98 
ENSG00000258168 AC025569.1 <0.00001 0.96 
ENSG00000176571 CNBD1 <0.00001 0.96 
ENSG00000174125 TLR1 <0.00001 0.95 
ENSG00000167355 AC087380.1 <0.00001 0.94 
ENSG00000165078 CPA6 <0.0001 0.93 
ENSG00000187189 TSPYL4 <0.0001 0.92 
ENSG00000173157 ADAMTS20 <0.0001 0.92 
ENSG00000106034 CPED1 <0.0001 0.92 
ENSG00000081148 IMPG2 <0.0001 0.92 
ENSG00000165424 ZCCHC24 <0.0001 0.92 
ENSG00000170915 PAQR8 <0.0001 0.92 
ENSG00000162139 NEU3 0.0001 0.91 
ENSG00000173930 SLCO4C1 0.0001 0.91 
ENSG00000141219 C17orf80 0.0001 0.91 
ENSG00000270157 NA 0.0001 0.91 
ENSG00000179331 RAB39A 0.0002 0.91 
ENSG00000196449 YRDC <0.0001 -0.92 
ENSG00000054116 TRAPPC3 0.0001 -0.91 
ENSG00000116288 PARK7 0.0002 -0.90 
 
Pearson correlation between NAT1 gene abundance in constructed cell lines and all genes in the 
transcriptomics dataset was conducted. Twenty-two genes were significantly correlated (r > 0.90) 
with NAT1 transcript abundance. q-value is the Pearson correlation q-value, and correlation is the 
Pearson correlation coefficient. Correlation coefficients were color coded according to direction of 
correlation with green for positive correlation and red for inverse (negative) correlation. 
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Table 5.6 
 
Genes Correlated with NAT2 Transcript Abundance (Abbreviated to top 50 genes) 
ENSEMBLE  
GENE ID  
GENE p-value CORRELATION 
COEFFICIENT 
ENSG00000156006 NAT2 NA 1.00 
ENSG00000186479 RGS7BP <0.00001 1.00 
ENSG00000158270 COLEC12 <0.00001 1.00 
ENSG00000021645 NRXN3 <0.00001 1.00 
ENSG00000188086 PRSS45 <0.00001 1.00 
ENSG00000179097 HTR1F <0.00001 1.00 
ENSG00000197506 SLC28A3 <0.00001 1.00 
ENSG00000134247 PTGFRN <0.00001 1.00 
ENSG00000267313 KC6 <0.00001 1.00 
ENSG00000112902 SEMA5A <0.00001 1.00 
ENSG00000243486 AC068985.1 <0.00001 1.00 
ENSG00000129514 FOXA1 <0.00001 1.00 
ENSG00000261122 LINC02167 <0.00001 1.00 
ENSG00000233403 AC121342.1 <0.00001 1.00 
ENSG00000078596 ITM2A <0.00001 0.99 
ENSG00000095777 MYO3A <0.00001 0.99 
ENSG00000105383 CD33 <0.00001 0.99 
ENSG00000105851 PIK3CG <0.00001 0.99 
ENSG00000110002 VWA5A <0.00001 0.99 
ENSG00000115165 CYTIP <0.00001 0.99 
ENSG00000124429 POF1B <0.00001 0.99 
ENSG00000125848 FLRT3 <0.00001 0.99 
ENSG00000130224 LRCH2 <0.00001 0.99 
ENSG00000137745 MMP13 <0.00001 0.99 
ENSG00000140379 BCL2A1 <0.00001 0.99 
ENSG00000140563 MCTP2 <0.00001 0.99 
ENSG00000143061 IGSF3 <0.00001 0.99 
ENSG00000145649 GZMA <0.00001 0.99 
ENSG00000147246 HTR2C <0.00001 0.99 
ENSG00000149573 MPZL2 <0.00001 0.99 
ENSG00000152217 SETBP1 <0.00001 0.99 
ENSG00000155622 XAGE2 <0.00001 0.99 
*continued on next page 
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ENSG00000165061 ZMAT4 <0.00001 0.99 
ENSG00000165449 SLC16A9 <0.00001 0.99 
ENSG00000165795 MIR6717 <0.00001 0.99 
ENSG00000165868 HSPA12A <0.00001 0.99 
ENSG00000166669 ATF7IP2 <0.00001 0.99 
ENSG00000170927 PKHD1 <0.00001 0.99 
ENSG00000171004 HS6ST2 <0.00001 0.99 
ENSG00000178235 SLITRK1 <0.00001 0.99 
ENSG00000180287 PLD5 <0.00001 0.99 
ENSG00000183230 CTNNA3 <0.00001 0.99 
ENSG00000184564 SLITRK6 <0.00001 0.99 
ENSG00000189398 OR7E12P <0.00001 0.99 
ENSG00000205628 LINC01446 <0.00001 0.99 
ENSG00000223756 TSSC2 <0.00001 0.99 
ENSG00000224960 PPP4R3CP <0.00001 0.99 
ENSG00000226372 DCAF8L1 <0.00001 0.99 
ENSG00000255501 CARD18 <0.00001 0.99 
ENSG00000261780 LOC100505817 <0.00001 0.99 
ENSG00000238755 NA <0.00001 0.99 
ENSG00000253651 NA <0.00001 0.99 
ENSG00000228065 NA <0.00001 0.99 
ENSG00000151208 DLG5 <0.00001 -0.91 
 
Pearson correlation between NAT2 gene abundance in constructed cell lines and all genes in the 
transcriptomics dataset was conducted. Three hundred forty-two genes were significantly 
correlated (r > 0.90) with NAT1 transcript abundance. q-value is the Pearson correlation q-value, 
and correlation is the Pearson correlation coefficient. Correlation coefficients were color coded 
according to direction of correlation with green for positive correlation and red for inverse 
(negative) correlation.
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negatively correlated). This observation may be because of the low abundance of NAT2 in most 
of our cell lines. Notably, multiple genes associated with NAT1 transcript abundance are located 
on chromosome 8, the same chromosome on which NAT1 is located. There was no overlap in 
genes correlated with NAT1 and NAT2 transcript expression, suggesting different regulation 
mechanisms. 
Correlation Concordance 
 To determine if the genes strongly correlated with NAT1 and NAT2 transcript expression, 
respectively, show the same relationship in other independent datasets correlation was compared 
in publicly available data repositories. Gene expression data for top 20 genes in the lists as well 
as NAT1 and NAT2 were downloaded from the cancer cell line encyclopedia (CCLE) and the 
cancer genome atlas (TCGA). Breast cancer datasets were utilized since our original samples 
were from the breast cancer cell line MDA-MB-231. However, there are data for many different 
cancers in the repositories. Correlation between NAT1 and NAT2 and the genes they correlated 
with in the transcriptomics dataset was assessed in the two independent datasets using the 
Pearson method. 
Unsupervised hierarchical clustering of each sample revealed the global transcriptomic 
profile of each cell line is distinct (Figure 5.11). The individual sample replicates clustered 
accurately by group. The first split in the dendrogram of the hierarchical clustering is between the 
two CRISPR/Cas9 cell lines constructed using guide RNA 2 and the other four cell lines; this 
provides evidence that those two cell lines have global transcriptomic profiles that are more 
similar to each other than to the respective cell lines that express the same level of NAT1 N-
acetylation activity. The heatmap visualization of the data shows distinct clusters of gene 
transcripts whose expression is much more similar between the two cell lines constructed using 
CRISPR/Cas9 guide RNA 2 but have different levels of NAT1 activity than the two CRISPR/Cas9 
cell lines that were constructed using two different guide RNAs but both had no detectable NAT1 
activity. Differential gene expression between each cell line compared to Scrambled was also 













Figure 5.11: Hierarchical Clustering and Heatmap of Each Cell Lines Global Transcriptomics Signature.  
Genes colored red on the heatmap had a median scaled relative abundance less than 1, genes colored white had a median scaled relative 
abundance of 1, and genes colored blue had a median scaled relative abundance greater than 1. Each column represents a single gene and each 
row represents a single transcriptomics sample; rows are labeled with sample number. Samples are color coded according to cell line identity. 
Unbiased hierarchical clustering reveals the two CRISPR/Cas9 cell lines constructed using guide RNA 2 are more similar than the two NAT1 















Figure 5.12: Hierarchical Clustering and Heatmap of Differential Gene Expression Compared to Scrambled. 
Each column represents a single gene and each row represents the average gene expression for the specific comparison labeled across the three 
biological replicates. Red represents genes that were decreased compared to Scrambled, black represents no change, and green represents 
genes increased compared to Scrambled. U vs S: Up vs Scrambled; D vs S: Down vs Scrambled; C 212 vs S: CRISPR 2-12 vs Scrambled; C 219 
vs S: CRISPR 2-19 vs Scrambled; C 550 vs S: CRISPR 5-50 vs Scrambled. 
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Similarly, principal component analysis showed that the CRISPR/Cas9 generated cell 
lines had global transcriptomic profiles that were distinct from the siRNA generated cell lines as 
well as each other. In our dataset, principal component 1 explains 43% of the variance in the data 
while principal component 2 explains 17% of the variance (Figure 5.13). There are two types of 
variance within the data set; within group and between group variance. For our experimental 
question, we are most interested in the between group variance. The CRISPR 2-12, CRISPR 2-
19, and CRISPR 5-50 groups are separated from the other three groups by principal component 
1 (PC1). This reveals that the Scrambled, Up, and Down groups have global transcriptomic 
profiles that are similar to each other but very different from the other three groups given that PC1 
represents 43% of the variance in our dataset. The CRISPR 5-50 group is separated from the 
other five groups along principal component 2. 
WGCNA Analysis 
 Weighted gene correlation network analysis was conducted to analyze networks of genes 
whose expression suggested interaction and/or involvement in the same pathways. First, all 
transcriptomics data were analyzed with the WGCNA algorithm to create modules of genes 
(Figure 5.14). Next Pearson correlation was conducted on resulting modules to identify modules 
correlated with NAT1 N-acetylation activity (Figure 5.15). We used this analysis to identify genes 
whose network topology suggested interaction with NAT2 as a strategy to identify genes that may 
have a role in the transcription of NAT2 (Figure 5.16). 
Pathway Analysis 
Pathway enrichment analysis was conducted on each group compared to the Scrambled 
group (Figure 5.17). Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways173,174 that 
had a normalized enrichment score of ≥ 1.60 were focused on. Disease associated pathways 
were removed from the analysis results because samples are known to be malignant thus 
confounding any possible conclusions about other diseases. Many pathways were significantly 
enriched for differences; amino acid, lipid, and nucleotide metabolism pathways were significantly 
enriched. Some enriched pathways did not include all group comparisons suggesting differential 
impacts on metabolism. 




Figure 5.13: Transcriptomics Principal Components Analysis. 
Each symbol represents an individual transcriptomics sample and is color coded by cell line. 
Principal component one represents 43% of the total variance in the dataset and separates the 
CRISPR 2-12 and CRISPR 2-19 cell lines from all other cell lines. Principal component 2 
represents 17% of the total variance in our dataset and separates the CRISPR 5-50 cell line from 


































Figure 5.14: WGCNA Transcript Module Branches by Color 
The Weighted Gene Correlation Network Analysis (WGCNA) algorithm was used to create modules of correlated genes based on topological 









Figure 5.15: Correlation Between WGCNA Transcript Modules and NAT1 N-acetylation Activity. 
To identify gene modules related to varying levels of NAT1 correlation analysis between the module score of each sample and NAT1 N-acetylation 
activity was conducted. Four modules, white, yellow3, thistle, and tan, were associated with NAT1 activity. Each point represents a single 
metabolomics sample and is color coded according to cell line. 
 
NAT1 Activity (log scale) 




Figure 5.16: Heatmap of genes in WGCNA white module. 
Heatmap showing relative gene expression for each gene in the white module. NAT2 is contained 
in this module. Clustering of genes in the white module is shown. Genes colored red on the 
heatmap had a median scaled relative abundance less than 1, genes colored white had a median 
scaled relative abundance of 1, and genes colored blue had a median scaled relative abundance 









































































































































































































































































































































































































































Figure 5.17: Transcriptomics Enrichment Analysis. 
Pathway enrichment analysis was conducted for each group compared to Scrambled and is color-coded by comparison. We utilized the 
normalized enrichment score to determine the relative degree of enrichment. U vs S: Up vs Scrambled; D vs S: Down vs Scrambled; C212 vs S: 
CRISPR 2-12 vs Scrambled; C219 vs S: CRISPR 2-19 vs Scrambled; C550 vs S: CRISPR 5-50 vs Scrambled. 
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Discussion  
Given that (theoretically) only a single gene, NAT1, was genetically altered in each cell 
line, it was expected that only a small proportion of genes would be differentially expressed, given 
the vast homeostasis mechanisms present175-177. However, a very large proportion (~90%) of all 
genes were observed to be significantly differentially expressed. Additionally, very few, if any, 
differences in gene expression were expected between the two NAT1 knockout cell lines because 
each cell line should otherwise have the exact same genome. Yet one of the most striking 
observations of this study is the differences in gene expression between the two complete NAT1 
knockout cell lines. The hierarchical clustering, principal components analysis, and pathway 
enrichment analysis show there were significant differences between the two cell lines 
constructed using CRISPR/Cas9 guide RNA 2 and the cell line constructed using CRISPR/Cas9 
guide RNA 5. Even though, in terms of NAT1 activity the CRISPR 2-19 and CRISPR 5-50, cell 
lines are identical, their transcriptomic profiles are extremely different. This result suggests there 
are additional genetic differences between the two cell lines. The large number of differentially 
expressed genes between each knockout cell line compared to the Scrambled cell line and 
compared to each other could be because the cell lines have undergone additional unique 
mutations and/or because each CRISPR guide RNA used caused unique off-target effects in 
addition to targeting NAT1. To focus on transcriptome differences associated with varying levels 
of NAT1 in breast cancer, interpretation of this study has been focused on differentially expressed 
genes that agreed between the two CRISPR NAT1 knockout cell lines. 
The observation that the complete knockout, but not knockdown, of NAT1 lead to NAT2 
transcript production leads to the postulation that there may be a compensation mechanism that 
occurs when NAT1 N-acetylation is lost, suggesting NAT1 has an essential role. There have been 
reports of genetic compensation in a zebrafish model in which a gene was knocked out by a 
deleterious mutation but not in a zebrafish model where the same gene was knocked down by 
siRNA216. There have been cases reported of humans that have no detectable NAT1 N-
acetylation activity but NAT2 expression and/or activity was not investigated. Notably, a 
retrospective analysis of publicly available NAT1 and NAT2 gene expression data in established 
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breast cancer cell lines, primary breast tumor tissues, and normal breast tissues showed a small 
positive correlation between the two genes217. One reason that study did not observe an inverse 
relationship between NAT1 and NAT2 gene expression may be because complete knockout of 
NAT1 may be necessary before the compensation mechanism occurs since NAT2 transcripts 
were only observed in the complete NAT1 KO cell lines but not the cell lines with decreased 
NAT1.  
NAT1 has been shown to have redundancy with methylthioribose-1-phosphate isomerase 
(MRI1) in the methionine salvage pathway107. However, MRI1 was only differentially expressed 
(increased) in one cell line, CRISPR 2-12, compared to Scrambled. As the MDA-MB-231 cell line 
does not have a functional methionine salvage pathway this result is not surprising. This example 
highlights the importance of studying the effects of varying NAT1 in multiple cell lines as each has 
unique mutations that may confound results. 
Summary and Conclusions 
This is the first study to measure the global transcriptome profile of breast cancer cells 
with varying levels of NAT1 N-acetylation activity. Most notably, NAT1 knockout and knockdown 
had a much greater impact on differential gene expression than the overexpression of NAT1. 
Additionally, NAT2 transcript production was observed in the two complete NAT1 knockout cell 
lines, CRISPR 2-19 and CRISPR 5-50, but not any of the other cell lines. This observation 
suggests NAT2 transcripts are produced as a compensation mechanism for the complete loss of 
NAT1. However, the mechanism by which the cell senses the loss of NAT1 and transcribes NAT2 
has not been identified and requires further investigation. Although NAT2 transcripts were 
detected in the NAT1 knockout cell lines, NAT2 N-acetylation activity was not thus the 
functionality of the NAT2 transcripts requires further investigation. Since this is the first study to 
measure the global transcriptome profile of breast cancer cells with varying levels of NAT1 N-
acetylation activity I envision this transcriptomics dataset being mined for years to come as new 
discoveries are made about NAT1. An important use of this data will be comparisons and joint 
analysis between the transcriptomics data presented in this chapter and the metabolomics data 
presented in Chapter 4; this comparison is discussed in Chapter 6. 






 The ability to combine multiple omics datasets for joint analysis is important for achieving 
a systems biology view of metabolism as there are many layers of regulation at each step, 
including transcriptional, translational, and post-translational regulation. Additionally, comparing 
results from multiple omics datasets can provide confidence that observations are not due to 
chance when multiple, independently measured datasets support a specific conclusion. Multi-
omics integration is a relatively new area of research and as such methodologies are still being 
developed and improved (reviewed in 218). There are many tools currently available, including 
MetaCore™, MetaboAnalyst219, InCroMAP220, PaintOmics221,222, Pathview223, MixOmics224, and 
3Omics225. However, the “best” methodology for multi-omics integration is a fiercely debated topic 
in the omics field. It is the author’s opinion that there is considerable room for improvement and 
development of tools in the field of multi-omics analyses. Currently, most tools for combining 
omics datasets perform a pathway enrichment analysis using data from the multiple datasets. 
However, pathway enrichment analysis is highly biased by what is currently known about 
metabolism and what can be measured/detected by the omics methods. Bioinformatics skills as 
well as broad knowledge of metabolism are indispensable when utilizing the above mentioned 
omics integration tools to obtain and interpret the results in a meaningful way. 
Methods and Results 
Bioenergetics and Transcriptomics 
To combine the bioenergetics and transcriptomics datasets expression of nuclear-
encoded mitochondrial genes from the transcriptomics data was compared between constructed 
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cell lines. First, a list of ENTREZ gene IDs was created containing all mitochondrial complex 
genes from the HUGO gene nomenclature committee website226; the list contained 96 genes. 
Although the hg.38 reference assembly, which includes the human mitochondrial genome, was 
utilized for transcript mapping, mitochondrial DNA (mtDNA) encoded genes were not detected in 
the transcriptomics dataset. It is hypothesized that this is because of the relatively low abundance 
of mitochondrial DNA compared to nuclear DNA. Nuclear-encoded mitochondrial gene 
expression in all cell lines was visualized utilizing a heatmap (Figure 6.1). Fold change and 
significance of differential expression of those mitochondrial genes was visualized using volcano 
plots (Figure 6.2). Tables 6.1 – 6.4 lists fold-change and significance of all differentially expressed 
mitochondrial genes by cell line comparison. Notably, no mitochondrial genes were significantly 
differentially expressed between the Up and Scrambled cell lines. Additionally, most 
mitochondrial genes in the cell lines with decreased or knockout NAT1 N-acetylation activity 
(Down, CRISPR 2-12, CRISPR 2-19, and CRISPR 5-50) were downregulated compared to the 
cell line with parental NAT1 N-acetylation activity (Scrambled). Table 6.5 lists mitochondrial 
genes that were concordantly differentially expressed (q ≤ 0.05) in the two NAT1 knockout cell 
lines, CRISPR 2-19 and CRISPR 5-50. 
Metabolomics and Transcriptomics 
To combine the metabolomics and transcriptomics datasets a combined pathway 
enrichment analysis was performed and both metabolite abundance (from metabolomics dataset) 
and gene expression (from transcriptomics dataset) were mapped onto KEGG pathway maps for 
visualization utilizing Pathview223, an R/Bioconductor package for pathway-based data integration 
and visualization. For the combined enrichment analysis, the normalized enrichment score for 
each pathway from both datasets was averaged. Many KEGG pathways showed significant 
enrichment in the combined analysis (Figure 6.3), including 1. lysine degradation (Figure 6.4), 2. 
alanine, aspartate, and glutamate metabolism, 3. amino sugar and nucleotide sugar metabolism, 













Figure 6.1: Heatmap of Mitochondrial Gene Expression. 
Mitochondrial gene expression from the transcriptomics dataset was compared between constructed cell lines. A list of 96 ENTREZ gene IDs was 
created for all mitochondrial complex genes from the HUGO gene nomenclature committee website226. Transcript abundance was plotted as a 
heatmap. Cyan represents genes not expressed, yellow represents genes lowly expressed, and orange and red represent genes with high 
expression. Each row represents average transcript expression for 3 biological replicates from each cell line and columns represent a single 
mitochondrial gene. 
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Figure 6.2: Mitochondrial Gene Expression 
Mitochondrial gene expression was compared in the constructed cell lines. Genes were selected 
by creating a list of ENTREZ gene IDs for all mitochondrial complex genes from the HUGO gene 
nomenclature committee website226. Each point represents a single mitochondrial gene and is 
color coded by cell line compared to Scrambled. US: Up vs Scrambled; DS: Down vs Scrambled; 
C212S: CRISPR 2-12 vs Scrambled; C219S: CRISPR 2-19 vs Scrambled; C550 S: CRISPR 5-50 
vs Scrambled. (A) All data was visualized as a volcano plot. (B) Only genes significantly 
differentially expressed were plotted. 
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Table 6.1 
 
Differentially Abundant Nuclear-encoded Mitochondrial Genes in Down Cell Line Compared to 
Scrambled 







ENSG00000099624 513 ATP5D -2.80 0.0005 
ENSG00000124172 514 ATP5E -0.68 0.0042 
ENSG00000135390 517 ATP5G2 -0.86 0.0005 
ENSG00000131143 1327 COX4I1 -1.21 0.0005 
ENSG00000135940 1329 COX5B -0.69 0.0005 
ENSG00000126267 1340 COX6B1 -0.79 0.0005 
ENSG00000131174 1349 COX7B 0.55 0.0129 
ENSG00000127184 1350 COX7C -0.40 0.0257 
ENSG00000176340 1351 COX8A -1.34 0.0005 
ENSG00000179091 1537 CYC1 -1.10 0.0005 
ENSG00000170906 4696 NDUFA3 -1.62 0.0387 
ENSG00000099795 4713 NDUFB7 -3.06 0.0005 
ENSG00000167792 4723 NDUFV1 -0.94 0.0005 
ENSG00000164258 4724 NDUFS4 -0.38 0.0431 
ENSG00000145494 4726 NDUFS6 -0.80 0.0045 
ENSG00000110717 4728 NDUFS8 -1.47 0.0005 
ENSG00000010256 7384 UQCRC1 -1.02 0.0005 
ENSG00000127540 10975 UQCR11 -1.20 0.0005 
ENSG00000184076 29796 UQCR10 -1.14 0.0005 
ENSG00000186010 51079 NDUFA13 -2.13 0.0005 
ENSG00000147123 54539 NDUFB11 -0.60 0.0260 
ENSG00000174886 126328 NDUFA11 -2.22 0.0005 
ENSG00000115286 374291 NDUFS7 -2.07 0.0005 
 
Nuclear-encoded Mitochondrial Genes Differentially Abundant in the Down Cell Line Compared to 
Scrambled are listed. 
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Table 6.2 
 
Differentially Abundant Nuclear-encoded Mitochondrial Genes in CRISPR 2-12 Cell Line 
Compared to Scrambled 







ENSG00000110955 506 ATP5B -0.53 0.0038 
ENSG00000124172 514 ATP5E -0.73 0.0087 
ENSG00000135390 517 ATP5G2 -0.58 0.0009 
ENSG00000127184 1350 COX7C -0.43 0.0178 
ENSG00000128609 4698 NDUFA5 -1.11 0.0005 
ENSG00000184983 4700 NDUFA6 -0.49 0.0326 
ENSG00000139180 4704 NDUFA9 -0.58 0.0280 
ENSG00000004779 4706 NDUFAB1 -0.75 0.0005 
ENSG00000183648 4707 NDUFB1 -0.55 0.0059 
ENSG00000090266 4708 NDUFB2 -0.95 0.0024 
ENSG00000164258 4724 NDUFS4 -0.64 0.0005 
ENSG00000160194 4731 NDUFV3 0.78 0.0005 
ENSG00000156467 7381 UQCRB -0.73 0.0005 
ENSG00000169021 7386 UQCRFS1 -0.59 0.0005 
ENSG00000178741 9377 COX5A -0.64 0.0005 
ENSG00000241468 9551 ATP5J2 -0.83 0.0393 
ENSG00000167863 10476 ATP5H| -0.64 0.0034 
ENSG00000127540 10975 UQCR11 -0.83 0.0097 
ENSG00000164405 27089 UQCRQ -0.50 0.0313 
ENSG00000184076 29796 UQCR10 -0.66 0.0005 
ENSG00000174886 126328 NDUFA11 -0.62 0.0230 
 
Nuclear-encoded Mitochondrial Genes Differentially Abundant in the CRISPR 2-12 Cell Line 
Compared to Scrambled are listed. 
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Table 6.3 
 
Differentially Abundant Nuclear-encoded Mitochondrial Genes in CRISPR 2-19 Cell Line 
Compared to Scrambled 





ENSG00000165629 509 ATP5C1 -0.73 0.0013 
ENSG00000099624 513 ATP5D -1.36 0.0076 
ENSG00000124172 514 ATP5E -0.98 0.0013 
ENSG00000135390 517 ATP5G2 -1.07 0.0005 
ENSG00000131143 1327 COX4I1 -0.80 0.0094 
ENSG00000126267 1340 COX6B1 -0.55 0.0312 
ENSG00000127184 1350 COX7C -1.06 0.0005 
ENSG00000176340 1351 COX8A -1.09 0.0016 
ENSG00000131495 4695 NDUFA2 -1.47 0.0398 
ENSG00000128609 4698 NDUFA5 -0.83 0.0005 
ENSG00000184983 4700 NDUFA6 -0.59 0.0306 
ENSG00000119421 4702 NDUFA8 -0.61 0.0039 
ENSG00000139180 4704 NDUFA9 -0.59 0.0494 
ENSG00000004779 4706 NDUFAB1 -0.60 0.0076 
ENSG00000183648 4707 NDUFB1 -0.64 0.0057 
ENSG00000090266 4708 NDUFB2 -0.85 0.0336 
ENSG00000065518 4710 NDUFB4 -0.61 0.0272 
ENSG00000099795 4713 NDUFB7 -1.00 0.0051 
ENSG00000167792 4723 NDUFV1 -0.58 0.0231 
ENSG00000164258 4724 NDUFS4 -0.80 0.0005 
ENSG00000160194 4731 NDUFV3 0.86 0.0033 
ENSG00000156467 7381 UQCRB -0.58 0.0071 
ENSG00000169021 7386 UQCRFS1 -0.62 0.0005 
ENSG00000178741 9377 COX5A -0.51 0.0156 
ENSG00000241468 9551 ATP5J2 -0.93 0.0356 
ENSG00000167863 10476 ATP5H -0.68 0.0042 
ENSG00000127540 10975 UQCR11 -0.99 0.0039 
ENSG00000164405 27089 UQCRQ -1.06 0.0005 
ENSG00000184076 29796 UQCR10 -0.94 0.0005 
ENSG00000160471 125965 COX6B2 2.04 0.0013 
ENSG00000174886 126328 NDUFA11 -1.77 0.0005 
ENSG00000115286 374291 NDUFS7 -2.25 0.0005 
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Nuclear-encoded Mitochondrial Genes Differentially Abundant in the CRISPR 2-19 Cell Line 
Compared to Scrambled are listed. 
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Table 6.4 
 
Differentially Abundant Nuclear-encoded Mitochondrial Genes in CRISPR 5-50 Cell Line 
Compared to Scrambled 





CRISPR 5-50 vs 
Scrambled 
ENSG00000110955 506 ATP5B -0.55 0.0013 
ENSG00000124172 514 ATP5E -0.80 0.0005 
ENSG00000154518 518 ATP5G3 -0.38 0.0383 
ENSG00000169020 521 ATP5I -0.75 0.0005 
ENSG00000135940 1329 COX5B -0.46 0.0160 
ENSG00000127184 1350 COX7C -0.90 0.0005 
ENSG00000125356 4694 NDUFA1 0.57 0.0023 
ENSG00000128609 4698 NDUFA5 -0.48 0.0217 
ENSG00000184983 4700 NDUFA6 -0.85 0.0005 
ENSG00000004779 4706 NDUFAB1 -1.81 0.0005 
ENSG00000183648 4707 NDUFB1 -0.62 0.0013 
ENSG00000065518 4710 NDUFB4 -0.49 0.0361 
ENSG00000158864 4720 NDUFS2 0.55 0.0074 
ENSG00000164258 4724 NDUFS4 -0.63 0.0005 
ENSG00000145494 4726 NDUFS6 -0.53 0.0271 
ENSG00000204370 6392 SDHD -0.68 0.0294 
ENSG00000156467 7381 UQCRB -0.58 0.0013 
ENSG00000169021 7386 UQCRFS1 -0.53 0.0009 
ENSG00000178741 9377 COX5A -0.52 0.0027 
ENSG00000167863 10476 ATP5H -0.53 0.0068 
ENSG00000164405 27089 UQCRQ -1.12 0.0005 
ENSG00000160471 125965 COX6B2 2.05 0.0005 
 
Nuclear-encoded Mitochondrial Genes Differentially Abundant in the CRISPR 5-50 Cell Line 






Nuclear-encoded Mitochondrial Genes Concordantly Differentially Abundant in CRISPR 2-19 and CRISPR 5-50 Cell Lines 
ENSEMBL GENE ID ENTREZ ID GENE SYMBOL/DESCRIPTION 
log2FC.C.R 
CRISPR 2-19/S CRISPR 5-50/S 
ENSG00000124172 514 ATP5E|ATP synthase, H+ transporting, mitochondrial F1 complex, epsilon subunit -0.98 -0.80 
ENSG00000127184 1350 COX7C|cytochrome c oxidase subunit VIIc -1.06 -0.90 
ENSG00000128609 4698 NDUFA5|NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 5 -0.83 -0.48 
ENSG00000184983 4700 
NDUFA6|NADH dehydrogenase 





(ubiquinone) 1, alpha/beta subcomplex, 1, 
8kDa 
-0.60 -1.81 
ENSG00000183648 4707 NDUFB1|NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 1, 7kDa -0.64 -0.62 
ENSG00000065518 4710 NDUFB4|NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 4, 15kDa -0.61 -0.49 
ENSG00000164258 4724 
NDUFS4|NADH dehydrogenase 
(ubiquinone) Fe-S protein 4, 18kDa 
(NADH-coenzyme Q reductase) 
-0.80 -0.63 
ENSG00000156467 7381 UQCRB|ubiquinol-cytochrome c reductase binding protein -0.58 -0.58 
ENSG00000169021 7386 UQCRFS1|ubiquinol-cytochrome c reductase, Rieske iron-sulfur polypeptide 1 -0.62 -0.53 
ENSG00000178741 9377 COX5A|cytochrome c oxidase subunit Va -0.51 -0.52 
ENSG00000167863 10476 ATP5H|ATP synthase, H+ transporting, mitochondrial Fo complex, subunit d -0.68 -0.53 
ENSG00000164405 27089 UQCRQ|ubiquinol-cytochrome c reductase, complex III subunit VII, 9.5kDa -1.06 -1.12 
ENSG00000160471 125965 COX6B2|cytochrome c oxidase subunit VIb polypeptide 2 (testis) 2.04 2.05 
 






































































































































































































Figure 6.3: Combined Metabolomics and Transcriptomics Enrichment Analysis. 
Pathway enrichment analysis was conducted for each group compared to Scrambled and is color-coded by comparison. The normalized 
enrichment score was utilized to determine the relative degree of enrichment. U vs S: Up vs Scrambled; D vs S: Down vs Scrambled; C212 vs S: 












Figure 6.4: Metabolites and Genes Projected onto the KEGG Lysine Degradation Pathway. 
NAT1 knockout cell lines, CRISPR 2-19 and CRISPR 5-50, metabolite abundance and gene expression data compared to Scrambled cell line 
projected onto the KEGG lysine degradation pathway. Metabolite abundances in yellow are decreased in the NAT1 knockout cell lines, 
metabolites in gray are unchanged, and metabolites in blue are increased in the NAT1 knockout cell lines. Gene abundances in red are decreased 
in the NAT1 knockout cell lines, genes in gray are unchanged, and genes in green are increased in the NAT1 knockout cell lines. The CRISPR 2-
19 cell line abundance and expression data are shown on the right of the circles and boxes, respectively, while the CRISPR 5-50 cell line 
abundance and expression data are shown on the left of the circles and boxes, respectively.
  155 
mannose metabolism, 7. glycerolipid metabolism, 8. glycerophospholipid metabolism, 9. 
pyrmidine metabolism, 10. sphingolipid metabolism, and 11. sulfur metabolism. Notably, the Up 
cell line compared to the Scrambled cell line was not significantly enriched in 5 of the pathways.  
MixOmics224, an R package for omics feature selection and multiple data integration, was 
additionally utilized to conduct sparse partial least squares-discriminant analysis (sPLS-DA)227 
utilizing the metabolomics and transcriptomics datasets as blocks. The transcriptomics dataset 
was first filtered to remove genes that had no detected expression in any sample, leaving 25,515 
genes. A second filter was then applied to remove genes from the analysis for which 16 or more 
of the 18 total samples had no expression recorded; this left 23,931 genes in the dataset after 
both filters were applied. Additionally, because the chosen analysis relies on paired biological 
samples, only data from metabolomics samples that had corresponding transcriptomics data 
were utilized. This analysis had 18 samples total with 3 samples in each group.  
Tuning of the algorithm parameters was required. First, a design matrix was created 
where blocks (metabolomics and transcriptomics datasets) were correlated with a link of 0.1. 
Utilizing four components was found to be optimal in minimizing the overall error rate. Therefore 4 
components were utilized in the final model (Figure 6.5). The model was also tuned for the 
optimal number of variables to be selected from each dataset. It is important to note that the 
tuning function was set to favor relatively small numbers of variables to aide in interpretation of 
the final model results. The discriminant ability of components 1 and 2 was then visualized for 
each group in each block (metabolomics and transcriptomics; Figure 6.6). Component 1 
separated the CRISPR 5-50 cell line from the other cell lines; the corresponding loadings plot of 
component 1 visualized metabolites and genes that contribute the most to this discrimination 
(Figure 6.7; Tables 6.6 and 6.7). Conversely, component 2 separated the CRISPR/Cas9 
constructed cell lines from the siRNA constructed cell lines; however, the metabolites and genes 
of component 2 have greater contribution to the separation of the cell lines constructed using 
guide RNA 2 from all other cell lines. The corresponding loadings plot of component 2 visualized 
metabolites and genes that contributed the most to this discrimination and are each color coded 
by which group it is contributing to most (Figure 6.8; Tables 6.8 and 6.9). This result suggests that 
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Figure 6.5 
 
Figure 6.5 Optimization of Number of Components Included in sPLS-DA. 
Solid lines represent the overall error rate. Blue line represents the max distance measure, 
orange line represents the centroids distance measure, and gray line represents the mahalanobis 


































Figure 6.6: sPLS-DA Scores Plot. 
Scores plot showing the discriminant ability of sPLS-DA components 1 (variate 1) and 2 (variate 
2) for each group in each block (metab=metabolomics dataset and trans=transcriptomics 
dataset). S: Scrambled; U: Up; D: Down; C12: CRISPR 2-12; C19: CRISPR 2-19; C50: CRISPR 
5-50. 
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Figure 6.7  
 
 
Figure 6.7: sPLS-DA Component 1 Loadings Plot. 
Component 1 separates the CRISPR 5-50 cell line from the other cell lines; the corresponding 
loadings plot of component 1 visualizes metabolites and genes that are contributing the most to 
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Table 6.6 
 
sPLS-DA Component 1 Metabolites 
M# BIOCHEMICAL 
M327 indolelactate 
M462 phenyllactate (PLA) 
M259 galactosylglycerol* 
M265 gamma-glutamyl-epsilon-lysine 
M324 imidazole lactate 
M189 beta-citrylglutamate 
M180 argininosuccinate 
M364 methionine sulfoxide 
M530 sulfate* 
 
Metabolites included in sPLS-DA component 1. 
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Table 6.7 
 
sPLS-DA Component 1 Genes 
ENSEMBL GENE ID ENTREZ GENE NAME 
ENSG00000019186 cytochrome P450 family 24 subfamily A member 1 (CYP24A1) 
ENSG00000030304 muscle associated receptor tyrosine kinase (MUSK) 
ENSG00000100628 ankyrin repeat and SOCS box containing 2 (ASB2) 
ENSG00000126752 SSX family member 1 (SSX1) 
ENSG00000131370 SH3 domain binding protein 5 (SH3BP5) 
ENSG00000138347 myopalladin (MYPN) 
ENSG00000156395 sortilin related VPS10 domain containing receptor 3 (SORCS3) 
ENSG00000162366 PDZK1 interacting protein 1 (PDZK1IP1) 
ENSG00000162639 HEN1 methyltransferase homolog 1 (HENMT1) 
ENSG00000170848 pregnancy specific beta-1-glycoprotein 6 (PSG6) 
ENSG00000173432 serum amyloid A1 (SAA1) 
ENSG00000183668 pregnancy specific beta-1-glycoprotein 9 (PSG9) 
ENSG00000231924 pregnancy specific beta-1-glycoprotein 1 (PSG1) 
ENSG00000248596 centrosomal protein 192kDa pseudogene (LOC643201) 
ENSG00000249306 long intergenic non-protein coding RNA 1411 (LINC01411) 




Genes included in sPLS-DA component 1. 




Figure 6.8: sPLS-DA Component 2 Loadings Plot. 
Component 2 separates the CRISPR/Cas9 constructed cell lines from the siRNA constructed cell 
lines; however, the metabolites and genes of component 2 have greater contribution to the 
separation of the cell lines constructed using guide RNA 2 from all other cell lines. The 
corresponding loadings plot of component 2 visualizes metabolites and genes that are 
contributing the most to this discrimination and are each color coded by which group it is 
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Table 6.8 
 




M452 palmitoylcholine * 
M31 1-lignoceroyl-GPC (24:0) 
M78 1-stearoyl-GPC (18:0) 
 
Metabolites included in sPLS-DA component 2. 
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Table 6.9 
 
sPLS-DA Component 2 Genes 
ENSEMBL GENE ID ENTREZ GENE NAME 
ENSG00000084734 glucokinase regulator (GCKR) 
ENSG00000100181 transmembrane phosphatase with tensin homology pseudogene 1 (TPTEP1) 
ENSG00000115216 nuclear receptor binding protein 1 (NRBP1) 
ENSG00000168032 ectonucleoside triphosphate diphosphohydrolase 3 (ENTPD3) 
ENSG00000185860 coiled-coil domain containing 190 (CCDC190) 
ENSG00000213190 myeloid/lymphoid or mixed-lineage leukemia; translocated to, 11 (MLLT11) 
ENSG00000227372 TP73 antisense RNA 1 (TP73-AS1) 
ENSG00000263753 long intergenic non-protein coding RNA 667 (LINC00667) 
ENSG00000084734 glucokinase regulator (GCKR) 
 
Genes included in sPLS-DA component 2. 
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while choline metabolism is altered in the CRISPR/Cas9 constructed cell lines it is dysregulated 
to a greater extent in the cell lines constructed using guide RNA 2. 
We have additionally utilized a chord diagram (also known as circos plot) to visualize the 
correlations between variables of different types (i.e. metabolites and genes; Figure 6.9). A 
correlation cut-off of 0.9 was chosen; positive correlations are shown with green connectors while 
negative correlations are shown with red connectors. A high degree of correlation between 
variables was observed with most correlations being positive. The data are also presented as a 
clustered heatmap specifically implemented to represent the multi-omics molecular signature 
expression for each sample (Figure 6.10). Each cell line has a unique multi-omics signature with 
distinct clusters of both metabolites and genes that appear to differentiate each cell line. This 
result agrees with the hierarchical clustering and heatmaps generated for each dataset 
independently, as each cell line had a unique global metabolomics and transcriptomics signature, 
respectively. 
Additionally, differential gene expression of SAT1 and SAT2 in the transcriptomics 
dataset were evaluated because SAT1 and SAT2 are known to N-acetylate putrescine and N-
acetylputrescine was positively correlated with NAT1 N-acetylation activity in the metabolomics 
dataset. SAT1 expression was significantly increased in the Down, CRISPR 2-12, and CRISPR 2-
19 cell lines compared to the Scrambled cell line (Table 6.10). This result suggests the Down, 
CRISPR 2-12, and CRISPR 2-19 cell lines should have increased N-acetylputrescine abundance 
compared to Scrambled. However, N-acetylputrescine abundances were observed to be 
decreased in those cell lines in the metabolomics dataset compared to the Scrambled cell line. 
These findings suggest the expression of SAT1 is not responsible for the N-acetylputrescine 
abundance observations. SAT2 was not significantly differentially expressed in any cell lines 
compared to the Scrambled cell line (Table 6.10).  
Discussion 
 The presence of additional differences other than NAT1 (presented in Chapter 7) 
complicates interpretation of the results. However, the combined results from all experiments 
have been utilized to develop a working postulation of the role of NAT1 in breast cancer cell 
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Table 6.10 
 
Differential Expression of the Spermidine/Spermine N1-Acetyltransferase (SAT) Genes 
COMPARISON GENE Log2 FC Comparison/Scrambled q-value 
Up vs Scrambled 
SAT1 0.17 0.85 
SAT2 -0.61 0.84 
Down vs Scrambled 
SAT1 0.41 0.02 
SAT2 -0.81 0.56 
CRISPR 2-12 vs Scrambled 
SAT1 0.93 <0.001 
SAT2 -0.08 0.97 
CRISPR 2-19 vs Scrambled 
SAT1 1.50 <0.001 
SAT2 -0.56 0.73 
CRISPR 5-50 vs Scrambled 
SAT1 0.24 0.24 
SAT2 0.15 0.94 
 
SAT transcript fold-changes between each cell line compared to the Scrambled cell line. Fold-
change and q-value were calculated using cuffdiff. Genes with q≥0.05 were considered 
significantly differentially expressed. Significant differential gene expression is color-coded by 
direction of fold-change with increases shown in green.  
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Figure 6.9 
 
Figure 6.9: Circos Plot of Metabolites and Transcripts Included in sPLS-DA Model. 
Metabolites are colored orange and genes are colored blue. A correlation cut-off of 0.9 was 
chosen; positive correlations are shown with green connectors while negative correlations are 
shown with red connectors. Relative abundances are shown with color coded lines on the outside 















































































































































































































































































































































































































































































































































































































































































































































Figure 6.10: Combined Metabolomics and Transcriptomics Hierarchical Clustering and Heatmap. 
Each row represents a single biological replicate and each column represents a single variable (gene or metabolite). Variables colored purple, 
blue, or green on the heatmap had a median scaled relative abundance less than 1, genes colored yellow had a median scaled relative 
abundance of 1, and genes colored orange or red had a median scaled relative abundance greater than 1. S: Scrambled; U: Up; D: Down; C12: 
CRISPR 2-12; C19: CRISPR 2-19; C50: CRISPR 5-50. Green represents the Up cell line, yellow represents the Down cell line, light red 
represents the Scrambled cell line, cyan represents the CRISPR 2-12 cell line, sky blue represents the CRISPR 2-19 cell line, and pink/purple 
represents the CRISPR 5-50 cell line.
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metabolism (Figure 6.11). Although many pathways were significantly enriched in the combined 
pathway analysis, the lysine degradation pathway has been focused on. Both carnitine and 
saccharopine, significant metabolites from the metabolomics dataset, are included in the lysine 
degradation pathway. Carnitine, an important metabolite in many pathways related to acetyl-CoA, 
is biosynthesized from methionine and lysine178. Notably, NAT1 has a role in the methionine 
salvage pathway107. Saccharopine is the first metabolite formed in the main lysine degradation 
pathway in mammals201,202. Further experiments will be necessary to understand how NAT1 is 
connected to the lysine degradation pathway.  
More generally, it was observed in the experiments presented in this dissertation that 
manipulation of NAT1 alters many metabolic pathways including amino acid, fatty acid, and 
nucleotide metabolism however it has been harder to narrow in on NAT1’s role specifically due to 
the presence of differences other than NAT1. While the exact mechanism by which NAT1 affects 
breast cancer cell metabolism has not been identified, significant “pieces” have been added to the 
“puzzle”. I predict, that as more experiments investigating the role of NAT1 in breast cancer are 
conducted, the bioenergetics, metabolomics, transcriptomics and combined analyses results 
presented here will not only have better context for interpretation but can also be utilized to add 
supporting or refuting information to those studies. 
Summary and Conclusions 
 Combined analysis of the bioenergetics & transcriptomics and metabolomics & 
transcriptomics datasets was conducted utilizing currently available bioinformatics tools. The joint 
analysis of the bioenergetics and transcriptomics analysis suggest differential mitochondrial gene 
expression may help explain some of our bioenergetics observations however further 
experiments investigating mitochondrial number and morphology are needed to gain a better 
understanding of the relationship between NAT1 and mitochondria. Notably, mitochondrial 
function has been linked to regulation of metabolism, cell-cycle control, and cell death in addition 
to mitochondria’s well-known role as the energy producers of the cell228. 
 Although the combined metabolomics and transcriptomics pathway analysis indicated 11 
KEGG biochemical pathways were significantly enriched, the lysine degradation pathway was 




Figure 6.11: Overall Dissertation Conclusion. 
The overall dissertation conclusion is that NAT1 has a role in the lysine degradation pathway 
however whether it is a direct role or a result of NAT1’s ability to hydrolyze acetyl-CoA remains 
unknown. By utilizing a systems biology approach we were able to measure that fatty acyl-CoA 
carnitine conjugates are decreased when NAT1 is knocked out. Fatty acyl-CoA conjugates are 
necessary for transporting fatty acyl-CoAs to the mitochondria for beta-oxidation which in turn 
produces acetyl-CoA. We observed differences in mitochondrial bioenergetics. Additionally, 
carnitine is biosynthesized from methionine and lysine and lysine is degraded to saccharopine. 
Saccharopine is increased when NAT1 is knocked out. 
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focused on. Interpretation of the other pathways was complicated by the strong evidence of 
differences in addition to NAT1 in the genetically modified cell lines. Additionally, the strongly 
suggested presence of mutation of genes in addition to NAT1 lead to the sPLS-DA model not 
yielding useful information about genes and transcripts, that together, vary based on NAT1 N-
acetylation activity. As better methods to integrate omics datasets become available, the datasets 
generated in this dissertation can be re-evaluated for novel insights. Currently available methods 
either have a reliance on pathway databases (hindering detection of unknown biochemical 
reactions) or have been developed to aide in the discovery of biomarkers or classification of 
patient samples.  
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CHAPTER 7
 




 The constructed MDA-MB-231 cell lines utilized for the experiments presented in this 
dissertation were designed to vary only in NAT1 and were expected to have otherwise identical 
genomes. The guide RNAs utilized for construction were specifically designed to target only the 
NAT1 genomic sequence, thus limiting the risk of off-target effects. However, in all three datasets, 
bioenergetics (Chapter 3), metabolomics (Chapter 4), and transcriptomics (Chapter 5), evidence 
of differences in addition to NAT1 were observed in the constructed MDA-MB-231 cell lines which 
we discuss in detail in this chapter (Figure 7.1). Although evidence of differences in addition to 
NAT1 were observed between the CRISPR/Cas9 NAT1 knockout cell lines, the additional genes 
altered have not been identified. A whole genome sequencing (WGS) approach would be 
necessary to determine what additional genes differ between the cell lines. I postulate that the 
observed additional differences are likely due to both CRISPR/Cas9 off-target effects as well as 
mutations in the cell lines that may have occurred during clonal isolation, passaging, and/or 
propagation. STR-profiling authenticated all constructed cell lines as MDA-MB-231 but is limited 
by the fact that only a few genomic locations are interrogated. Mutations could have occurred at 
locations not probed by STR-profiling. 
While I acknowledge that there is very strong evidence of differences in addition to NAT1 
expression in the constructed cell lines, the elegant study design and sample selection utilized in 
this dissertation allowed those differences to be filtered out and focus to be placed on results that 











Figure 7.1: Evidence of Additional Differences Between Cell Lines Other Than NAT1. 
There are many sources of evidence for the assertion that there are differences other than NAT1 in the constructed cell lines. Concordance 
between both metabolites and genes was lower than disagreement between the two MDA-MB-231 cell lines with no detectable NAT1 N-
acetylation activity but constructed using two different guide RNAs; metabolites and genes in green were increased while metabolites and genes in 
red were decreased. Additionally, the first branch in hierarchical clustering, in both the metabolomics and transcriptomics datasets, separated the 
two MDA-MB-231 cell lines constructed utilizing guide RNA 2 but with different levels of NAT1 N-acetylation activity. In the bioenergetics dataset, 
both mitochondrial reserve capacity and baseline ECAR were significantly increased in the CRISPR 2-19 cell line compared to the CRISPR 5-50 
cell line, even both have no detectable NAT1 activity. Principal component analysis in the metabolomics dataset revealed most of the variance in 
the dataset was between the two MDA-MB-231 cell lines constructed utilizing guide RNA 2 but with different levels of NAT1 N-acetylation activity 
and all other cell lines. Data is color coded by cell line; Scrambled:salmon, Up:green, Down:mustard, CRISPR 2-12:teal, CRISPR 2-19:sky blue, 
CRISPR 5-50:pinkish purple. 
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in both NAT1 knockout cell lines were focused on, given any off-target effects caused by the use 
of a single guide RNA are likely not present in both cell lines. Additionally, mutations that 
occurred during clonal isolation or passaging are not likely to have occurred in the same gene in 
multiple cell lines thus allowing a focus on similarities rather than differences in the two NAT1 
knockout cell lines. 
Bioenergetics  
Mitochondrial reserve capacity was increased in both NAT1 knockout cell lines (CRISPR 
2-19 and CRISPR 5-50) compared to the Parent, Scrambled, and Up cell lines. However, it was 
also significantly higher in the CRISPR 2-19 cell line compared to the CRISPR 5-50 cell line 
suggesting differences other than NAT1 between the two cell lines. Baseline ECAR was also 
significantly increased in the CRISPR 2-19 cell line compared to the CRISPR 5-50 cell line. In the 
bioenergetics conclusions (Chapter 3), observations have been attributed to the modulation of 
NAT1 only if the change was observed in the same direction in both NAT1 knockout cell lines, 
CRISPR 2-19 and CRISPR 5-50. Unfortunately, the CRISPR 2-12 cell line was not utilized in the 
Bioenergetics studies thus preventing comparison between the two cell lines constructed via 
guide RNA 2. 
Metabolomics  
Multiple analyses of the metabolomics dataset suggested there are differences in 
addition to NAT1 between the constructed cell lines. Comparing metabolites that were 
concordantly differentially abundant in the two complete NAT1 knockout cell lines revealed many 
more metabolites were uniquely differentially abundant than agreed between the two NAT1 
knockout cell lines, with only 16% concordance between the CRISPR 2-19 and CRISPR 5-50 cell 
lines. Additionally, hierarchical clustering analysis revealed the cell lines constructed using guide 
RNA 2, CRISPR 2-12 and CRISPR 2-19, had more similar global metabolomics profiles than the 
cell lines with comparable NAT1 N-acetylation activity, Down and CRISPR 5-50, respectively. 
Furthermore, principal component analysis of the data revealed that nearly 53% of the total 
variance in the metabolomics data was between the two cell lines generated using guide RNA 2 
and all other cell lines while approximately 17% of the total variance in the data was between the 
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CRISPR 5-50 cell line and all other cell lines. The first two principle components, together, 
account for approximately 70% of the total variance in the dataset and separate the 
CRISPR/Cas9 constructed cell lines from the siRNA constructed cell lines. 
Transcriptomics 
Similar to the metabolomics dataset, many more genes were uniquely differentially 
expressed than were concordantly differentially expressed between the two NAT1 knockout cell 
lines with only 27% concordance between the CRISPR 2-19 and CRISPR 5-50 cell lines. 
Additionally, hierarchical clustering analysis revealed the cell lines constructed using guide RNA 
2, CRISPR 2-12 and CRISPR 2-19, had more similar global transcriptomics profiles than the cell 
lines with comparable NAT1 N-acetylation activity, Down and CRISPR 5-50, respectively. 
Furthermore, principal component analysis supported this conclusion although the results were 
not as striking as the metabolomics principal component analysis. 
Combined Analysis 
 Analysis of the combined metabolomics and transcriptomics datasets also indicates there 
are differences other than NAT1 in our constructed cell lines. Component 1 of the sPLS-DA 
discriminates the CRISPR 5-50 cell line from all others; the metabolites found in component 1 are 
characterized by lactate and sulfate moieties thus suggesting the CRISPR 5-50 has additional 
mutations in pathways that contain these metabolites. Component 2 of the sPLS-DA 
discriminates the CRISPR 2-12 and CRISPR 2-19 cell lines from all others; the metabolites found 
in component 2 are characterized by choline moieties thus suggesting the CRISPR 2-12 and 
CRISPR 2-19 cell lines have additional mutations in pathways that contain choline metabolites.  
Discussion 
 Since February 2013, when it was first reported that the CRISPR/Cas9 system could be 
used to edit eukaryotic genomes229, many researchers and labs around the world have taken 
advantage of this system as a research tool to study the role of single genes in a variety of 
diseases230-239. Although the CRISPR/Cas9 system has been shown to have high specificity, it is 
still possible for the guide RNAs used to cause off-target effects240-242. Also, when using the clonal 
isolation method to select single cells where the gene of interest has been knocked-out rather 
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than a pool of cells, the chance of spontaneous, independent mutations occurring in each 
generated cell line increases. These off-target effects and spontaneous mutations may lead to 
incorrect conclusions about the role of the specific gene under investigation.  
There are multiple online tools, including MIT CRISPR Design Tool243 and E-CRISP244, 
that use algorithms to generate CRISPR gRNA sequences and predict off-target mutation sites of 
those gRNAs based on “rules” about mismatch number and position. The E-CRISP web-based 
“evaluation” algorithm has been utilized to predict off-target mutation sites based on the 
sequences of the two guide RNAs utilized during construction (Table 7.1 & 7.2); MIT CRISPR 
Design Tool does not allow posteriori evaluation of gRNA sequences. The transcriptomics 
dataset was then utilized to compare gene expression of genes in which there was a predicted 
off-target sites. The author acknowledges that RNA expression does not always correlate 
perfectly with protein function and will not indicate definitely if a mutation causing knockout of the 
gene has occurred. However, a decrease in NAT1 transcripts in the two NAT1 knockout cell lines 
was observed and decreases in transcript abundance of off-target genes can serve as a proxy 
measure for off-target effects. No differences were observed in any of the genes predicted by the 
web-based algorithms to have off-target mutations. 
Additionally, there are currently multiple methods available that have been developed 
specifically to detect off-target activity of CRISPR-Cas9 guide RNAs such as integrase-defective 
lentiviral vectors (IDLVs)245, Digenome-seq246, GUIDE-seq247, and qEva-CRISPR248, however 
these need to be performed during construction. Additionally, some researchers use whole 
genome sequencing (WGS) to evaluate the presence of possible off-target mutations. This is the 
only method that can definitively identify additional mutations a posteriori construction. Notably, 
however, not all researchers make use of these technologies to profile their cell lines. Moreover, 
many studies utilizing CRISPR/Cas9 technology to construct knockout cell lines do not conduct 
global, holistic profiling of the resulting cell lines but rather make small, very targeted, reductionist 
measurements. Additionally, very few studies utilize two different guide RNAs to knockout the 






Guide RNA 2 predicted targets 
TARGET 




NAME SEQUENCE DIRECTION 
20 62393719 62393742 ENSG00000149679 CABLES2 TGAAGGGAACAACTCAGATCAAG fw 
5 149360724 149360747 ENSG00000145882 PCYOX1L CAAAGGGAACAGCTCGGACAAAG fw 
9 78994637 78994660 NA NA TAAAGAGAACAGCTGGGATCAAG fw 
17 74041132 74041155 NA NA CTAAGGGGACAGCTGGGATCCAG fw 
4 1816643 1816666 ENSG00000168924 LETM1 AGAAGGGCCCAGCTCGGATCCAG fw 
2 63708726 63708749 ENSG00000143951 WDPCP AAATGGGAACAGCTCCGATCTAG rc 
8 18222137 18222160 ENSG00000171428 NAT1 CAAAGGGAACAGCTCGGATCTGG rc 
8 18400093 18400116 ENSG00000156006 NAT2 CAAAGGGAACAGCCCGGATCTGG rc 
 
E-CRISP web-based “evaluation” algorithm was utilized to predict off-target mutation sites based on the sequences of the guide RNA 2 utilized 






Guide RNA 5 predicted targets 
TARGET 
CHROMOSOME START END 
GENE TARGETS 
(ENSBL ID) GENE NAME SEQUENCE DIRECTION 
3 122941233 122941256 ENSG00000082684 SEMA5B ACATTGGCTCTAAGAAGCCTAAG fw 
8 77188268 77188291 NA NA TCATTGGCTAGAACAAGTCTTAG rc 
21 24269418 24269441 NA NA GAATTGGCTATCAGAAGTCCTAG fw 
2 194868769 194868792 NA NA AAAATGGCTACAAGAAGTCTTAG fw 
CHR_HSCHR6_ 
MHC_COX_CTG1 30001513 30001536 ENSG00000229653 NCRNA00171 CTATTGGTTATAAGAAGTCACAG fw 
CHR_HSCHR6_ 
MHC_APD_CTG1 30004125 30004148 ENSG00000236598 NCRNA00171 CTATTGGTTATAAGAAGTCACAG fw 
CHR_HSCHR6_ 
MHC_DBB_CTG1 30001951 30001974 ENSG00000225618 NCRNA00171 CTATTGGTTATAAGAAGTCACAG fw 
8 91943377 91943400 NA NA TTATTGGCTATAAGATGCCTCAG rc 
2 208352693 208352716 ENSG00000115020 PIKFYVE GAATTGGTTATAAGAACTCTCAG fw 
3 104893231 104893254 NA NA TCATTGGATATGAGAAGTCTCAG fw 
5 117577755 117577778 NA NA TAATTGGCTAGAAGAAGTTTCAG rc 
6 123305929 123305952 ENSG00000186439 TRDN TCAGTGGCTATAACAAGTCTCAG fw 
18 39817888 39817911 NA NA GGATTGGCTATAAGAAGTAAGAG fw 
5 91359933 91359956 NA NA TGGTTGGCTATAAGAAGACTGGG fw 
7 22336060 22336083 ENSG00000136237 RAPGEF5 GCATTGGGAATAAGAAGTCTGGG rc 
8 18222075 18222098 ENSG00000171428 NAT1 GAATTGGCTATAAGAAGTCTAGG fw 
8 18400031 18400054 ENSG00000156006 NAT2 GAATTGGCTATAAGAACTCTAGG fw 
1 90780522 90780545 NA NA GGATTGGCTATATGAAGTCAAGG fw 
11 37011189 37011212 NA NA TTATTAGCTATAAGAAGGCTAGG rc 
 
E-CRISP web-based “evaluation” algorithm was utilized to predict off-target mutation sites based on the sequences of the guide RNA 5 utilized 
during construction. fw = forward orientation, rc = reverse orientation
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generated cell lines most likely have additional differences in addition to their gene of interest but 
do not make measurements that would allow detection of such differences. Convincing evidence 
has been presented in this chapter that greater caution should be applied when interpreting 
results from studies utilizing CRISPR/Cas9 to knockout a single gene of interest especially when 
those studies have not profiled the cell lines globally, utilizing at least one omics technology 
and/or utilizing two different guide RNA’s to knockout the gene thus constructing two knockout 
cell lines for comparison. Great bias is introduced via the reductionist approach in those studies 
and that bias may lead to naivety about additional mutations in samples. 
 As an example, in a study by Tsai et al. multiple CRISPR/Cas guide RNAs were used to 
edit the gene VEGFA, on chromosome 6, to compare on-target and off-target mutations247. The 
authors found the selected guide RNAs could also target genes on virtually every one of the other 
22 human chromosomes. Although each CRISPR guide RNA had zero to a dozen or so predicted 
off-target sites (by previously discussed web-based algorithms), neither algorithmic software used 
(MIT CRISPR Design Tool243 and E-CRISP244) identified the vast majority of off-target sites247; 
depending on the guide RNA, 0 to >150 off-target mutations were observed. Additionally, the off-
target sites had diverse sequences making prediction of where off-target effects occur rather 
difficult. Without prediction of these off-target sites, scientists would have no idea where to look in 
the genome for possible off-target mutations and no idea those errors were possible. This 
example highlights the importance of global profiling (unbiased measurement of many aspects of 
the global system) of CRISPR/Cas9 generated cell lines as well as the importance of including 
cell lines generated with multiple different guide RNAs to be able to filter out off-target effects. 
Notably, another study found that many off-target sites were mutated with frequencies 
comparable to or even higher than the on-target site249. 
Summary and Conclusions 
 The results from all experiments presented in this dissertation, 1. bioenergetics (Chapter 
3), 2. metabolomics (Chapter 4), and 3. transcriptomics (Chapter 5), strongly suggest the 
constructed MDA-MB-231 cell lines had differences in gene(s) other than NAT1 that were 
unexpected. Without the sophisticated study design in which a global systems biology approach 
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was utilized as well as multiple guide RNAs, I most likely would not have been aware that there 
were additional differences between the cell lines. Additionally, it would have been nearly 
impossible to parse out what effects were due to NAT1 and what effects were due to these 
additional differences. These findings have especially great implications for researchers planning 
to utilize CRISPR/Cas9 gene editing technology in humans; I assert that the potential for off-
target effects using CRISPR/Cas9 has been underappreciated and under-reported in the 
literature due to the lack of global profiling. Currently, considerable research is being conducted 
on ways to optimize CRISPR editing efficiency and decrease the number of off-target effects that 
occur when utilizing CRISPR/Cas9 technology to edit genes250. Additionally, researchers in the 
field are working on better ways to detect and/or predict off-target effects given both are still a 
major challenge. 
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CHAPTER 8
 
SUMMARY AND CONCLUSIONS 
 
Summary 
This dissertation presents convincing evidence that NAT1, whether directly or through an 
effect on acetyl-CoA levels, has a role in cellular metabolism and energetics in MDA-MB-231 
breast cancer cells. Mitochondrial bioenergetics, specifically reserve capacity, maximal 
respiration, and glycolytic reserve capacity were increased in the NAT1 knockout cell lines 
(CRISPR 2-19 and CRISPR 5-50) while bioenergetics in the cell line with increased NAT1 N-
acetylation activity (Up) were not significantly different from the cell lines with parental NAT1 N-
acetylation activity (Parent and Scrambled). Additionally, in both the metabolomics and 
transcriptomics experiments presented in this dissertation, metabolite abundances and gene 
transcript expression were more dysregulated in the NAT1 knockout cell lines (CRISPR 2-19 and 
CRISPR 5-50) than the cell line with increased NAT1 (Up) compared to the cell line with parental 
NAT1 N-acetylation activity (Scrambled) suggesting the loss of NAT1 has a greater impact on 
metabolism than its overexpression. 
 By utilizing a global systems biology approach, new directions for future research on 
NAT1’s role in breast cancer cell metabolism have been generated that would not have been 
considered otherwise. Systems biology allows a more unbiased view compared to traditional 
reductionist approaches, thus enabling NAT1 research to be stimulated in a novel direction. The 
data presented in this dissertation has also shown that the knockout of NAT1 induced more 
changes bioenergetically, metabolically, and transcriptionally compared to the overexpression of 
NAT1. As there is active research in the NAT field on the development of small molecule 
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inhibitors of NAT1, it is important to understand how the knockout of NAT1 N-acetylation activity 
and expression affects global cellular metabolism. 
Strengths of This Work 
The experimental design strategies and research presented in this dissertation have 
several strengths that enabled many novel insights as well as the formulation of additional 
hypotheses about NAT1’s role in breast cancer and, more generally, metabolism. The first major 
strength I will discuss is the use of publicly available data to annotate previously undefined 
relationships between NAT1, NAT2, & ESR1 in established breast cancer cell lines, primary 
breast tumors, and normal breast tissue. For these analyses data was accessed and analyzed 
(fairly quickly) without the need to do, what would have been, expensive wet-lab experiments. 
Publicly available data repositories offer a wealth of knowledge but, until now, have been under-
utilized in NAT research. Additionally, the data repositories can be utilized to evaluate whether 
the relationships observed in the datasets presented in this dissertation are also present in the 
larger publicly available datasets. 
A second strength of this work was the careful and thoughtful selection of samples. By 
choosing a single breast cancer cell line and genetically modifying only NAT1 (theoretically) any 
confounding factors that might be introduced when utilizing breast cancer cell lines with innately 
different levels of NAT1 activity due to different genetic backgrounds and the presence of 
additional unique mutations in each cell line have been eliminated. The MDA-MB-231 cell line 
was chosen rather than an estrogen receptor positive cell line because cell lines with NAT1 
knocked out as well as overexpressed were desired. To this end, a breast cancer cell line with an 
approximate mid-level of NAT1 activity was selected. However, very few of the breast cancer cell 
lines available for research (approximately 57 total) have been characterized for NAT1 N-
acetylation activity. Therefore, RNA expression was used as a proxy for NAT1 N-acetylation 
activity because publicly available data on NAT1 RNA expression of all 57 breast cancer cell lines 
are available (discussed and utilized in Chapter 2). The MDA-MB-231 cell line expresses an 
approximate mid-level of NAT1 RNA compared to the other 56 breast cancer cell lines. 
Additionally, this cell line is frequently utilized in breast cancer research and has been utilized in 
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previous studies looking at NAT1’s role in breast cancer thus allowing comparison of experiments 
and observations more readily. 
Additionally, during construction of the MDA-MB-231 breast cancer cell lines with varying 
levels of NAT1 N-acetylation activity two different methods, siRNA and CRISPR/Cas9, were 
utilized. This strategy helped to ensure any results or conclusions reported are truly due to 
differences in NAT1 activity and not a result of the methodology utilized to modulate NAT1 
expression. To this end, during construction of the complete NAT1 knockout cell lines via 
CRISPR/Cas9 technology two unique NAT1 targeting guide RNAs were utilized, again ensuring 
any results or conclusions reported are truly due to differences in NAT1 activity because guide 
RNAs have been shown to cause off-target effects. In fact, as presented in Chapter 7, there is 
strong evidence of additional differences other than NAT1 in the genetically modified cell lines; 
without inclusion of NAT1 knockout cell lines constructed via different guide RNAs (CRISPR 2-19 
and CRISPR 5-50) and cell lines constructed with the same guide RNA but that had different 
levels of NAT1 N-acetylation activity (CRISPR 2-12 and CRISPR 2-19), this observation would 
most likely have been missed and the results would be unknowingly confounded. 
The third major advantage of the work presented in this dissertation is the systems 
biology approach utilized to evaluate the dissertation hypothesis rather than the more traditional 
reductionist approach. Notably, by using the exact same biological samples, collected and grown 
at the exact same time in the metabolomics and transcriptomics experiments we integrated the 
two resulting datasets on cells under identical biological conditions. Additionally, bioenergetics 
and transcriptomics experiments were integrated by comparing mitochondrial gene expression. A 
global systems biology approach has enabled stimulation of NAT1 research in new directions.  
Caveats and Weaknesses 
Although the work presented in this dissertation was well planned and executed there are 
nevertheless caveats and weaknesses. The first caveat to acknowledge is that although this 
dissertation asserts that a global analysis of the complete system was performed, that is not 
entirely true. The field of metabolomics is limited by the number of metabolites that can be 
detected analytically. Therefore, that assertion must be qualified to acknowledge that this study 
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was a global metabolomics experiment in that data was collected on as many metabolites as was 
feasible which still represents a small proportion of all metabolites present in the human 
metabolome (Figure 8.1). Additionally, because metabolites were only isolated from cell pellets 
and not the surrounding media, metabolites excreted from the cell that would be important in 
understanding NAT1’s effects on cellular metabolism may have been missed. However, media 
was collected and reserved during collection of cell pellet samples for possible future analyses. 
Another caveat to acknowledge is the bias introduced by reliance on NAT1 N-acetylation 
activity as a measure for NAT1 function. Although NAT1 N-acetylation is increased, decreased, 
and not detectable in the constructed cell lines, it remains unknown if possible additional 
functions/roles of NAT1 were not also affected and contribute to our overall observations in an as 
yet uncharacterized manner. It will also be important for future studies to evaluate the findings 
presented in this dissertation in additional breast cancer cell lines, untransformed (normal) breast 
cell lines, and other cancers. 
Notably, although sample choice was a major strength in this work it can also be viewed 
as a weakness. The conclusions presented in this dissertation are based on results derived from 
modulating NAT1 in a single breast cancer cell line; however, breast cancer is a very 
heterogenous disease. The MDA-MB-231 breast cancer cell line may have unique mutations in 
genes that are regulators, interactors, producing or metabolizing substrates for NAT1, or altering 
metabolism independent of NAT1 status. It will be important for future work to conduct 
experiments in other breast cancer cell lines and more generally, other cancer types where NAT1 
is commonly overexpressed, to determine if our observations hold true. Although human breast 
tumor samples would have been more biologically relevant, as the tumor microenvironment would 
have been better represented, human samples would add more confounding factors when 
interpreting results. Additionally, there is a great need to analyze data from human subjects to 
see if these observations correlate with samples from a complete human system. Similarly, the 
research presented here was conducted on samples that were already malignant in nature, 
making inferences about NAT1’s role in breast cancer risk or tumorigenesis not possible. Results 
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Figure 8.1 
 
Figure 8.1: Limitations of “Global” Metabolomics. 
A Venn diagram depicting a significant issue in “global” metabolomics. Researchers are limited by 
metabolite annotation, the ability to analytically detect metabolites, and the localization of 
metabolites. When attempting to make inference about changes in metabolic pathways 
metabolites in the intersection of the three circles are observed when the target metabolic 
pathway is the entire rectangle. These difficulties limit the ability to obtain a true global view of 












Adapted from PJ Trainor 
(unpublished work). 
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may be different if experiments were performed on non-malignant breast cells and further studies 
in non-malignant cells are necessary. 
Another weakness of the work presented here was the presence of differences other than 
NAT1 in the constructed cell lines (presented in Chapter 7). These additional differences 
complicated interpretations of the data. However, without a global systems biology approach, we 
would not have realized there were additional differences and may have incorrectly attributed 
results to the modulation of NAT1. It is the author’s opinion that other CRISPR/Cas9 studies also 
have off-target effects. However, the measurements or observations that are made do not allow a 
high-level global view so these off-target effects may be missed. Additionally, inclusion of two 
NAT1 knockout cell lines that were generated using two different guide RNAs differences that 
were truly due to the modulation of NAT1 to be focused on. In the future, whole genome 
sequencing of the cell lines utilized in this study should be conducted to determine exactly which 
genes these additional differences have occurred in. This may aide interpretation of some of the 
results presented in this dissertation. 
The final weakness of this work to be discussed was the inability to stably rescue NAT1 
in the constructed NAT1 knockout cell lines. This rescue would have allowed greater confidence 
that observations and results were truly due to the knockout of NAT1. It is predicted that any 
observations truly due to NAT1 knockout would be reversed with the rescue of NAT1 activity and 
conversely, predicted that any observations due to differences other than NAT1 would not be 
reversed by the rescue of NAT1. 
Future Directions 
In addition to the results and conclusions that were presented in this dissertation, many 
novel hypotheses about the role of NAT1 in breast cancer, and more generally cellular 
metabolism, have been generated. As such, I propose numerous future directions to further 
delineate the mechanism by which NAT1 affects breast cancer progression and the possible role 
of NAT1 in cellular metabolism. 
The first future direction, which is currently in progress, is to incubate the cell lines used 
in this study with L-asparagine to measure how this supplementation affects cell growth and 
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invasive ability, given the strong positive correlation between NAT1 N-acetylation activity and N-
acetylasparagine and the recently proposed role of L-asparagine in breast cancer cell growth and 
metastasis189,190. Although our lab currently does not have the ability to readily measure L-
asparagine and/or N-acetylasparagine, the proposed experiments will help determine if cell lines 
with varying NAT1 N-acetylation activities respond differently to L-asparagine supplementation. If 
differences in growth and metastatic are observed based on NAT1 activity, that will add evidence 
to the hypothesis that there is a relationship between NAT1 and L-asparagine. Additionally, our 
lab is currently working with collaborators to develop an HPLC-fluorescence detection method to 
detect N-acetylasparagine and L-asparagine. Once this method is optimized, recombinant human 
NAT1 expressed in yeast lysates could be incubated with acetyl-CoA and L-asparagine to 
evaluate if NAT1 is directly catalyzing the N-acetylation of L-asparagine more directly. Until then, 
our lab is conducting competitive activity assays between PABA and L-asparagine to see if the 
rate of N-acetylation of PABA is affected in the presence of L-asparagine in the reaction. 
Similarly, studies using putrescine instead of L-asparagine could be performed given there is 
evidence both biochemicals may be NAT1 substrates. 
An additional area of future research will be further evaluating the mechanism by which 
NAT2 transcripts are increased in NAT1 knockout cell lines (CRISPR 2-19 and CRISPR 5-50). 
From the results of the transcriptomics data, a list of candidate genes that are predicted to 
interact with NAT2 has been created. The candidate genes were chosen based on correlated 
expression with NAT2 expression and also based on clustering with NAT2 in the WGCNA 
analysis. While this phenomenon was observed in the constructed breast cancer cell lines, it is 
unclear if this occurs in humans. I propose analyzing NAT1 and NAT2 gene expression data in 
human subjects with no detectable NAT1 activity to see if the phenomenon is present. One 
foreseeable limitation is the relatively rare occurrence of humans with no detectable NAT1 
activity. While functional NAT2 N-acetylation activity was not observed in the NAT1 knockout cell 
lines, investigating the mechanism by which NAT2 transcripts are produced will be an important 
area of NAT research in the future. An additional area of research will be investigating miRNAs 
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that possibly target NAT2 to help explain the observation of NAT2 transcripts but no NAT2 N-
acetylation activity. 
On the basis that many of our observations and results can be traced to reactions that 
involve mitochondria, an additional future direction is to probe mitochondrial mass, biogenesis, 
and morphology in our constructed cell lines. Additionally, reactive oxygen species (ROS) in 
mitochondria can be evaluated. This will help determine if the observations presented in this 
dissertation are related to changes in mitochondria biogenesis/number directly or dysregulation of 
the reactions that occur in mitochondria. 
Given the strong evidence of genetic differences in addition to NAT1 in the constructed 
cell lines utilized in the studies presented in this dissertation, I propose performing WGS to 
determine the exact location of the differences. This method is the only way to definitively 
determine the genetic differences between the constructed cell lines. Once additional genetic 
differences between the cell lines are determined, that information may be utilized to study those 
genes. Additionally, the results of this proposed experiment will have great implications for past, 
present, and future studies utilizing CRISPR/Cas9. 
The final future direction proposed is integrating the three datasets presented in this 
dissertation with the proteomics and acetylomics previously collected by our lab (collected only 
for the complete NAT1 knockout cell lines, CRISPR 2-19 and CRISPR 5-50). As human 
metabolism is a very highly regulated process and composed of many layers, combining these 
datasets would add an additional level to the systems biology approach presented in this 
dissertation. Combining the datasets will not be easy but improved methodology for combining 
multi-omics datasets is currently a rich area of development (discussed in Chapter 6) in the 
systems biology field. 
Overall Conclusions 
This dissertation has presented evidence that greater caution should be exercised in 
interpretation of results from single gene knockout studies utilizing CRISPR/Cas9. The elegant 
study design utilized in this dissertation enabled me to conclude CRISPR/Cas9 can cause off-
target effects in sites not predicted by web-based algorithms that would confound conclusions. 
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Furthermore, I have shown that publicly available datasets can be used to complement and 
enhance wet-lab experiments very quickly and inexpensively. 
I have presented strong evidence that NAT1, whether directly or through the effect of 
NAT1 on acetyl-CoA levels, has an effect on acyl-CoA carnitine conjugates, lysine degradation, 
and mitochondrial function (Figure 6.11). Saccharopine is the first product formed during lysine 
degradation in mammals and was increased in cell lines with decreased levels and knockout 
NAT1 (Down, CRISPR 2-12, CRISPR 2-19, and CRISPR 5-50). Notably, carnitine is 
biosynthesized from methionine and lysine. Increases in saccharopine suggest more lysine is 
degraded, leaving less lysine for carnitine biosynthesis. Fatty acyl-CoA carnitine conjugate 
metabolites were decreased in the NAT1 knockout cell lines (CRISPR 2-19 and CRISPR 5-50) 
and those metabolites were strongly correlated with carnitine abundance. In humans, fatty acyl-
CoAs are conjugated to carnitine for transport to the mitochondria and subsequent beta oxidation 
producing acetyl-CoA. The decrease in fatty acyl-CoA conjugates in the NAT1 knockout cell lines 
(CRISPR 2-19 and CRISPR 5-50) suggest less acetyl-CoA is produced by this mitochondrial 
pathway. It remains unknown whether this is a dysregulation of energetics or complex feedback 
due to increased acetyl-CoA because of decreased NAT1 catalyzed hydrolysis of acetyl-CoA.  
Overall, this dissertation describes the first studies to investigate the effect varying 
human NAT1 activity has on the bioenergetics profile, metabolome, and transcriptome of a breast 
cancer cell line. This dissertation has generated vast amounts of data that I foresee being utilized 
for years to come as we learn more about NAT1 thus providing a valuable resource for future 
studies. Additionally, I have used this data to generate novel hypotheses about the role of NAT1 
in breast cancer, and more generally cellular metabolism. Furthermore, I have identified 
biochemicals that are likely products of NAT1 N-acetylation, N-acetylasparagine and N-
acetylputrescine, however further studies are needed to confirm this. While I have not identified 
the exact mechanism by which NAT1 affects cellular metabolism or breast cancer progression, 
the data presented in this dissertation add important pieces to the puzzle, putting NAT 
researchers one step closer to that goal. 
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ABBREVIATIONS
 
r  Spearman Correlation Coefficient 
2-AF  2-aminoflourene 
4-ABP  4-aminobiphenyl 
3’UTR  3 Prime Untranslated Region 
Acetyl-CoA Acetyl Coenzyme A 
ACS   American Cancer Society 
ACY1  Aminoacylase 1 
ALK  Anaplastic Lymphoma Receptor Tyrosine Kinase 
AMPK  5' Adenosine Monophosphate-Activated Protein Kinase 
ANOVA  Analysis of Variance 
ASPA  Aminoacylase 2 
ATCC  American Type Culture Collection 
ATP  Adenosine Triphosphate 
BRCA  Breast Invasive Cohort in TCGA 
BRCA1  Breast Cancer 1, Early Onset 
BRCA2  Breast Cancer 2, Early Onset 
CCLE  Cancer Cell Line Encyclopedia 
cDNA  Complementary Deoxyribose Nucleic Acid 
CGeMM Center for Genetics and Molecular Medicine 
cKIT  KIT Proto-Oncogene Receptor Tyrosine Kinase 
CRISPR Clustered Regularly Interspaced Short Palindromic Repeats 
CRISPR/Cas9 Clustered Regularly Interspaced Short Palindromic Repeats/CRISPR Associated 
Protein 9 
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DMEM  Dulbecco's Modified Eagle Medium 
DNA  Deoxyribonucleic Acid 
ECAR  Extracellular Acidification Rate 
EGFR  Epidermal Growth Factor Receptor 
ER+  Estrogen Receptor Positive 
ER-  Estrogen Receptor Negative 
ER  Estrogen Receptor 
ESR1  Estrogen Receptor 1 
ESI  Electrospray Ionization 
FA  Formic Acid 
FCCP  Carbonyl Cyanide-p-trifluoromethoxyphenylhydrazone 
FRT  Flippase Recognition Target 
GFP  Green Fluorescent Protein 
GI  Gastrointestinal 
GNAQ/GNA11 G Protein Subunit Alpha Q/G Protein Subunit Alpha 11 
gRNA(s) Guide Ribonucleic Acid(s) 
HER2  Human Epidermal Growth Factor Receptor 2 
HESI  Heated Electrospray Ionization 
HILIC  Hydrophilic Interaction Liquid Chromatography 
HMDB  Human Metabolome Database 
HPLC  High Performance Liquid Chromatography 
HUGO  Human Genome Organization 
IDLVs  Integrase-Defective Lentiviral Vectors 
IGV  Integrative Genomics Viewer 
IQR  Interquartile Range 
KBRIN  Kentucky Biomedical Research Infrastructure Network 
KEGG  Kyoto Encyclopedia of Genes and Genomes 
KO   Knockout 
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LIMS  Laboratory Information Management System  
MATCH Molecular Analysis for Therapy Choice 
MET  Hepatocyte Growth Factor Receptor 
MIT  Massachusetts Institute of Technology 
MR1  Methylthioribose-1-Phosphate Isomerase 
mRNA  Messenger Ribonucleic Acid 
MS  Mass Spectrometry 
MTAP  Methylthioadenosine Phosphorylase 
mTOR  Mechanistic Target of Rapamycin Kinase 
MTT  3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide 
m/z   Mass to Charge Ratio 
NAT1  arylamine N-acetyltransferase 1 
NAT2  arylamine N-acetyltransferase 2 
NATs  arylamine N-acetyltransferases 
NCI  National Cancer Institute 
NTRK  Neurotrophic Tyrosine Kinase 
OCR  Oxygen Consumption Rate 
ORF  Open Reading Frame 
PABA  p-aminosalicylate 
pABG  p-aminobenzoylglutamate 
PAS  p-aminosalicylate 
PBS  Phosphate Buffered Saline 
PC1  Principal Component 1 
PCR  Polymerase Chain Reaction 
PCA  Principal Component Analysis 
PFPA  Perfluoropentanoic Acid 
PR  Progesterone Receptor 
QA/QC  Quality Assessment/Quality Control 
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QC  Quality Control 
qPCR  Quantitative Polymerase Chain Reaction 
r  Pearson Correlation Coefficient  
RI  Retention Index 
RNA  Ribonucleic Acid 
RNA-Seq Ribonucleic Acid Sequencing 
ROS1  ROS Proto-Oncogene 1, Receptor Tyrosine Kinase 
RP  Reverse Phase 
RPKM  Reads Per Kilobase of Transcript per Million Mapped Reads 
RSD  Relative Standard Deviation 
RSEM  RNA-Seq by Expectation- Maximization  
RT-PCR Reverse Transcription-Polymerase Chain Reaction 
RT-qPCR Reverse Transcription-Quantitative Polymerase Chain Reaction 
SAT1  Spermidine/Spermine N1-Acetyltransferase 1 
SAT2  Spermidine/Spermine N1-Acetyltransferase 2 
SEM  Standard Error of the Mean 
shRNA  Short Hairpin Ribonucleic Acid 
siRNA  Silencing Ribonucleic Acid 
SMO/PTCH1 Smoothened, Frizzled Class Receptor/Patched 1 
SMZ  Sulfamethazine 
SNPs  Single Nucleotide Polymorphisms 
sPLS-DA Sparse Partial Least Squares-Discriminant Analysis 
STR  Short Tandem Repeat 
TCA  Citric Acid Cycle 
TCGA  The Cancer Genome Atlas 
TNBC  Triple Negative Breast Cancer 
TSC1  Tuberous Sclerosis Complex Subunit 1 
TSC2  Tuberous Sclerosis Complex Subunit 2 
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UPLC  Ultra Performance Liquid Chromatography 
UPLC- MS/MS Ultra Performance Liquid Chromatography- Tandem Mass Spectrometry 
VEGFA  Vascular Endothelial Growth Factor A 
WGCNA Weighted Gene Co-expression Network Analysis 
WGS  Whole Genome Sequencing 
WPGMA Weighted Pair Group Method with Arithmetic Mean 
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